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Transcriptional Regulation of the Developing Retina 





The retina is a complex stratified neural tissue required for all mammalian vision. During 
development, tightly controlled transcriptional regulation drives diversification from a 
homogenous population of retinal progenitor cells into seven major types and dozens of subtypes 
of cells. Here, we explored the role of the transcription factors Otx2, Prdm1, Prdm13, and Vsx2 
in driving the formation of specific neurons from a homogenous pool of retinal progenitors. We 
first showed that PRDM13 is expressed in a subset of developing amacrine interneurons. Loss of 
Prdm13 leads to a 25% reduction in amacrine cells and disruption of retinal sublamina 
formation. Next, we explored the role of Prdm1 and Vsx2 in driving the correct formation of rod 
photoreceptors and bipolar interneurons. In OTX2+ cells late in retinal development, Prdm1 and 
Vsx2 work in opposition, such that Prdm1 promotes photoreceptor cell fate and Vsx2 bipolar cell 
fate. We deleted Prdm1 and Vsx2 or their cell type-specific enhancers simultaneously using a 
CRISPR/Cas9 in vivo retina electroporation strategy. Double enhancer targeting favored bipolar 
outcomes whereas double gene targeting favored photoreceptor fates. Both conditions generated 
excess amacrine cells. We show photoreceptors are a default fate outcome in OTX2+ cells and 
VSX2 is required during a narrow temporal window to drive bipolar cell formation. Prdm1 and 
Vsx2 appear to redundantly restrict the competence of OTX2+ cells, preventing amacrine cell 
formation. Next, we explored the stability of VSX2+ bipolar fates. To do this, we created a 
system to conditionally misexpress Prdm1 during bipolar cell development. We found that 
Prdm1 blocks bipolar formation if expressed before the fate choice decision occurred. 
Constitutive PRDM1 expression in nascent bipolar cells can cause a fate shift to rods but has no 
effect on mature bipolar cells. PRDM1 was selectively toxic to mature rods. Our data show that 
bipolar fate is malleable, but only for a short period following fate specification. OTX2+ cells 
use Prdm1 and Vsx2 to stabilize photoreceptor and bipolar cell identities during development and 
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maturation of proper amacrine subtypes requires Prdm13. Our work provides novel insights into 
the complex regulatory mechanisms that control cell fate choice in the developing murine retina. 
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Retinal Disease and Neural Degeneration Cause Permanent Blindness 
 The retina is a thin layer of neural tissue at the back of the eye and is the foundational 
sensory processing center for visual information. This tissue is less than 0.5mm thick in humans 
and is composed of multiple layers of neurons that perform a variety of functions. Rod and cone 
photoreceptors convert photons into neural signals. Various interneurons including bipolar, 
horizontal, and amacrine cells conduct complex calculations on the raw data from the 
photoreceptors. Ganglion cells compute the processed inputs and pass their signals out through 
the optic nerve to the brain where further signal decoding and encoding is performed.  
 The retina is supported by a group of cells called Müller glia, which provide support to 
the high-functioning neurons by maintaining structure and mediating neurotransmitter 
maintenance. Underlying the retina is the retinal pigmented epithelium (RPE). This supporting 
structure plays a critical role in the visual cycle by retinoid recycling, providing ion buffering, 
light absorption, controlling oxidative stress, and mediating immune privilege within the retina.  
 Dysfunction in any part of the retinal or associated RPE tissue can cause loss of visual 
function. This can result from genetic disorders, like retinitis pigmentosa, diseases of aging like 
macular degeneration, other disease states like diabetic retinopathy, various forms of cancer, 
autoimmune diseases like uveitis, or traumatic events like retinal detachment. Untreated, nearly 
all forms of retinal degeneration will lead to permanent blindness. Indeed, nearly 90% of legal 
blindness in the United States is caused by degradation of the retina or its supporting tissue1.  
 Blindness due to loss of retinal neurons is permanent and affects more than 10 million 
Americans2.  This is because once retinal neurons begin to die, they are not regenerated within 
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mammalians systems. This has led to significant work attempting to understand the foundations 
of developmental and degenerative diseases of the retina. A critical prerequisite to producing 
therapies that alleviate human disease is answering questions about the underlying biological 
mechanisms. For example, what are the mechanisms of retinal degradation in various disease 
states and how can they be stopped?  How do we created regenerative therapies that restore 
vision to those who have already suffered significant neural loss? Pursuing either of these lines 
of inquiry requires significant advancement in our understanding of the mechanisms governing 
how neurons of the retina differentiate into unique cell types, laminate appropriately, and 
develop into functional neural circuits.  
Here I explore the role of a variety of genes in retinal development, several of which have 
been associated with disorders of the developing eye or congenital degenerative diseases. 
Throughout this introduction I will introduce the broad evolutionary patterns of visual 
development, the structure and diversity within a retina, and the major forces that contribute to 
the development of retinal neuron formation in vertebrates including various transcription factors 
and DNA enhancer regions. I then specifically explore how three key transcription factors 
Prdm1, Prdm13, and Vsx2, contribute to the development of the murine retina.  
 
Evolution of the Vertebrate Eye 
 The detection of photons and their conversion into behaviorally relevant information may 
be one of the oldest sensory systems in biology. There are numerous examples of single celled 
organisms responding to light to migrate, change their metabolic functions, or modify cell cycle 
processes3,4. The first proto-eye likely evolved around 600 million years ago during the 
Cambrian explosion4. Visual systems across the animal kingdom are incredibly diverse and some 
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of the most complex eyes in existence are found in non-vertebrate species. The eyes of the 
mantis shrimp have twelve or more unique kinds of photoreceptors that see from deep ultraviolet 
to far-red with incredible spatiotemporal clarity5.  
 The eye is a functional visual organ that is not merely a light detector. All eyes involve 
some form of lens that focuses light onto one or more photoreceptors which then pass light onto 
the rest of the central nervous system for further processing6. They can be divided into 
compound eyes and non-compound eyes7. Compound eyes, like those found in the mantis 
shrimp, have thousands of individual photo-detection units called ommatidia. Each one functions 
as a small eye with a visual focusing lens and photoreceptors. Compound eyes are further 
divided into apposition eyes, in which each lens focuses onto a photoreceptor with no gap 
between, and superposition eyes in which there is a gap between the lens and the rhabdom, 
where photoreception takes place. Superposition eyes create poor visual acuity, but provide 
incredible light sensitivity7.  
 Non-compound eyes, sometimes called simple eyes, have evolved numerous times 
throughout evolution through unique developmental pathways (Fig 1.1)8,9. The humblest version 
are called pit eyes, which are a simple sheet of photoreceptors set in a tissue pit, and are 
considered by many a proto-eye or visual detector rather than a camera eye6. Spherical lens eyes 
possess a lens with some form of refractive abilities to focus light onto the visual tissue. This 
allows for improved visual clarity, as well as increased aperture diameter, improving light 
sensitivity. Simple spherical lens eyes exist across the animal kingdom from insects and 
arachnids to fish and mammals. In rare cases, animals have evolved multi-lens eyes, that 
function more like a camera lens where a series of unique lens tissues perform separate functions 
to focus the light properly6.  
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 Vertebrate eyes themselves have enormous diversity, however many share a common 
structure and I will focus on these species for the remainder of this work. Broadly, light enters 
the eye through an aperture called an iris which controls light access. Light is then passed 
through a clear crystalline structure called a lens which focuses light onto the back of the eye 
(Fig 1.2A). At the back of the eye the light is encoded into neural information by the thin 
multilayered neural tissue called a retina. The retina itself sits on top of a supporting retinal 
pigment epithelium (RPE). Between the lens and the retina is a space filled with a clear 
gelatinous liquid called the vitreous. Surrounding the eye is the sclera at the back and sides and 
cornea on the outward facing portion of the tissue. Small muscles in the ciliary body may be used 
to stretch the lens and change focus. There are additional supporting structures in many systems, 
like muscles that move the entire eye, tear ducts that provide lubricant and protectant to the 
sclera, and systems for correctly maintaining eye pressure by draining excess fluid10.  
 In mammals, the retina may be the highest energy demanding tissue in the body when 
scaled to size11. To maintain this demand, the retina is an incredibly vascularized tissue. But the 
vasculature itself is not sufficient to control the energy needs and waste flow of the retina10. The 
underlying RPE plays a critical role in the cycling of visual metabolites and breakdown in the 
structure, function, or metabolic function of the RPE results in retinal dysfunction12. Each 
portion of the eye is essential to processing information effectively. However, the single most 
functionally, structurally, and cellularly complex tissue of the eye is the retina.  
 
Structure and Function of the Retina 
The retina is a laminated tissue and is positioned “upside-down” to the flow of light. That 
is to say, photons pass through the layers of tissue and impact the photoreceptors located at the 
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back of the eye. The encoded neural signal is then transduced back through the tissue toward the 
front of the eye, out the optic nerve, and back to the brain (Fig 1.2A-C). The basic signal path is 
photoreceptors to bipolar cell to ganglion cell. Horizontal and amacrine cells are involved in 
modifying signals for circuit-specific functions. Ganglion cells are projection neurons that carry 
signals to the brain. Müller glia and the RPE are supporting cells13. There are ten major layers of 
the retina passing from the vitreous toward the back of the eye. First is an inner limiting 
membrane (ILM) which separates the vitreous from the retina and then the nerve fiber layer 
(NFL) where ganglion cell axons pass on their way to the optic nerve (Fig 1.2B). Next is the 
ganglion cell layer (GCL) which contains ganglion cell nuclei and some amacrine cells. These 
project dendrites into the inner plexiform layer (IPL), which contains bipolar cell axons, 
amacrine dendritic arbors, and ganglion cell dendrites in a laminated structure. The IPL itself is 
divided into at least five major sub-lamina in mammals and plays a critical role in signal 
processing14. The majority of amacrine cells, all bipolar cells, and horizontal cells have their 
nuclei in the inner nuclear layer (INL)14,15. Bipolar cells and horizontals have projections into the 
outer plexiform layer (OPL) where signals from photoreceptors are passed to bipolar cells16. The 
photoreceptor nuclei are located in the outer nuclear layer (ONL) and they project their outer 
segments (OS) toward the back of the eye where they are surrounded by cells from the retinal 
pigmented epithelium (RPE)17. Between photoreceptors’ outer segment and nuclei is a tissue 
barrier called the outer limiting membrane (OLM). The ten lamina of the retina are composed of 
seven major cell types, each of which plays a unique role in processing visual signals. 
Photoreceptors are divided into two classes: rods and cones. Rods are sensitive to low 
light signals and their ability to detect visual input is driven by the protein Rhodopsin. Rods are 
so sensitive that a single photon of light can generate a cascade leading to a neural signal (Fig 
6 
 
1.2C)18. Cones have two primary functions: First, they detect color information and second, they 
are involved in high acuity vision in many species. Color vision is generated by cones expressing 
unique opsins that are sensitive to different wavelengths of light. A given cone will only express 
one kind of opsin in higher vertebrates, and thus represents a single color-channel. In humans, 
there are three primary opsins that are most sensitive to red, green, or blue light respectively19. 
Cones are also involved in high acuity vision in many species, including humans. They require 
two to three orders of magnitude more photons to activate their photo cascade than rods20. This 
means that they are only functional in high-light settings which explains their role in diurnal 
vision. The acuity itself is a function of the circuitry. Rods, particularly within the peripheral 
retina, tend to cluster multiple inputs onto a single bipolar cell. Functionally, this means the 
spatial input of this signal is imprecise but highly photosensitive. In general, fewer cones synapse 
onto a single bipolar cell compared to rods. But in the central retina at the macula, and 
particularly in the fovea of humans, cones and bipolars can form circuits as tightly coupled as 
1:120. While not all mammals have the level of central acuity of the human fovea, the general 
pattern from peripheral to central retina is consistent. This allows the output from the circuit to 
provide high spatial-temporal precision.  
Bipolar interneurons play a critical role within the retina. They pass all visual signals 
from sensory neurons to projection neurons. However, they are not simply a non-processing 
intermediate. As mentioned above, they may take inputs from 15-50 rods all the way down to a 
single cone. In mice, there are up to 15 unique bipolar cell subtypes depending on how you 
quantify morphology and molecular markers (Fig 1.2C, E)21–24. Some have proposed that only 
one kind of rod bipolar exists, called rod bipolar cells. Others have suggested based on molecular 
markers that there are two rod bipolar cells subtypes, rod bipolar 1 and rod bipolar 2 cells23,24. 
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Whether there are one or two kinds of rod bipolar cells, the remainder of the bipolar diversity in 
mammals exists within cone bipolars. There are two broad classifications of cone bipolars: ON 
or OFF. ON-bipolar cells send signals when their associated cones respond to light. OFF-
bipolars send their signals when the cones do not respond to light. This ability of cone bipolars to 
send signals through a positive as well as negative information channel has significant 
implications for downstream processing of information and the sorting of visual information into 
circuits. ON or OFF signals are sent through unique information channels that are spatially 
separated within the retina. I previously mentioned that the IPL is a laminated structure. It has 
distinct layers where dendrites of amacrines and ganglion cells synapse with the axons of bipolar 
cells. These layers are numbered one through five with layer one being closest to INL and five 
closests to the GLC. This lamination is integral to signal processing in ON and OFF bipolar cells.  
ON bipolar cells project their axons to layers four and five of the IPL, whereas OFF bipolars 
project to layers one and two. Rod bipolars also generally project their axons to layers four and 
five of the IPL. Some bipolar subtypes project to multiple layers as well as layer three where ON 
and OFF projections are both processed24–26. 
Integrating the signal passed from photoreceptors to bipolar cells are a group of 
interneurons called horizontal cells. These cells have their nuclei in the INL, but project dendritic 
processes into the OPL (Fig 1.2B-C). Horizontal cells are networked together through 
connexin57 gap junctions that allow signals to be transported and diffused across a network. 
They form unique triad synapses at the junction between photoreceptors and bipolar cells27–29. 
This network has been shown to feed back onto photoreceptors as well as feed forward onto 
bipolar cells depending on the nature of the signal. The signal transduction between 
photoreceptors, bipolars, and horizontals is reciprocal. Horizontal cells receive glutamatergic 
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input from photoreceptors and can then send negative or positive signals back onto the 
photoreceptors or onto their targeted bipolar cells30–34. The complexity of this network is poorly 
understood. However, if horizontal cells are deleted during development, the outer nuclear layer 
fails to pattern perfectly, and the loss of so-called triad synapses effects retinal function35–37. 
When horizontal cells were knocked out in a mature retina, the signals to ON-bipolar cells were 
impaired while OFF-bipolar signal were less effected, but the net retinal output appeared to 
largely compensate for this loss37. It is likely that horizontal cells play roles in specific neural 
networks within the retina, though their function and subtypes are not well understood at this 
time.   
Amacrine cells primarily function as inhibitory interneurons that alter and control the 
signal transduction between bipolar cells and ganglion cells (Fig 1.2B-C, E). They make up 
approximately 8% of the mouse retina but there are over 30 unique subtypes as defined by 
morphology alone38,39. There are three primary categories of amacrines by molecular markers: 
GABAergic amacrines that express GAD65/67 and are about 43% of amacrines, glycinergic 
amacrines that express GlyT1 but make up about 43%, and finally non-glycinergic, non-
GABAergic (nGnG) make up the remaining 15%40. However, each of these broad categories can 
project to all five laminae of the IPL. Additionally, there are numerous other molecular markers 
that span multiple morphological subtypes, including transcription factors like AP2a, EBF3, and 
BHLHB5, calcium binding proteins like calretinin and calbindin, and neurotransmission proteins 
including ChAT, TH, and vGlut330,40–45. The morphological and molecular diversity does not 
always align, with some types of morphological amacrines expressing divergent molecular 
expression patterns30,40–45. Taken together, the identification and classification of amacrine 
cellular subtypes within the retina is a critical undertaking and may be considered a preamble to 
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electrophysiological studies of circuit function. I discuss our efforts exploring amacrine subtype 
development and identification in Chapter II of this work. 
Retinal ganglion cells are the projection neurons of the retina (Fig 1.2B-C, E). They 
receive inputs from bipolar cells and target their axons to the brain, but they represent a 
functionally diverse group of neurons that are tiled across the retina. There are ganglion cells that 
send signals based on local motion, directional motion, as well as direct illumination46–49. Within 
the mouse, ganglion cells have been classified into at least 12 unique functional groups based on 
responses to light, but morphological studies show up to 20 unique subtypes (Fig 1.2F)50–54. It is 
unclear if morphology perfectly overlaps with function and how retinal ganglion cell subtypes 
are best identified55. While the responses to light and the morphology are one consideration, 
axon targeting is another. In mice, ganglion cells are known to target over 10 major areas of the 
brain and over 40 unique cellular population targets (Fig 1.2F)56,57. Further studies based 
physiological cell signals have shown there are up to 49 subtypes of ganglion cells including fast 
and slow firing ON and OFF signals as well as intermediate signals, and immense diversity 
within each subcategory55. Taken together, this suggests that information conveyed from the 
retina to the brain is massively sorted into unique processing channels. It also highlights the fact 
that the processing of visual information that occurs via retinal interneurons is likely integral to 
the proper function of the mammalian visual system.  
The final major cell type within the retina is the Müller glia. These supporting cells 
extend the width of the retina and are laid out in a mosaic pattern with extended radiating 
processes touching the surrounding cells. Müller glia are physically integrated into retinal 
structure, surrounding blood vessels and the extracellular clefts and touching every neuron in the 
retina58. Müller glia play a significant role in regulating metabolism, controlling neural functions, 
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and are involved in every form of retinal degeneration58–60. Additionally, Müller glia are 
important to light scattering in the retinal tissue, maintenance of structural integrity, and are 
involved in nearly every biochemical cycle of the retina58. Not only are Müller glia involved in 
almost every function of the retina, in non-mammalian species, they are the source of neural 
regeneration in response to damage61–63. Unlike other types of retinal cells, there do not appear to 
be subtypes of Müller glia. Each cell is arranged in a mosaic columnar fashion across the retina 
and does not overlap much, if at all, with the field of other Müller glia. They arrange themselves 
during development so that all retinal neurons, including photoreceptors, interneurons, and 
project neurons, are contacted by a Müller glia59.  
 
Functional Neural Circuits of the Retina 
 The seven major cell types and dozens of subtypes of neurons within the retina work in 
circuits to transform information about the presence of photons into meaningful computational 
visual information. As discussed, this results in ganglion cells projecting to 10 areas of the brain 
with over 40 targets receiving unique computationally relevant information (Fig 1.2F). Many of 
the circuits driving this output are poorly understood at this time because of barriers to studying 
them, like limited unique markers of interneuron subtypes. A thorough review of known retinal 
circuits is beyond the scope of this work (see Baden et al., 2018 to start)64. However, there are 
well studied circuits that are relevant to our understanding of retinal development, patterning, 




Physiological Patterns of Retinal Neural Circuits 
 A central feature of retinal physiology is that two sets of parallel neurons often respond in 
an opposite fashion to the same input signal. This creates parallel lanes of opposing signaling 
which broadly functions to reduce signaling noise and refine net circuit computational output64. 
Photoreceptors hyperpolarize in response to the presence of photons meaning that their 
glutamatergic output decreases when light is present, however, only one in three bipolar cells 
respond similarly64. Bipolar cells can process the same glutamatergic input with various levels or 
even an opposite response65–67. Mammalian OFF bipolar cells have ionotropic glutamate 
receptors and fire most when photoreceptors are not responding to light. ON bipolar cells express 
metabotropic glutamate receptors and their signaling increases in response to decreased 
photoreceptor output, when light is highest64,66,68.  
 These ON and OFF or dark and light signaling pathways are integrated in a complex 
fashion in the IPL based on the specific layer as previously mentioned. Amacrine cells may 
further mediate the signal from ON or OFF bipolar cells and incorporate the information into 
numerous circuits with ganglion cells. Some amacrines provide glycinergic inhibition to retinal 
ganglion cells while other provide glutamatergic excitation. By segregating dendritic arbors to 
different regions of the IPL, some amacrines perform both of these functions simultaneously69. 
In the context of a neural circuit, an excitatory signal may at times be inhibitory to the function 
of the circuit by creating excess noise or increasing a post-depolarization refractory period70. An 
inhibitory signal may actually provide increased probability of signaling by providing input 
synchrony69,71,72. The combination of ON and OFF currents with complex excitatory and 
inhibitory interactions create a multitude of potential retinal circuits. I previously mentioned the 
massive morphological and histological variance among amacrine cells and ganglion cell output. 
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It is likely that this emmense diversity integrates into fascinating, yet to be studied, neural 
circuits. 
 
Center-Surround Receptive Fields 
 One of the challenges in identifying a specific retinal circuit is there needs to be a testable 
visual input that results in consistent output from a specific set of neurons. Once you have 
identified a physiologically testable circuit, it is much easier to begin dissecting the roles of 
various interneurons on regulating the flow of information. One way the retina is known to 
leverage the ON and OFF currents is through the use of center-surround receptive fields (Fig 
1.2D). 
 There are two kinds of center-surround receptive fields. Imagine a light spot, surrounded 
by dark, or a dark spot surrounded by light. These two overlapping dots are center (dark or light) 
and surround (the opposite). There are bipolar cells that respond specifically to center-surround 
dots within their field of the retina. A given center-surround bipolar cell may hyperpolarize in 
response to a 1000µm laser dot with a dark circle enclosed, but depolarize in response to a 
200µm laser dot surrounded by a dark sphere in primate retinas (Fig 1.2D)73. Extensive 
additional studies have shown this mechanism to be critical to retinal ganglion cell processing 
across the retina and subtypes of ganglion cells have been identified that respond better as the 
center grows larger or grows smaller suggesting that one role for these circuits may be 
identifying when an object is approaching or receeding73–75. This fundamental ability for neurons 
within a region of the retina to process ON and OFF patterns can be combined into even more 




Starburst Amacrine Cells and Directional Selectivity 
 Directional selective neurons were first recorded in the visual cortex of cats and the 
Nobel Prize winning work was published in 195976. This work showed that certain neurons 
responded positively to an object moving in one direction across visual field and did not respond 
to the same object moving in other directions. Unique neurons are tuned to different spatial 
orientations. While these recordings were originally made in the cortex, evidence, starting with 
work in rabbits, showed that certain retinal ganglion cells exhibited this same directionally 
selective property77. Years of evidence eventually revealed that there are direct lines of 
communication from directionally selective ganglion cells, through the lateral geniculate 
nucleus, where information was further refined and sent directly on to the directionally selective 
neurons in the superficial layers of the visual cortex78.  
 For directionally selective information to be computed, both spatial and temporal 
information needs to be encoded and computed simultaneously within a neuron. A bright/dark 
difference will appear, passing over hundreds to millions of photoreceptors that send signals in 
sequence in response to the photons. Yet only a subset of photoreceptors are involved in 
directional selectivity and within a given region of the retina. There are directionally selective 
circuits tuned to each direction. How then are these complex computations computed within the 
retina?  
 At the heart of the directionally selective circuit is the Starburst Amacrine Cell, 
commonly called SACs. These unique amacrines are both cholinergic and GABAergic. SACs 
have their nuclei in either the INL or the GCL. They have large diffuse arbors of dendrites with 
processes in either ON or OFF layers of the IPL79. The function of SACs is incredibly complex 
and not fully understood (for a thorough review see Mauss et al 2017)79. However, the basic 
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mechanism is that when stimulated SACs produce inhibitory signals in their null direction and 
excitatory signals in the positive direction. Significant debate about the species-specific 
mechanisms exists. However, what is clear is that precise radial and laminar wiring of their 
dendrites within the IPL is absolutely critical to the function of directionally selective neurons79.  
  
Neural Circuits and the Developing Retina 
These two circuits encapsulate many of the challenges faced when attempting to 
understand retinal development. For directionally selective ganglion cells of center-surround 
circuits to function properly, the retina must give rise to all the major cell types. These neurons 
then need to migrate to the correct layer and laminate properly. But more than just types are 
needed, specific subtypes of bipolars, amacrines, and ganglion cells must form meaningful 
circuits by interconnecting their axons and dendritic arbors across the retina in a mosaic pattern, 
accurately express a suite a cell-cell signaling molecules and finally adjust and tune the circuit so 
that there is directional selectivity in every direction across the entire retina that functions in both 
high contrast and low contrast situations. In the case of directionally selective circuits, the 
ganglion cells must correctly target directionally selective interneurons in the lateral geniculate 
nucleus and convey information in a precise spatiotemporal way. This involves a subset of 
photoreceptors, one subtype of amacrine cell, a bipolar population, and one type of ganglion cell 
and thus represents only a fraction of information the retina is processing and encoding. 
Understanding the complex cascade of intrinsic developmental changes and extrinsic signaling 
mechanisms involved in developing such a complex circuit represents and monumental 
undertaking, yet it is required to uncover a complete picture of retinal development. In chapter II, 
I attempt to elucidate molecular markers for a subset of amacrine interneurons which likely 
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function in similarly complex yet to be studied retinal circuits. Loss of these neurons 
dysregulates the proper lamination of the IPL and likely results in meaningful changes in the 
function of specific retinal circuits. 
 
Patterns and Mechanisms of Neural Development 
 Development of the retina involves exit from the cell cycle (e.g. birthdate) of seven major 
cell types, specification into subtypes, maturation, correct migration of nuclei, lamination of 
dendrites and axons, and ultimately the formation of neural circuits (Fig 1.4)80. These processes 
take variable lengths of time depending on the species. The retina itself forms a mosaic tissue 
with circuits spread out in predictable yet stochastic patterns, like those observed in directionally 
selective circuits80. The general pattern in vertebrates is that there is more high acuity cone-rich 
tissue in the central retina, and more low light sensitive rod-rich tissue at the periphery, although 
across the whole retina rods outnumber cones 35:1 in mice80,81. The specifics of this can vary 
significantly by species from nocturnal creatures like mice and rats, to diurnal ones like humans. 
Yet, for cells to develop in any of these systems they must exit the cell cycle, make a fate choice, 
and mature into a functional neural circuit. Two dominant, non-exclusive models are used to 
describe the broad patterns of retinal development. 
 
Intrinsic and Stochastic Development Models 
 Foundational studies in retinal development showed that all the seven major cell types 
descend from a common progenitor pool82,83. A key finding of these and many other studies was 
that a given progenitor could, but does not always, give rise to each of the seven major cell 
types84. All cell types are not born at the same time. Certain types tend to be born early and other 
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cell types tend to be born late. At any given time in retinal development, progenitors appear to 
give rise to only a few types at a time81,83,85,86. These discoveries, along with many others, led to 
the competence model of retinal development. In this model, retinal progenitors pass through 
progressive states in which they are competent (able) to give rise to certain fates, but not others 
(Fig 1.3A-B)84. An early progenitor may decide between a ganglion cell and a cone, while a later 
progenitor may decide between a bipolar cell and a rod photoreceptor. The model is considered 
progressive, because late progenitors will not give rise to early cell types, and early progenitors 
generally do not give rise to late cell types, even when transplanted into different molecular 
contexts82–84. However, a given progenitor when fate tracked may first give rise to early cell 
fates, then middle cell fates, and finally late cell fates82–84. Indeed, numerous studies showed that 
cell fates appear to arise from specific competence windows, which change across 
developmental time (Fig 1.3A-B)87–89. Additionally, these windows of development do not 
appear to be regulated by extrinsic signaling but by changes in the internal environment of the 
progenitor90–94.  
The competence model states that retinal progenitors pass through progressive phases 
regulated by their intrinsic environment where they are competent to give rise to certain cells 
types but not others (Fig 1.3A-B). This model successfully defines the many of the phenomenon 
observed in lower vertebrates retinal development, like Xenopus laevis95. However, it does not 
fully explain retinal development in higher vertebrates like mice, rats, and humans. Why do 
some progenitors produce large lineages while others do not? Why do some progenitors give rise 
to predominantly early or predominantly late fates while others produce fates across all of 
developmental time? Why do some lineages occasionally produce late cell types before early 
ones96? A stochastic model of retinal development implies that there is a degree of 
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unpredictability at each decision point for a given progenitor cell. If a stochastic model of 
development were true, then patterns like whether a progenitor gives rise to two progenitors, a 
progenitor and a neuron, or two neurons would be unpredictable at each specific choice point, 
but on average fates would match the total cell number needed in the retina (Fig 1.3C-F). An 
additional aspect of a stochastic model is that it would predict the probability of a progenitor 
giving rise to a specific type of cell as directly correlated with the final percentage of that cell in 
the retina (Fig 1.3C-F). For example, rods make up ~78% of the mouse retina, and thus a 
dividing progenitor would have an 78% chance of generating a rod and this probability would 
increase toward the end of retinal development as other early born cell types, like ganglion cells 
and cones, were no longer generated96,97. The stochastic model of development is far better at 
explaining specific phenomenon in higher vertebrate retinal develop but may not be enough to 
explain all developmental patterns. 
Evidence suggests that both the intrinsic model of development and the stochastic model 
of development may be at play within mammalian systems and these two ways of approaching 
retinal development are non-exclusive (Fig 1.3). However, mechanisms by which either of these 
models’ function are not fully understood at this time. Indeed, what defines a progenitor 
competence state and how a decision is made from that competence window or why a given 
progeny will permanently exit the cell cycle while another remains in progenitor form are not 
well understood. Within this work I specifically explore the regulation of amacrine, bipolar, and 
rod cell fate determination at multiple competence windows. I am also able to disrupt a 
competence state and dysregulate cell fate leading to an increased understanding of the role of 




Mechanisms Underlying Retinal Developmental Models 
 The choice for a cell to remain a progenitor or exit the cell cycle and become a specific 
neuron is actively regulated by a variety of transcription factors (Fig 1.4C)98. During 
development, all cells go through a series of changes in gene expression and thus pass through 
different intrinsic cellular environments. The fate and maturation of the cell depends on 
transcription factors binding to specific regions of DNA and activating or repressing genes. The 
ability of an individual transcription factor to bind a given region of DNA depends on the 
ultrastructure of the chromatin. Chromatin can be open with reading frames readily accessible for 
transcription, or tightly wound around nucleosomes that prohibit access from the machinery 
necessary to transcribe it into mRNA. Regulators, like transcription factors, can cause the DNA 
to be more tightly wound and block transcription or less tightly wound allowing for transcription. 
However, unwound DNA where a specific gene exists within an open reading frame does not 
guarantee that the gene will be transcribed. Transcriptional regulators also affect the ability of 
transcriptional machinery to bind a specific gene. Thus, transcription factors are involved 
transcription of individual genes as well as epigenetic control of a cell’s state.  
These developmental paradigms are iterative. Tightly wound or open chromatin responds 
to the presences of specific transcriptional regulators, which are also able to drive production of 
different transcription factors. These new factors will then further alter the genes that are being 
transcribed, which in turn may wind specific regions of chromatin tight while other previously 
closed regions are now accessible for transcription. Understanding the state of a given cell, 
especially a developing one, is not as simple as knowing what mRNA or proteins are present. 
There may be robust production of an mRNA at the same time the gene is never translated into 
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protein because of post-translational modification. These complex processes make unpacking the 
specific means by which a cell develops extremely challenging. 
In this section I attempt to provide a broad picture of the identified roles of some 
transcriptional regulators of retinal development. The complexity of cell fate regulation and the 
multifaceted intrinsic landscape of a developing cell make the generation of a complete picture 
challenging. However, to identify the role of a given transcription factor in development there 
are some steps that can develop clarity. First, we can ask what happens to cell fate when a 
transcription factor is lost? Second, we can ask how cell fate changes if there is excess of a 
specific transcription factor during different developmental time frames? We can look for places 
that the factor binds and attempt to understand if it is acting as a driver of cell fate or through 
inhibition of gene expression. We may also ask questions about what regulates the expression of 
a given transcription factor as well as what genes that factor may be acting on. Putting these 
pieces together into a holistic picture of cell fate regulation, even within a limited temporal 
window, remains an incredible challenge. The dominant evidence in the field suggests that the 
majority of retinal cell fates and the shift in cell competence is largely regulated by intrinsic gene 
regulation. Thus, to advance our understanding of retinal development, we must refine our 
understanding of intrinsic transcriptional regulation of cell fate. 
 
The Roles of Transcription Factors in Developing Neurons 
 During development, a common pool of retinal progenitor cells give rise to all major 
subtypes, including rod and cone photoreceptors, bipolar, amacrine, and horizontal interneurons, 
ganglion projection neurons, and Müller glia82. As previously stated, a single retinal progenitor is 
capable of generating all the major cell types. However, the generation of this diversity does not 
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occur simultaneously, rather cell types are born in a stereotyped overlapping fashion with some 
cells like cones and ganglion cells born early, and others like bipolars are born late99. If the 
intrinsic progressive competence model is correct, how does it function84,99,100?  
Transcription factors are proteins that are involved in gene expression. There are a wide 
variety of transcription factors, but most function by binding a specific consensus sequence of 
DNA that is often 4-8 base pairs (bp) long, though this length can vary. Once bound to a 
consensus sequence, transcription factors will either work as an activator, promoting the binding 
of RNA polymerase to drive expression, or as a repressor, blocking the same suite of proteins84. 
Many transcription factors can act as activators or repressors, depending on the specific cellular 
context and even the site they are binding. They can do this by directly stabilizing or blocking 
the action of RNA polymerase, recruiting coactivators or corepressors, or through changing the 
chromatin accessibility by driving acetylation or deacetylation of histones101,102. Often a given 
transcription factor may be playing multiple roles in a cell at the same time and distinguishing 
their function(s) can be challenging. Added to this complexity is the fact that not all transcription 
factors function in the same way across vertebrate development. To limit the background to the 
model species I use, throughout the remainder of this section, unless specified, all studies refer to 
transcriptionally regulated developmental paradigms in mice. Next, I discuss several major 
classes of transcription factor and highlight the diverse functions in murine development.  
 
bHLH Transcription Factors in the Developing Retina 
Basic Helix-Loop-Helix (bHLH) transcription factors function throughout retinal 
development and play critical roles in patterning of the eye and driving specific cell fates103. The 
name basic helix-loop-helix refers to an approximately 60 amino acid protein structural motif 
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where two alpha-helices are connected via a loop. They are formed from dimeric helix domains 
that may not be the same size and diversity in region gives bHLH proteins a massive range of 
functions. However, they all bind to a specific consensus sequence referred to as an E-Box, 
though the nature of this sequence can vary depending on the specific protein104. Not only can 
bHLHs form homodimers, but they have been shown to also form heterodimers, leading to an 
immense array of functions that a given bHLH can perform, even within a single cellular 
context104. The dimer controls where the bHLH binds and the strength of the bond, however, the 
remainder of the protein can have an array of functions in transcriptional regulation including 
driving and inhibiting transcription. 
BHLHs have been implicated in numerous cell-fate determining roles in the retina. 
Mash1 (Ascl1) deletion causes a delay in bipolar cell differentiation and Math3 (Neurod4) seems 
to promote rod fates, but simultaneous deletion of both genes disrupts bipolar cell 
formation105,106. Almost all amacrine and horizontal interneurons require the expression of the 
bHLH Ptf1a and I discuss this gene in more detail later107,108. These genes are critical to 
controlling cell type formation, but bHLHs may also govern the development of specific 
subtypes, for example Bhlhb5, mentioned above regulating bipolar cells, is also required for 
GABAergic amacrines, and in its absence they fate shift to glycinergic amacrines42. While 
photoreceptor fates are predominately controlled by homeobox domain and zinc-finger 
transcription factors, some bHLHs including NeuroD, Mash1 have been implicated in 




PRDM Zinc-Finger Transcription Factors in the Developing Retina 
  The Prdm family of genes are the source of significant interest across multiple 
disciplines. The proteins are characterized by a PR domain at the N-terminus and a variable 
number of so-called zinc-finger binding motifs in the middle110–112. PRDMs may function in 
unique ways depending on the cofactors present at the time113–116. While there is some evolution, 
the genes have been shown to be fairly conserved across invertebrate and vertebrate species117.  
 PRDMs were independently discovered in various systems and have been implicated in 
extremely diverse roles including involvement in B cell lymphoma, tumor suppression, 
leukemia, breast cancer, and many other cancers112,118–120. PRDMs work through a variety of 
mechanisms to control DNA transcription. When bound to a consensus sequence they may 
recruit histone acetylases, acetyltransferases, or methyltransferases as well as factors associated 
with direct transcriptional activation121. These actions may be brought about by direction of from 
the PR domain or through recruiting associated epigenetic enzymes122,123.  
Within developing systems, Prdm1 has been implicated in numerous roles including, but 
not limited to enterocytes of developing milk-dependent mice, B and T cell function, primordial 
germ cell development, patterning of the heart, and proper skin development112,124–126. Of 
significant interest to us is the critical role PRDM1 plays in stabilizing photoreceptor identity 
within the retina though its mode of action is not fully understood127,128. Prdm13 is known to 
function in the human retina in North Carolina Macular Dystrophy129. I explore the roles of both 
PRDM1 and PRDM13 in more detail later.   
In summary, PRDMs are capable of playing an enormous variety of roles within a 
developing system, possibly executing multiple actions at the same time. A single PRDM could 
theoretically inhibit one segment of DNA, drive histone acetylation on another portion of the 
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genome, and attract cofactors that perform deacetylation on still another set of histones all at the 
same time in the same cell. The ability of these transcription factors to interact with numerous 
co-factors to perform various complex tasks creates a significant challenge in understanding their 
role in the developing retina. However, when broadly generalized, PRDMs act to inhibit a 
specific cellular function or cell fate, not necessarily to instruct a fate choice in many cellular 
contexts97,112,127,130,131.  
  
Homeobox Domain Transcription Factors in the Developing Retina 
 Homeobox transcription factors contain a common 60 amino acid DNA binding sequence 
called a homeobox which canonically binds TAAT/ATTA motifs132. However, homeobox 
domain transcription factors can bind a variety of sequences and the presence of various 
additional domains within the protein may have a significant impact on the precise targeting133. 
Of all transcription factor families, homeobox domains may play the single largest role in 
patterning, shifting progenitor competence, and driving specific cell fates in the retina. 
Numerous homeobox domain transcription factors have been implemented in so many functions 
that I will not review them all here (see Holland 2013 and Zagozewski et al, 2014) (Fig 1.4)134. 
 Otx2 is at the center of a major gene regulatory network studied within this work and 
discussed in significant detail elsewhere. To summarize, early in mouse development OTX2 is a 
critical regulator of early neural development and patterning of head structures135. It is turned on 
again around embryonic day (E) 11.5 in the RPE and developing neural progenitor cells and its 
expression increases across neural development and is necessary for proper formation of the 
RPE136–138. Loss of Otx2 results in a complete loss of bipolar and photoreceptor fates and a 
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switch to amacrine fates, making Otx2 a critical regulator of cell competence in retinal 
progenitor cells138,139. 
 Like Otx2, Pax6 is expressed in the RPE and the neural epithelium of the developing 
retina140. Interestingly, in the absence of Pax6, retinal progenitors lose their competence and 
produce only amacrines, yet Pax6 is required in mature amacrine cells and remains on in them 
into adulthood141. Not only is Pax6 involved in progenitors and amacrines, but it plays divergent 
roles within the central and peripheral retina. Central retinal progenitors do not require PAX6 to 
specify their fates, but peripheral progenitors do142. The reasons for this differential regulation of 
cell fate are not understood.   
 Vsx2 is a complex homeodomain protein involved in numerous functions across several 
systems143–145. Like Pax6 and Otx2, Vsx2 appears to have multiple roles across retinal 
development. It is turned on as early as E9.5 and in its absence only a small neural retina 
forms146–148. Late in retinal development, progenitor VSX2 expression decreases, however as I 
discuss in more detail later, it is necessary for bipolar formation and in its absence bipolar cells 
are not formed148–150.  
Many transcription factors function like Pax6, Otx2, and Vsx2, with one role early and 
another role late, and at times even a third or fourth temporally linked role in retinal development 
and maturation. Since transcription factors have a limited and specific binding sequence there are 
two plausible explanations for why they drive different cell responses at different times. The 
associated binding proteins may change within the retina. In this scenario, a transcription factor 
that used to bind and activator now binds a repressor and thus reverses its function. Perhaps more 
common is that the epigenetic state shifts as cells progress through competence states. These 
changes in accessible chromatin allow transcription factors to bind to different enhancers or 
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promoters and thereby the same transcriptional regulator can have a novel or even contradictory 
function as a cell changes its fate. A perfect example of this mentioned above is that deletion of 
Pax6 early results in excess amacrines, yet Pax6 is on in all mature amacrine cells134. This 
suggests that PAX6 prevents amacrine formation early yet contributes to it later. How 
transcription factors play contradictory roles like this in development is not completely 
understood. What is clear is that the presence of a specific transcription factor alone is not 
sufficient to explain cell fate in the developing retina.  
 
Cis-regulatory Elements are Vital to Retinal Function  
 Cis-regulatory elements are non-coding DNA regions that control the transcription of 
DNA151. There are a wide variety of cis-regulatory elements including promotors, enhancers, 
silencers, and operators. Each plays a unique role by recruiting a set of transcription factors 
which may then drive or inhibit expression of a given gene. Nearly all cis-regulatory elements 
are acted upon by more than one transcriptional regulator and many may be hundreds or even 
thousands of base pairs away from the gene they are acting on152. The distance does not inhibit 
activity, because when bound by the appropriate transcription factors, the DNA may be looped to 
bring long distance regions close together, thus aiding in the initiation or inhibition of 
transcription153,154. Cis-regulatory elements are thought to be one of the primary mechanisms of 
species evolution155–158. However, they can also play a major role in human disease 
pathogenesis159. For example, a 6,523-bp deletion of a cis-regulatory region, 20-kb upstream of 
the gene ATOH7 (MATH5), causes congenital retinal nonattachment and blindness from birth160. 
This loss of a single distal enhancer bit is sufficient to cause a major developmental disorder 
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specific to the retina, highlighting the critical nature of cis-regulatory elements in controlling 
development. 
 
Promotors Are Highly Conserved 
 Every known gene that is expressed in eukaryotes has at least one, and occasionally more 
than one promotor which is located proximal to the site of transcriptional initiation but may be 
located before or in the middle of a gene153. Compared to the diversity of elements like 
enhancers, promotor sequences, like TATA boxes, are relatively conserved throughout the 
genome153–155. This makes them excellent at their job which is to coordinate with the conserved 
initiation machinery involved in transcription. Indeed, it may be that they are evolutionarily 
conserved because of the need to properly bind to limited transcriptional machinery153–155. Since 
thousands of genes within an organism may contain similar promotor sequences, these make 
poor regulatory elements. Additionally, significant evidence suggests that in most cases, 
sustained promotor activity requires the aid of additional transcription factors that bind DNA 
distally to maintain transcription153–155.  
 
Cell Type-Specific Enhancers  
 Unlike promotors which are relatively consistent in their location near a gene and their 
sequence, enhancers are a complex group of cis-regulatory elements that may be upstream, 
downstream, or in the introns of a given gene. Enhancers may have a broad function and act on a 




 Enhancers may be tens-of-thousands of base pairs away from the gene they act on. This 
makes identification challenging. However, the general method is to utilize computational 
approaches to identify conserved regions of open chromatin, and significant datasets already 
exist with predicted enhancer regions163–165. After a region is identified, further computational 
work can predict candidate binding sites. These can then be tested in vivo using a reporter 
assay166,167. Reporter assays can only show the sufficiency of an enhancer, but not its necessity. 
To demonstrate necessity, the enhancer must be removed, and the expression of the gene 
changed as a result.  
 An additional challenge exists in predicting which transcription factors bind to a specific 
enhancer. A given enhancer region may have several to dozens of consensus binding sites. Each 
one may be capable of binding a wide range of transcription factors. Additionally, it is likely that 
many enhancers work by the combinatorial action of several transcription factors 
simultaneously155. Immunoprecipitation of a given enhancer, followed by protein extraction and 
mass spectrometry or quantitative assessment on a microarray may provide insights into the 
bound transcription factors, but these assays are complex, time consuming, and have numerous 
technical limitations168–170.  
 Despite the technical constraints, understanding the interactions between enhancer 
regions and the transcription factors that bind them is critical to understanding developmental 
process. Indeed, the action of specific transcription factors on cell type-specific enhancers is one 
of the single most important elements in understanding intrinsic mechanisms of cell fate in 




Extrinsic Signaling Mechanisms in the Developing Retina  
 Extensive evidence compiled over years suggests that the development of the neural 
retina is dominated by intrinsic mechanisms of cell fate84. However, these mechanisms are 
insufficient to explain all the behaviors of cells within the tissue. For example, the formation of 
directionally selective circuits has been shown to involve SAC arbors specifically dispersing 
without interfering with proximal SACs79. A second example is the mosaic dispersion of Müller 
glia across the retina where each separate cell integrates columnarly within the tissue and does 
not interfere with adjacent cells58. These patterns indicate that cells are able to communicate 
during development. Indeed, the mosaicism that is a dominate characteristic of the retina itself 
suggest that cells are communicating in some fashion to arrange themselves appropriately 
throughout the developmental paradigm. Additionally, some external signaling mechanism must 
be present for cells to appropriately laminate and stratify.  
 It is possible that most of development is driven by intrinsic mechanisms of cell fate, but 
once fate is determined, cells utilize cell-cell signaling for alignment and circuit formation. 
Several extrinsic signaling mechanisms are known to play roles in early patterning of the retina, 
including WNT, Notch, and SHH.   
 Notch signaling plays a critical role in retinal development by maintaining progenitor like 
identity171–173. Suppression of notch signaling by the γ-secretase inhibitor DAPT has been shown 
to force cells out of their progenitor state and adopt neural fates within the retina173. As 
previously mentioned, Notch is required to properly maintain expression of HES1 and HES5 
which in turn maintain progenitor identity, though the mechanisms are not fully understood.  
 WNT and SHH signaling have been implicated in early formation of the eye cup174,175. In 
the absence of WNT the eye cup of zebrafish fails to form properly, but ectopic expression of 
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WNT11 results in abnormally large eyes174,176. WNT signaling also plays critical roles across 
vertebrate species in defining the lens, separating RPE from neural tissue, maintaining dorso-
ventral patterning, and proper retinal vascularization177,178.  
One role of SHH signaling is in the formation, propagation, and axon guidance of 
ganglion cells. Newborn ganglion cells will produce SHH early in retinal development and are 
the major stable source of SHH in the early retina179. In a complex feedback loop, mammalian 
SHH, produced by retinal ganglion cells, prevents progenitors from exiting the cell cycle, and 
blocking SHH early results in excess ganglion cells, the primary source of SHH in the retina180. 
Added to the multifaceted role in ganglion cells is how SHH interacts with axon guidance. 
Axons of the ganglion cells that are producing SHH proceed away from the high source and 
towards a low level of SHH located through the optic disc and at the ventral midline of the 
diencephalon181,182. Misregulation of SHH levels in the retina results in disorganized ganglion 
cell axon guidance and viral mediated overexpression of SHH at the optic chiasm restricts 
ganglion cell axon guidence183–186. How these cells are capable of creating a gradient that they 
also respond to is not well understood.  
 While WNT and SHH play roles in the early patterning and Notch maintains progenitor 
identity, few other mechanisms have been well elucidated within the field. The predominant 
theory remains that once the neural retina is established, intrinsic mechanisms of fate 
specification are the driving force84.  
 
Putting the Retina Together 
One simile for retinal development patterns is to think of transcription factors as tools. 
Each can perform a variety of functions, like a hammer, but they also perform specific functions. 
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You cannot use a hammer to drill a hole, but there are a variety of tasks you can use a hammer 
for at different stages of a construction project. Each stage of a developing cell may be somewhat 
like a construction site. It is roughly the same cell, but after a week of progress the nails you 
could hit last week are no longer accessible while a whole new set of nails are extant. In this 
analogy, cell type-specific enhancers represent the ability to bring out the correct tool in the 
correct context. Like a building that is under construction, cells are in a constant state of flux 
during development. Genes are upregulated and inhibited, this results in remapping of the 
chromatin structure, opening of certain regions, closing and tightly winding other regions, all 
while the cell may be migrating, dividing, or communicating to adjacent cells. These complex 
waves of interaction mean that the development of any tissue may pass through hundreds or even 
thousands of checkpoints in which the loss of a single transcription factor could disrupt the 
process. Because transcription factors are so multi-functional and because their expression is also 
driven by transcription factors, it is critical that developing tissue be able to precisely regulate 
expression of the regulatory proteins. To assemble a retina, each cell must properly manage the 
expression patterns of unique genes, assemble the cellular structure, organize and reorganize 
chromatin, signal associated neurons, and integrate into a fully formed visual tissue. 
  
Early Patterning of the Developing Retina 
 Before developing the complexity of the final retina, the developing embryo sets the 
rough pattern and gives rise to the progenitors which will eventually generate the ocular tissue. 
The inner layer of the optic cup transitions into the group of neural retinal progenitor cells that 
will give rise to all seven major types of retina cells by E10.5 in mice. The first visible formation 
of the eye occurs around E8 in mice when optic pits begin to form187. Over the course of the next 
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couple of days the expression of critical transcription factors pass through a series of steps to 
establish an eye field and ultimately an optic vesicle (Fig 1.4)187–189. This process involves both 
WNT and SHH signaling, as well as an array of transcription factors, including OTX2, PAX6, 
and VSX2, all critical regulators in early and late retinal development (Fig 1.4A). Loss of any of 
these three early will disrupt proper retinal formation187. The optic vesicle will expand outward 
till it impacts the surface ectoderm. Once there the vesicle will begin to invaginate, bringing with 
it the surface ectoderm and forming two nested cups. One of which will become the neural retina 
and the other the RPE. The surface ectoderm will form the lens, as well as other ocular tissue 
including the cornea. Significant crosstalk likely exists between each portion of this tissue and 
loss of any layer of this tissue results in a failure to properly form an eye (Fig 1.4B)187,190,191.  
The remainder of this work will explore events occurring after the patterning of the eye 
and development of the neural retina has occurred. I investigate the processes that drive this 




OTX2, VSX2, and PRDM13 in Developmental and Degenerative Retinal Diseases 
 I have briefly discussed the evolution of vision, explored the structure and function of the 
retina, and highlighted the major processes that govern retinal development, including the role of 
transcription factors in driving specific cell fates as well as neural patterning. Before delving into 
the regulation and function of specific transcription factors in a particular developmental context, 
I wanted to underscore the known roles of several genes studied here in human-specific disease 
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states. Otx2, Vsx2, and Prdm13 have been specifically implicated in human developmental 
disorders or retinal degenerative diseases.  
 
The Transcription Factor OTX2 can Cause Developmental and Degenerative Retinal Diseases 
 The homeobox domain transcription factor OTX2 is critical for retinal development138. 
Otx2 is involved throughout the process of initial patterning of the retina, through retinal 
neurogenesis, and remains on in mature photoreceptors and bipolar interneurons127,192,193. Loss-
of-function mutations in the OTX2 gene cause developmental alterations including anophthalmia, 
microphthalmia, and degradation of the optic nerve194–196. Certain OTX2 mutations have been 
associated with Leber congenital amaurosis, a progressive photoreceptor degenerative disease197.  
 
The Transcription Factor VSX2 is Associated with Microphthalmia  
 VSX2 is a transcription factor that plays a central role in the development of retinal 
progenitor cells, which ultimately give rise to all neural tissue within the retina. Loss of function 
in VSX2 can result in mild to severe microphthalmia as well as severe coloboma (holes in ocular 
tissues, like the retina and iris)149,198–202. At this time, there are no known retinal degenerative 
diseases associated with VSX2, but all published phenotypes for mutations in this gene in humans 
have severe degradation of the ocular tissue and generally little to no visual function.  
 
PRDM13 is Implicated in North Carolina Macular Dystrophy  
 The central portion of the human retina is called the macula. There is a high density of 
photoreceptors, and especially cones within this region, which is responsible for human high 
acuity vision203. Since the primary source of functional visual information in humans arises from 
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the macular region of the retina macular dystrophy or degeneration is considered a debilitating 
disease state. In macular dystrophy the central portion of the retina begins to degrade, 
photoreceptors die, and visual function is permanently lost204.  
 North Carolina Macular Dystrophy (OMIM-136550) is a rare form of the disease, named 
for the location where it was first characterized205. The disease is an autosomal dominant 
disorder and has variable phenotypes. Unlike many other forms of macular dystrophy, North 
Carolina Macular Dystrophy is generally not progressive and is thus likely a developmental 
disorder.  
 The zinc-finger transcription factor PR Domain Zinc Finger Protein 13 (Prdm13) has 
been implicated in a large subset of North Carolina Macular dystrophy patients129. Within these 
patients, 14 distinct variants along a single allele resulting in five distinct mutations of the 
Prdm13 gene129. These mutations resulted in failure to properly maintain the macular region of 
the retina and cause lifelong visual deficits.  
 
Prdm13 and Amacrine Cell Formation  
Cellular diversity within the retina, and indeed all neural tissues, can be approached from 
three broad categories of classification: 1) cellular morphology, 2) molecular markers, and 3) 
neural circuits. In most cases, these three categories will broadly harmonize to identify specific 
subtypes of neurons. However, it is not always possible to collate techniques in these disciplines 
together. If a cell subtype cannot be clearly labeled by a molecular marker that corresponds to a 
specific morphology, identifying that cell’s role within neural circuits is challenging. Indeed, one 
of the major advances required to improve our understanding of retinal development and 




Challenges in Defining Amacrine Subtypes 
Amacrine interneurons are one of the most diverse and least defined groups of cells 
within the retina. As mentioned previously, amacrine nuclei are located in the INL or GCL and 
they project dendritic arbors in the IPL where they are involved in mitigating the signals passing 
from bipolar cells to ganglion cells. There are numerous morphological and histological markers 
of amacrines but identifying the specific molecular markers and developmental history of 
subtypes has remained challenging38–40,206,207. Here I define a subtype of amacrine cells as a 
group that are characterized by a specific morphology including dendritic arborization and 
function within an explicit neural circuit30,40–42,44,45,208,209.  
All mature amacrines are marked by the transcription factor PAX6, but many share a 
variety of other markers. A given amacrine might express both GLYT1 and AP2a, while the next 
cell is only marked by AP2a210. Further, just because a cell expresses common markers, say 
AP2a/GLYT1, does not mean it is morphologically or functionally homogenous with other 
similarly labeled cells. As a consequence of this incredible cellular diversity, studying specific 
amacrine subtypes is problematic. To advance our understanding of retinal circuits, the unique 
subtypes of amacrine cells need to be identified by a specific group of molecular markers that 
allow the cells to be labeled, tracked, and their population segregated for physiological studies.  
 
Patterns of Amacrine Cell Formation and Transcriptional Regulation 
Amacrine cells in mice are born from E12.5 through P2 with the majority being born 
embryonically, peaking around E16.585,211,212. The transcription factors FOXN4 and RORB work 
in concert to turn on PTF1a, and these cells are then lineage committed to amacrine or horizontal 
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cell fates107,108,213. PTF1a+ cells may then turn on Prox1 and go on to become horizontal cells214. 
The mechanisms by which they remain amacrine cells are not fully understood, though all 
mature amacrines express PAX6.  
There is temporal patterning to amacrine subtype formation. Extensive birthdating 
experiments have shown that GABAergic amacrines tend to birthdate early, while glycinergic 
amacrines are late-born212. Even when amacrine cells were disassociated from their tissue 
context and raised in culture, they tended to express transcription factors that matched their 
birthdate, suggesting that there were intrinsic mechanisms of subtype-specification present in 
cells upon cell-cycle exit212. This led us to ask, how do PTF1a+ cells choose between becoming 
an amacrine or horizontal cell? Additionally, what intrinsic forces cause early born cells to form 
some amacrine subtypes while late born amacrines choose other subtypes? If it is driven by cell 
birthdate, how is that tied to the intrinsic environment of a neuron and what is it about that 
internal transcriptional environment that drives an amacrine toward a specific subtype? Finally, 
can we utilize an improved understanding of amacrine subtype formation to generate identifiable 
subpopulations of amacrine cells and thereby study their role in retinal circuits?  
While it has been shown that amacrine subtypes correlate with their birthdate, there are a 
number of transcription factors that are implicated in playing diverse roles in type and subtype 
formation42,44,212. There are factors that set primary type-fate, like Ptf1a. Loss of these results in a 
failure to form any amacrine cells. Others are intermediate, like Islet1, loss of these factors 
causes a subset of amacrines to not form or die during development, decreasing total amacrine 
numbers215. Still other factors appear to promote specific subtypes; loss of Neurod6 causes a 
subtype fate-shift, but there is no change in the total number of amacrines40. This argues that fate 
choice is progressive, where PTF1a+ cells first adopt amacrine/horizontal identity before 
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becoming further restricted to a type and then particular subtype identity. The finding that cells 
will go through these processes in culture, suggests that amacrine neurons may be predisposed at 
cell-cycle exit to follow a particular specification pathway. The means by which such 
mechanisms of intrinsic fate specification work are not well understood. 
 
Ptf1a and Prdm13 in the Developing Retina 
PTF1a is the prerequisite transcriptional regulator of horizontal and amacrine cells108. 
Mice that lack Ptf1a die at birth and essentially lack horizontal and amacrine cells108. During 
development, Ptf1a will come on in nascent horizontals and amacrines and then turn off after a 
short period of time. This suggests that it may play some role in activating particular cellular 
machinery and that once active these mechanisms repress Ptf1a. To better understand the 
temporal and spatial mechanisms that diversify the PTF1a+ precursor population, I looked for 
factors that act downstream of PTF1a.  
The zinc finger transcription factor Prdm13 is genetically downstream of Ptf1a in the 
mouse spinal cord and retina216. PTF1a directly activates Prdm13, which acts as a transcriptional 
repressor to promote inhibitory interneuron identity at the expense of excitatory fates216. In the 
developing spinal cord, the primary function of PRDM13 appears to be inhibitory. Additionally, 
PRDM13 acts in a co-repressive manner, collaborating with associated transcriptional regulators 
to control cell fate217. In particular, PRDM13 interacts with bHLH factors like PTF1a in the 
developing spinal cord to convert transcriptional activators into repressors, helping to silence 
competing gene expression programs in bistable precursors217. Evidence suggests that PRDM13 
is involved in retinal amacrine cells during development218. Taken together with data from the 
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spinal cord, I suspected that PRDM13 may be acting downstream of PTF1a within the retina to 
set interneuron subtypes and potentially label a subpopulation.  
Here, I explored the expression pattern and developmental role of PRDM13 in the retina 
utilizing a combination of antibodies, Prdm13-GFP knock-in mice, and a hypomorphic version 
of Prdm13 (Prdm13-∆115)217. I set out to ask a variety of questions, first I wanted to explore the 
expression pattern of PRDM13 during development and if it remains on into adulthood. Second, 
I asked what role PRDM13 plays in developing and mature interneurons of the mouse retina. 
What population of cells does PRDM13 effect and is it a necessary cell type-specific enhancer? 
Without PRDM13, do these cells fail to form, do they die off, or do they fate shift to alternative 
identities? Ultimately, I attempted to further unpack the processes of interneuron fate 
specification in the developing murine retina (Chapter II). 
 
Otx2, Prdm1, and Vsx2 Control Bipolar and Rod Fates in the Developing Retina 
One of the fundamental questions in development is how progenitor cells give rise to the 
incredible variety of cell types found in the central nervous system. A pool of retinal progenitor 
cells generate all of the primary cell fates within the retina (Fig 1.4C). However, as I have 
discussed, these fates do not arise at the same time. Certain cell types like ganglion cells are born 
early, and others are born late. In the first portion of this work I focus on the role of Prdm13 in 
amacrine subtype formation. Next, I explore the roles a gene regulatory network that occurs late 
in retinal development during the postnatal period when progenitors primarily give rise to rod 
photoreceptors or bipolar interneurons81–83,85,219,220. 
There are three cell types that are predominantly born postnatally in mice; rods, bipolars, 
and Müller glia. Some amacrine subtypes are also born postnatally, but these are a small portion 
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of the cells. As discussed previously, a dominant theory is that cells pass through stages of 
progressive competence and this competence is regulated by the presence of specific 
transcription factors84,97,100,127,221–224. How transcription factors control cell competence and drive 
specific cell fates is only partially understood.  
 
OTX2 is a Key Regulator of Cell Fate Competence in the Retina 
A key regulator within late retinal development is the transcription factor Otx2. In early 
development, Otx2 is necessary for patterning of the eye, and its loss results in major structural 
defects225. If Otx2 is conditionally knocked out in the retina after initial eye patterning is 
established, rods and bipolars fail to form and instead supernumerary amacrine cells are 
produced138,139,226. Otx2 remains on in all mature photoreceptors and bipolar cells and significant 
evidence shows it is a critical regulator of progenitors’ competence to form bipolar cells or 
photoreceptors130,138,227,228. OTX2 is turned on in the majority of late born progenitors as they 
exit the cell cycle (Fig 1.5)229. It will remain on in cells that go onto become bipolars or rods, but 
may be transiently active and then turned off in nascent amacrine cells (Fig 1.5)230. OTX2 is so 
prevalent in late born post-mitotic cells that it is not clear at this time if it comes on in all of them 
for at least a short period of time, or only a dominant subset. 
PRDM1 and VSX2 work downstream of OTX2 in a gene regulatory network that 
governs rod photoreceptor and bipolar interneuron fates (Fig 1.5). In the absence of PRDM1, 
OTX2+ cells precociously upregulate Vsx2 and excess bipolar cells are generated at the expense 
of photoreceptors. Indeed, the conditional loss of PRDM1 in postnatal nascent photoreceptors 
that have already turned on rod-specific markers, results in a transdifferentiation of developing 
rods into VSX2+ bipolar interneurons127,128,231.  PRDM1 overexpression results in the opposite 
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effect, with a decrease in VSX2+ bipolar cells (Fig 1.5)128,231. Zinc-finger transcription factors, 
like PRDM1, primarily work in concert with other transcriptional elements to inhibit the 
expression of specific genes, though PRDM1 has been shown to have both repressive and 
activating activity112. Taken together with previous studies, it is possible that PRDM1 is not 
instructing photoreceptor fates, but instead inhibiting bipolar fates, though the mechanisms of 
PRDM1 action in the retina are not well understood at this time.  
VSX2 works in opposition to PRDM1 and drives bipolar fates. Like Otx2, Vsx2 is 
necessary for early retinal development and its deletion results in microphthalmia and a small 
neural retina. However, if Vsx2 is knocked down later in development, the retina fails to generate 
bipolar cells. Indeed, significant evidence suggests that no bipolar cells will form in the absence 
of VSX2 (Fig 1.5)148–150,232. While VSX2 is on in progenitors, it turns off during late retinal 
development and appears to be upregulated using a separate mechanism in bipolar cells233. 
OTX2 directly interacts with cell type-specific enhancers that are sufficient to drive 
expression of the transcription factors Prdm1 and Vsx2. The Brzezinski lab has shown that 6kb 
upstream of Prdm1 there is a 139bp cell type-specific enhancer that requires OTX2 binding to 
drive expression167. Approximately 18kb upstream from Vsx2 there is a 164bp bipolar-specific 
enhancer sequence that is directly bound by OTX2 and is sufficient to drive expression in 
nascent bipolar cells234,235. OTX2 binds both of these enhancers and is necessary for their 
expression. However, there are additional binding sites within these enhancers and OTX2 may 
not be sufficient to drive transcription of either without the aid of additional, as yet unknown, 




PRDM1 and VSX2 Act in a Gene Regulatory Network Downstream of OTX2 
PRDM1 and VSX2 act in a gene regulatory network to produce rod photoreceptor and 
bipolar interneurons within the OTX2+ lineage, late in retinal development. Upregulation of 
PRDM1 drives photoreceptor fates and inhibits bipolar fates. Upregulation of VSX2 has the 
opposite effect. Loss of PRDM1 causes a 1:1 fate shift toward bipolar cells. Loss of VSX2 
results in a failure to generate bipolar interneurons. Both genes have sufficient cell type-specific 
enhancers that are bound by OTX2. Collective evidence suggests that OTX2 establishes 
competence and then VSX2 and PRDM1 compete in some way to drive specific cell fates or 
correctly establish the number of rods and bipolar cells.  
Despite these similarities, many questions remain about the function of this gene 
regulatory network. First, rods appear to form even when PRDM1 is absent, though there is a 
decrease in their numbers127,231. Evidence suggests that in the absence of VSX2, bipolar cells are 
not formed148–150,232. PRDM1 is expressed transiently from late embryonic periods through early 
development, while bipolar-specific VSX2 is activated postnatally and remains on into 
adulthood130. Taken together, it is clear that VSX2 and PRDM1 compete in some way to set 
OTX2+ cell fate. However, they may have different modes of action.  
One hypothesis is that VSX2 and PRDM1 are competing to control the correct number of 
bipolar cells and rods. Alternatively, they may play a role in stabilizing cell fate after a choice 
has been made. In the case of Prdm1, this would explain its transient activation and likely 
inhibitory role, as it would be preventing alternative fates and allowing rod transcriptional 
machinery to take over. Another possibility is that rods or bipolars are a default fate in OTX2+ 
cells, and that either Prdm1 or Vsx2 are working to drive an alternative state.   
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While this gene regulatory network is primarily implicated in fate choice, it may be 
playing a role in fate stability. The conditional loss of Prdm1 in postnatal eyes can cause nascent 
rods to fate shift to bipolar cells231. This shows that for some time after a fate has been selected, 
cells are capable of a fate shift. I wondered how long this window of malleability exists. For 
example, will mature bipolar cells change fate to photoreceptors in the presence of PRDM1?  
 
Determining the Fate of OTX2+ Cells that Lack PRDM1 and VSX2 
I developed a variety of methods to explore this gene regulatory network and ask two 
broad questions. 1) I asked what happens if OTX2+ cells lacked both PRDM1 and VSX2. Do 
cells default to bipolars or photoreceptors? Do both cell types fail to form or is there a shift in the 
number of specific types? 2) What happens to a VSX2+ nascent or mature bipolar cell when 
PRDM1 is present? 
  To simultaneously remove PRDM1 and VSX2, I developed a CRISPR/Cas9 system that 
could be delivered in vivo to the developing mouse retina. I created multiple versions of this 
system. The first directly targeted necessary exons of Prdm1 and Vsx2. The second system 
targeted the sufficient cell type-specific enhancer of Prdm1 and Vsx2. I reasoned that if these 
enhancers were not just sufficient but necessary for the expression of these genes in nascent rods 
or bipolar cells then deletion would result in synchronous loss of PRDM1 or VSX2 at the precise 
time when it would normally be upregulated within the cell.  
In agreement with previous loss-of-function experiments, singly targeting Prdm1 or Vsx2 
genes affected the formation of photoreceptors or bipolar cells127,128,148,149. Targeting either cell 
type-specific enhancer resulted in an equal reduction of protein expression and an alteration in 
the fate of the CRISPR targeted cell. Despite the consistency in single loss-of-function 
42 
 
experiments, targeting both enhancers or both genes simultaneously did not have the same result 
and caused a surprising dysregulation of the gene regulatory network (Chapter III).  
Our results shed significant insight on the function of this gene regulatory network, 
suggesting that rods are the default cell fate for OTX2+ cells, but in the absence of PRDM1, 
progenitor-derived VSX2 drives excess bipolar cells. I demonstrate that bipolar-specific VSX2 is 
regulated downstream of the fate-choice-point to become a bipolar cell. Finally, our results show 
that VSX2 and PRDM1 work in a redundant fashion to restrict competence of OTX2+ cells and 
loss of both resulted in excess late born amacrines. By targeting multiple genes and cell type-
specific enhancers simultaneously, I have gained significant insight into the regulation of this 
gene regulatory network, as well as the role of redundancy in maintaining progenitor competence 
restriction in the retina. 
 
Determining the Stability of Bipolar Cells in the Presence of PRDM1 
 I previously mentioned that the loss of PRDM1 in nascent rods is sufficient to cause a 
fate shift to bipolar cells130. I wondered if the presence of PRDM1 in nascent or mature bipolars 
would be sufficient to cause a fate shift to rods or if VSX2+ bipolar fates were stable once 
established. To test VSX2+ bipolar cell stability at different developmental time points, I created 
a CRE-mediated conditional Prdm1 overexpression mouse. I first utilized a transgenic mouse 
that expresses Cre in progenitors to see how PRDM1 would affect bipolar fate before VSX2 was 
present. This early constitutive PRDM1 expression blocked bipolar formation. I next asked if 
VSX2+ nascent bipolars that had not matured would fate shift in the presence of PRDM1. I 
electroporated newborn mice conditional PRDM1 overexpression mice with a bipolar-specific 
Cre plasmid. After seven days, some, but not all, nascent bipolar cells fate shifted to rod 
43 
 
photoreceptors. Finally, I utilized a bipolar-Cre-virus to drive PRDM1 expression in mature 
bipolar cells. While constitutive expression of PRDM1 did not have any observable effect on 
mature bipolar cells, it was toxic to rods. This work suggests that there is a window in which 
nascent bipolar cells will lose VSX2 and become rods in the presence of PRDM1 (Chapter IV). 
However, mature bipolar cells do not readily change their fate and PRDM1 must be 
downregulated in mature rods for their survival.  
Taken together with the work in Chapter III I have significantly advanced our 
understanding of this gene regulatory network and shed light on critical developmental 
paradigms, including the roles of cell type-specific enhancers and timing in regulating cell fate 





Chapter I Figures 
 
Figure 1.1 Evolution of the eye1   
 
1Portions of figure reproduced from cited literature and used with permission from the copyright holder; copyright 
2007 National Academy of Sciences 
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The eye has evolved multiple times throughout history. Here is an example of the evolution in 
mollusks, starting with limpets which possess basic light/dark detectors, through to the complex 





Figure 1.2 Anatomy, patterning, and cell morphology of mammalian retina neurons2  
 
2Portions of figure reproduced from cited literature and used with permission from the copyright holder  
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A) Cross section of mouse eye showing the primary anatomical features236. B) Zoomed cross 
section of the retina highlighting the layers including Sclera, Retinal Pigmented Epithelium 
(RPE), Outer Limiting Membrane (OLM), Outer Segment (OS), Outer Nuclear Layer (ONL), 
Outer Plexiform Layer (OPL), Inner Nuclear Layer (INL), Inner Plexiform Layer (IPL), 
Ganglion Cell Layer (GCL), and Inner Limiting Membrane (ILM). C) Unique types of cells 
within the retina including Rods (R), Cones (C), Horizontal Cells (Hz), Bipolar Cells (BP), 
Amacrine Cells (A), Ganglion Cells (G), and Müller glia. D) Center-surround ON and OFF 
stimulus and signals recorded from bipolar cells in primates73. E) Morphological diversity of rat 
retinal neurons including photoreceptors (P), Horizontal Cells (H), Bipolar Cells (B) and bottom 
area, Amacrine Cells (A), and Ganglion Cells (G)237. F) Primary projections from the mouse 





Figure 1.3 Models of retinal development include intrinsic and stochastic approaches3 
 
3Portions of figure reproduced from cited literature and used with permission from the copyright holder  
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A) Under an intrinsic paradigm of development, progenitor cells progress through layers of 
competence. B) The result is that progressive progenitors give rise to the diversity of cells within 
the retina84. C) A stochastic model of development in rats predicts fate outcomes based on 
probability, including D) the total numbers of a given cell type and E) the percentage probability 
as development progresses. F) At each stage within a stochastic model outcomes are 








Figure 1.4 Intrinsic and extrinsic regulation of mammalian retinal development4 
 




A) The early eye formation is tightly controlled by intrinsic transcription factors like VSX2, 
PAX6, and OTX2, as well as extrinsic signaling from WNT and SHH187. B) The optic vesicle 
extends and contacts the surface epithelium and then invaginates, eventually forming the eye 
tissue239. C) Neural epithelium differentiates into neural retina by E10 and then expands into all 







Figure 1.5 Gene regulatory network governing cell fate in the retina  
Late in development, retinal progenitor cells will turn on OTX2 and permanently exit the cell 
cycle. They will then activate PRDM1 and become rods or VSX2 and become bipolar cells. 
OTX2 is necessary to activate either transcription factor but may not be sufficient. PRDM1 and 
VSX2 may work through direct cross repression or by repressing the alternative cell fate. If 
OTX2 expression is lost, cells can go on to enter the PTF1a lineage and become amacrine cells 





PRDM13 IS REQUIRED FOR EBF3+ AMACRINE CELL FORMATION IN THE 
RETINA5 
Chapter II Summary 
Amacrine interneurons play a critical role in the processing of visual signals within the 
retina. They are highly diverse, representing 30 or more distinct subtypes. Little is known about 
how amacrine subtypes acquire their unique gene expression and morphological features. We 
characterized the gene expression pattern of the zinc-finger transcription factor Prdm13 in the 
mouse. Consistent with a developmental role, Prdm13 was expressed by PTF1a+ amacrine and 
horizontal precursors. Over time, PRDM13 expression diverged from the transiently expressed 
PTF1a and marked just a subset of amacrine cells in the adult retina. While heterogeneous, we 
show that most of these PRDM13+ amacrine cells express the transcription factor EBF3 and the 
calcium binding protein calretinin. Loss of Prdm13 did not affect the number of amacrine cells 
formed during development. However, we observed a modest loss of amacrine cells and 
increased apoptosis that correlated with the onset timing of EBF3 expression. Adult Prdm13 
loss-of-function mice had 25% fewer amacrine cells, altered calretinin expression, and a lack of 
EBF3+ amacrines. Forcing Prdm13 expression in retinal progenitor cells did not significantly 
increase amacrine cell formation, EBF3 or calretinin expression, and appeared detrimental to the 
survival of photoreceptors. Our data show that Prdm13 is not required for amacrine fate as a 
class, but is essential for the formation of EBF3+ amacrine cell subtypes. Rather than driving 
 
5The contents of this chapter have been published and are used with copyright permission: 
Goodson, N. B. Nahreini, J., Randazzo, G., Uruena, A., Johnson, J. E., and Brzezinski J. A. 




subtype identity, PRDM13 may act by restricting competing fate programs to maintain identity 
and survival.  
 
Rationale 
The retina is a thin neural tissue that detects and relays photic information. The 
mammalian retina has a highly organized structure consisting of alternating nuclear and synaptic 
(or plexiform) layers. These layers are populated by seven major classes of retinal neurons and 
glia, each of which are essential for normal vision. These cell types (rod and cone 
photoreceptors, Müller glia, retinal ganglion cell output neurons, and bipolar, horizontal, and 
amacrine cell interneurons) are all derived from a common progenitor population during 
development82,222,240. Adding to the complexity of the system, most of the seven cell types can be 
further divided into more than 60 additional distinct subtypes66,241,242. While considerable 
progress has been made to uncover the transcription factors and signaling molecules that control 
major cell class development, relatively little is known about how subtypes acquire their 
identities.  
Amacrine cells are primarily inhibitory interneurons. They form synapses with 
glutamatergic bipolar interneurons and ganglion cell output neurons in the inner plexiform layer 
(IPL). Their somas are primarily located in the inner nuclear layer (INL), but a small fraction are 
displaced and localized to the ganglion cell layer (GCL). Amacrines make up only about 8% of 
retinal cells, but within this population more than 30 distinct subtypes have been 
described38,39,206,207. Amacrines can be grouped into three major categories based on whether 
they express GAD65/67 (GABAergic, ~43%), GlyT1 (glycinergic, ~43%), or neither of these 
markers (nGnG, ~15%)40. The transcription factor PAX6 is made by all amacrines, but 
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subpopulations express a wide array of additional markers in a highly heterogeneous fashion. For 
example, subsets of amacrines are marked by transcription factors (e.g. AP2a, EBF3, BHLHB5), 
calcium binding proteins (e.g. calretinin, calbindin), and proteins involved in neurotransmission 
(e.g. ChAT, TH, vGlut3)30,40–42,44,45,208,209. Many of these markers overlap in multiple subsets of 
amacrines, complicating the identification of individual subtypes. This has made interpreting the 
effects of gain- and loss-of-function experiments on amacrine cell development difficult.     
In mice, progenitors that give rise to amacrine interneurons permanently exit the cell 
cycle (birthdate) from approximately embryonic (E) day 12.5 to postnatal (P) 285,211,212. 
Progenitors that express the transcription factors FOXN4 and RORB are competent to express 
PTF1a107,108,213. PTF1a is a basic-helix-loop-helix (bHLH) transcription factor that is transiently 
expressed in postmitotic cells that are restricted to forming amacrines and horizontal cells108. 
Mice that lack Ptf1a die at birth and essentially lack horizontal and amacrine cells108. Several 
transcription factors that are expressed by subsets of amacrine cells perturb subtype development 
when they are mutated. For example, Isl1 mutants have reduced cholinergic (ChAT+) amacrines, 
loss of BHLHB5 decreases GABAergic subtypes, and Neurod6 loss reduces nGnG (neither 
GABAergic nor glycinergic) amacrines40,108,215. Birthdating experiments show that there is an 
overlapping genesis order for the major categories of amacrines, such that GABAergic cells are 
born early followed by glycinergic and nGnG amacrines40,211,212. While subtype choice is 
correlated with cell cycle exit timing, how and when postmitotic PTF1a+ precursors commit to a 
specific amacrine subtype identity is unclear. Some perturbations, like Neurod6 loss-of-function, 
alter subtype distribution without changing the total number of amacrines40. This argues that fate 
choice is progressive, where PTF1a+ cells first adopt amacrine identity before becoming further 
restricted to a particular subtype identity. To better understand the temporal and spatial 
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mechanisms that diversify the PTF1a+ precursor population, we looked for factors that act 
downstream of PTF1a.  
We have shown that the zinc finger transcription factor Prdm13 is genetically 
downstream of Ptf1a in the spinal cord and retina216. Within the spinal cord, PTF1a directly 
activates Prdm13, which acts as a transcriptional repressor to promote inhibitory interneuron 
identity at the expense of excitatory fates216. We have demonstrated that PRDM13 is recruited to 
enhancers by other transcription factors where it acts as a co-repressor217. In particular, PRDM13 
interacts with bHLH factors like PTF1a in the developing spinal cord to convert transcriptional 
activators into repressors, helping to silence competing gene expression programs in bistable 
precursors217. These data suggest that PRDM13 acts as a repressor in PTF1a+ retinal cells to 
control amacrine or horizontal interneuron development.  
We investigated the expression of PRDM13 during retinal development using specific 
antibodies and Prdm13-GFP knock-in mice. Consistent with our prediction, PRDM13 was 
expressed in PTF1a+ amacrine and horizontal precursors throughout development. PRDM13 
expression persisted into adulthood, primarily marking a heterogeneous subset of glycinergic and 
nGnG amacrines. The majority of PRDM13+ cells co-expressed calretinin and EBF3. Of note, 
the entire population of EBF3+ amacrine cells co-expressed PRDM13. Mice that lacked Prdm13 
died at birth, but showed no deficits in amacrine cell genesis. To bypass lethality, Prdm13-GFP 
mice were bred to mice carrying a hypomorphic Prdm13 allele (Prdm13-∆115)217. These 
compound heterozygous mice (Prdm13-GFP/∆115) were viable and had fewer amacrine cells in 
the adult retina compared to control mice. In particular, these mice lacked EBF3+ amacrines and 
calretinin+ cells that projected their dendrites to the middle of the IPL. Amacrine cell numbers 
were normal throughout their genesis period and declined only after the normal onset of EBF3 
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expression in these mutants. Despite early wide-spread expression in PTF1a+ cells, our data 
show that Prdm13 is not required for amacrine cell genesis. However, Prdm13 is required at a 
later step for amacrine subtype specification. Prdm13 overexpression did not upregulate EBF3 or 
calretinin, suggesting that Prdm13 acts to suppress alternative gene regulatory networks to 
maintain EBF3+ subtype identity and survival.  
 
Results  
PRDM13 Marks Developing Amacrine and Horizontal Cells 
 We previously showed that Prdm13 is expressed by a subset of retinal cells that is similar 
to those marked by the committed amacrine and horizontal precursor marker Ptf1a108,216. Prdm13 
in situ hybridization signal was lost in Ptf1a mutant embryos, suggesting that Prdm13 is 
expressed by developing amacrine and horizontal cells. To better evaluate the spatial and 
temporal features of PRDM13 expression during retinal development, we immunostained retinal 
sections with antibodies against PRDM13 and PTF1a. We focused on three time-points (E13.5, 
E15.5, and birth) when postmitotic nascent horizontals and amacrine cells co-express PTF1a108. 
We observed that both PRDM13 and PTF1a immunostaining formed a mosaic pattern with oval 
nuclei located between the apical photoreceptor area and the ganglion cell layer (GCL) (Fig 2.1). 
PRDM13 co-labeled 66.5% (± 21.3% SD) of PTF1a positive cells within the central and 
peripheral retina at E13.5 and all (100.0% ± 0.0% SD) of the PRDM13+ cells were PTF1a+ 
(Figs 2.1A-A’’’, D). We observed similar numbers of PRDM13+, PTF1a+, and double labeled 
cells at E15.5, but at this stage there was a statistically significant decrease in the percentage of 
PRDM13+ cells that co-expressed PTF1a+ (89.8% ± 6.9% SD, N=7, t-test, p<0.001) (Figs 2.1B, 
D-E). P0 retinas had more PRDM13+ and PRDM13+/PTF1a+ double labeled cells (Figs 2.1C, 
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E). However, the percentage of PRDM13+ cells that co-expressed PTF1a+ decreased further to 
80.0% at P0 (Fig 2.1D). This decreased percentage is consistent with the postnatal loss of PTF1a 
expression and the persistence of PRDM13 in a subset of postmitotic neurons. To determine 
whether PRDM13 was expressed in other cell types, we co-stained sections with OTX2, a 
marker of developing photoreceptors at these time-points108,130,138,227,228,243. We observed modest 
overlap of PTF1a, PRDM13, and OTX2 at all three time-points (Figs 2.1A-C, E). Since the Ptf1a 
lineage lacks photoreceptors, these double and triple labeled OTX2+ cells are already committed 
to becoming horizontals and/or amacrine cells. This plasticity in the OTX2+ lineage has been 
observed previously108,167,231,244,245. We also co-labeled sections with antibodies against the 
ganglion cell marker BRN3246. No PRDM13+/BRN3+ ganglion cells were observed (data not 
shown). These data suggest that PRDM13 is expressed downstream of PTF1a, marking only 
committed amacrine and/or horizontal cells. 
   
PRDM13 Null Mice Exhibit No Gross Changes in Embryonic Retinal Development  
 We created a Prdm13-GFP knock-in mouse line to accurately and persistently label 
Prdm13+ cells and conduct loss-of-function analysis217. These mice were created by inserting a 
cytoplasmic GFP cassette followed by a stop codon into exon 1 of the Prdm13 sequence (Fig 
2.2A-A’)217. We observed that homozygous GFP/GFP null mice died at birth while Prdm13 
heterozygous animals showed no overt phenotypes217. To track PRDM13 during retinal 
development, we examined Prdm13-GFP heterozygous and homozygous mice at E17.5 (Fig 
2.2), around the peak of amacrine cell genesis212. The pattern of GFP immunostaining in both 
GFP/+ and GFP/GFP mice at E17.5 mirrored that seen in wild-type (+/+) retinas labeled with 
anti-PRDM13 antibodies (Fig 2.1 and data not shown). GFP labeled the cytoplasm, revealing 
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apical and basal processes in both heterozygous and mutant animals (Fig 2.2). Little if any 
staining was seen in the ganglion cell layer. There was appreciable basal clustering, with more 
staining in what will become the inner nuclear layer (Figs 2.2B-E). GFP intensity levels were 
lower in GFP/+ mice compared to homozygous mutants, but the total number of GFP+ cells did 
not vary between the two populations (Fig 2.2F) (N=6, t-test, p=0.9366), suggesting that Prdm13 
is neither required for its own expression nor to maintain cell survival at E17.5.  
Next, we stained transgenic mice with antibodies against PRDM13 (Figs 2.2B-C). 
PRDM13 immunostaining overlapped highly with GFP in Prdm13 heterozygous mice (Figs 
2.2B, G). Some GFP+ cells in the nascent inner nuclear layer lacked PRDM13 staining. This 
population likely represents neurons that recently inactivated PRDM13 expression, but remained 
labeled due to the long half-life of GFP. PRDM13 immunostaining was completely absent from 
Prdm13-GFP/GFP null mice (Figs 2.2C, F-G), demonstrating the specificity of the antibody. 
The number of PRDM13+ cells was equivalent between Prdm13 heterozygous and wild-type 
mice (N=6, t-test, p=0.8627) (Fig 2.2G and data not shown). 
To determine whether changes in cell fate occurred in Prdm13 mutants, we examined 
E17.5 sections with antibodies against OTX2 to mark developing photoreceptors. The 
immunostaining pattern and intensity of OTX2+ nuclei was unchanged between Prdm13 
heterozygous and homozygous mutant retinas (Figs 2.2B-E). Consistent with our observations 
above (Fig 2.1), a small number of PRDM13-GFP+ cells co-expressed OTX2 in both 
heterozygous and mutant animals (Figs 2.2B-E). Nonetheless, the number of these double 
labeled cells was unchanged between heterozygous and homozygous mice. This suggested that 
there was no change in photoreceptor genesis in Prdm13 knockout animals. We then 
immunostained retinas with antibodies against PTF1a to determine whether Prdm13 affects the 
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formation of horizontal and amacrine precursor cells (Figs 2.2D-E). The PTF1a spatial labeling 
pattern was similar between Prdm13 heterozygous and null animals (Figs 2.2D-E). The total 
number of PTF1a+ cells was equivalent between wild-type, heterozygous, and Prdm13 
homozygous mutants (N=8, ANOVA, p=0.8131) (Fig 2.2H). There were no differences in the 
number of Pft1a+/GFP+ cells between our lines (N=5, t-test, p=0.7193) or the fraction of 
PTF1a+ cells that co-expressed GFP (N=5, t-test, p=0.3805) (Figs 2.2I-J). Similarly, we 
observed no differences in the number of cells that co-expressed PTF1a and OTX2 between the 
three genotypes (N=8, ANOVA, p=0.2510) (Fig 2.2K). These data argue that Prdm13 is not 
required for the formation of amacrine and horizontal cell precursors. Though the number of 
PTF1a cells was unaltered in mutants, the PTF1a staining was typically more intense. This 
suggests that PRDM13 mediates a negative feedback loop onto Ptf1a in the retina, as has been 
observed in the spinal cord217. Lastly, we examined retinas with antibodies against BRN3 to 
mark ganglion cells, but saw no differences in their numbers between genotypes (data not 
shown). Taken together, our data suggest that the loss of Prdm13 does not alter the balance of 
cell fates formed during embryonic retinal development.  
 
PRDM13 Labels a Subset of Amacrine Cells in the Adult Retina  
 PTF1a is an early postmitotic marker for amacrine and horizontal cell precursors that is 
necessary for their development108. Although PRDM13 initially overlaps with PTF1a, as 
development progressed PRDM13+/PTF1a negative cells became localized to the nascent inner 
nuclear layer. This suggested that PRDM13 expression remained in subsets of amacrine or 
horizontal cells. To test this, we immunostained mature (P30) Prdm13 GFP/+ retinas for several 
amacrine and horizontal markers (Fig 2.3). Nearly all of the GFP+ cell bodies were located in the 
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inner aspect of the INL with cell processes extending into the inner plexiform layer (IPL). There 
were also a few GFP+ cell bodies within the GCL (Fig 2.3). Immunostaining with PRDM13 
antibodies overlapped with the GFP+ somas in heterozygous animals (data not shown). PRDM13 
immunostaining was not as robust in adult animals, so we used GFP staining to better 
characterize the PRDM13+ population. Immunostaining for the pan-amacrine marker PAX6 
revealed that 100.0% (± 0.0% SD) of GFP+ cells co-expressed PAX6+ (Fig 2.3E and data not 
shown). However, only a subset of PAX6+ cells in the INL were GFP positive. These GFP+ 
cells accounted for 38.6% (± 2.9% SD) of all PAX6+ cells in the INL, suggesting that PRDM13 
marks a subset of amacrine cells (Fig 2.3F). No GFP+ cells co-expressed the photoreceptor and 
bipolar cell marker OTX2 (Fig 2.3E) or the ganglion cell marker BRN3 (data not shown). We 
then immunostained retinas with markers that define subsets of amacrine and other interneuron 
populations in the retina. The transcription factor AP2a marks a large subpopulation of amacrine 
cells (Bassett et al., 2007). We observed that AP2a co-stained 31.3% (± 3.7% SD) of GFP+ cells 
(Figs. 3A, E). The transcription factor BHLHB5 marks type II cone OFF bipolars and subsets of 
GABAergic and other amacrine cells44,108. BHLHB5 marked 34.9% (± 8.6% SD) of GFP+ cells 
(Figs 2.3A, D-E). In both cases, only subsets of AP2a+ (23.2% ± 3.5% SD) and BHLHB5+ 
(27.1% ± 6.5% SD) cells co-expressed GFP (Fig 2.3F and data not shown), reflecting the highly 
heterogeneous nature of amacrine cells and these markers. Calretinin and calbindin each mark 
complex subsets of amacrine cells in the mouse247. Calretinin stains amacrine and ganglion cell 
somas in the INL and GCL, as well as three highly stereotypical dendritic sublaminae within the 
IPL247,248. We observed that about half of PRDM13-GFP+ cells co-expressed calretinin (50.3% ± 
9.2% SD) (Figs 2.3B, E). In contrast, GFP+ cells rarely co-expressed calbindin (0.6% ± 1.3% 
SD) and none of the intensely calbindin labeled horizontal cells made GFP (Figs 2.3B, E)249. Co-
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staining with the glycinergic marker GlyT1 and the GABAergic marker GAD65/67 revealed that 
most of the PRDM13-GFP+ cells were glycinergic (Figs 2.3C, E)247,249,250. GlyT+ glycinergic 
amacrines accounted for 44.7% (± 9.2% SD) of GFP+ cells, while GABAergic GAD+ cells 
accounted for only 2.8% (± 2.4% SD) (Fig 2.3E). These percentages may be underrepresented as 
not all amacrine somas were robustly labeled with these antibodies. Nonetheless, there is a clear 
preference for glycinergic overlap, consistent with the paucity of GFP+ displaced amacrine cells. 
We examined cholinergic amacrines by co-staining with Sox2 antibodies211,251,252 (data not 
shown). We did not observe any overlap of GFP with Sox2 (Fig 2.3E), showing that PRDM13 
does not mark cholinergic amacrine cells. Similarly, we observed no overlap with vGlut3, which 
marks a small population of mostly glycinergic amacrines or with the dopaminergic amacrine 
marker TH (data not shown). Lastly, we examined PRDM13-GFP/+ retinas with antibodies to 
EBF343,212. EBF3 marks glycinergic and nGnG amacrines along with subsets of ganglion 
cells40,253. Many GFP+ cells co-expressed EBF3 (70.4% ± 7.6% SD) (Figs 2.3D-E). To eliminate 
the possibility of counting EBF3+ ganglion cells, we narrowed our quantification parameters to 
the EBF3+ cells within the INL and found that 100% (± 0.0% SD) of them co-expressed GFP 
(Fig 2.3F). This suggests that Prdm13 marks the entire cohort of EBF3+ amacrines, while also 
marking a smaller diverse set of non-EBF3+ amacrine cells.  
  
EBF3+ Amacrine Cells are Absent from Prdm13 Mutants 
  Many amacrine subtype differentiation markers appear postnatally. For example, EBF3 
expression in amacrine cells is first seen at P440. To overcome the neonatal lethality of Prdm13-
GFP/GFP null mice, we took advantage of a Prdm13 allele with a 115bp deletion in the first 
exon (Fig 2.4A)217. This Prdm13-∆115 modification was predicted to result in a frame shift with 
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early truncation of the PRDM13 protein (Fig 2.4A). However, homozygous Prdm13-∆115 mice 
express some PRDM13 protein and were viable, suggesting that the 115bp deletion created a 
hypomorphic allele217. We crossed the Prdm13-GFP mouse line with ∆115 to create mice that 
had severely reduced Prdm13 function. These GFP/∆115 mice were viable, and adults had a 
conspicuous loss of GFP+ cells (3.97 cells/100µm ± 1.07 SD) compared to Prdm13-GFP/+ 
heterozygotes (16.06 cells/100µm ± 2.66 SD) (Figs 2.4B-C). The GFP+ cells remaining in 
GFP/∆115 mice were localized to the INL and generally had larger cell bodies compared to 
heterozygous control retinas (Fig 2.4B). We next examined whether this loss of roughly 12 
GFP+ cells/100µm was due to a reduction in amacrine cells or GFP expression. PAX6 
immunostaining revealed no changes in the number of labeled cells in the GCL (N=6, t-test, 
p=0.299), but there was a significant decrease in PAX6+ INL cells from 39.68 (SD ± 3.24) 
cells/100µm in control mice to 31.11 (SD ± 5.71) cells/100µm in GFP/∆115 mice (N=6, t-test, 
p=0.028) (Fig 2.4M and data not shown). This loss of PAX6 staining in the INL was similar in 
magnitude to the GFP reduction, suggesting that a subset of PRDM13+ amacrine cells were lost 
in GFP/∆115 mice. We then examined whether Prdm13 perturbation affected specific amacrine 
subtypes. Immunostaining for GABAergic and glycinergic amacrines revealed no changes in the 
number of GAD+ cells, but a modest decrease in GlyT+ cells was observed in the GFP/∆115 
mice (N=9, t-test, p=0.014) (Figs 2.4D-E, M). More conspicuous was the reduced number of 
GFP+ cells that co-expressed GlyT (N=9, t-test, p=<0.001) (Figs 2.4D-E, N). This suggested that 
the glycinergic amacrines that normally co-express PRDM13 were selectively reduced in 
mutants. We observed a slight increase in the number of GFP+ cells that co-expressed GAD65 in 
GFP/∆115 mice (N=9, t-test, p=0.014), but this modest change was not enough to alter the 
overall number of GABAergic amacrines in the retina (Figs 2.4D-E, M-N). The total number of 
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AP2a and BHLHB5+ amacrines was significantly reduced in GFP/∆115 mice compared to 
GFP/+ controls (Figs 2.4F-G, M). The number of GFP+ cells that co-expressed AP2a or 
BHLHB5 decreased proportionately in GFP/∆115 animals (Figs 2.4F-G, M-N). These data 
suggest that the PRDM13+ subpopulations of AP2a+ and BHLHB5+ amacrines were 
specifically lost in mutants.  
PRDM13 marked large fractions of calretinin and EBF3 expressing amacrine cells in 
adult retinas (Fig 2.3). As expected, calretinin staining was strikingly different between 
heterozygous control and GFP/∆115 mice (Figs 2.4H-I). There was a conspicuous loss of cell 
bodies and a change in the distribution of dendritic staining in the IPL (Figs 2.4H-I, L). 
Calretinin positive somas in the INL decreased from 13.47 (± 3.13 SD) cells/100µm in controls 
to 9.89 (± 1.52 SD) cells/100µm in the GFP/∆115 mice (N=9, t-test, p=0.0019) (Fig 2.4M). 
There was nearly a total loss of GFP+/calretinin+ cells in the GFP/∆115 mice (N=9, t-test, 
p<<0.001) (Figs 2.4H-I, N). Calretinin strongly marks three (2, 3, and 4) of the five synaptic 
sublaminae of the IPL247,253. Heterozygous control mice displayed this trilaminar calretinin 
pattern, while the GFP/∆115 mice had a thinner IPL that contained only two sublaminae (Figs 
2.4H-I, L). The cholinergic amacrine marker ChAT, which labels sublaminae 2 and 4 was 
normal in GFP/∆115 mice (data not shown)247,254. There was a minor increase in the number of 
GFP+ cells that co-expressed calbindin in GFP/∆115 mice, but the IPL staining of sublaminae 2 
and 4 was normal (Figs 2.4H-I, M-N). These data argue that calretinin positive cells that project 
to sublamina 3 are lacking in GFP/∆115 mice (Fig 2.4L)247. Since essentially all EBF3+ 
amacrine cells co-expressed PRDM13, we expected this population to be the most disrupted in 
GFP/∆115 retinas. Indeed, we observed a nearly complete loss of EBF3+ cells from the INL of 
these mutants (Figs 2.4J-K, M). This loss of about 10 EBF3+ amacrine cells/100µm was nearly 
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the same as the loss of PAX6+ INL cells in GFP/∆115 mice (Fig 2.4M). Consistent with an 
amacrine cell-specific deficit, the number of EBF3+ cells in the GCL was unchanged (N=9, t-
test, p=0.26). The loss of both EBF3+ and calretinin+ cells suggested that these populations 
overlap extensively. In adult wild-type mice, we observed that 72.2% (± 12.3% SD, N = 4) of 
calretinin+ cells in the INL co-expressed EBF3+ and that 64.4% (± 7.0% SD, N = 4) of EBF3+ 
cells in the INL were calretinin+ (Fig S2.1). Taken together, these data argue that Prdm13 is 
required for the formation or survival of EBF3+/calretinin+ cells.  
 
Loss of the PRDM13+ Amacrine Population Begins at P5  
We did not observe a change in GFP+ cells in E17.5 Prdm13 mutant mice (Fig 2.2), but 
P30 GFP/∆115 mice had considerably fewer GFP+ cells and about ~25% fewer amacrines (Fig 
2.4). There are three general mechanisms that account for this reduction in cell numbers. These 
include: (1) a reduction in the number formed during development, (2) altered amacrine subtype 
fate choice, and (3) cell death. To distinguish between these possibilities, we examined mice at 
intermediate developmental time-points (Fig 2.5). We stained E17.5 GFP/+ and GFP/GFP mice 
for PAX6 and observed no significant differences in cell number (N=4, t-test, p=0.62) (Figs 
2.5A-B). Next, we compared the number of intensely PAX6+ INL cells between GFP/+ and 
GFP/∆115 retinas at P2, the end of amacrine cell genesis. We observed no statistically 
significant differences (N=2, t-test, p=0.98) between the genotypes, arguing that amacrine fate 
specification as a class was unaltered by the loss of Prdm13 (Figs 2.5C-D).  
Many amacrine subtype-specific markers become expressed in the first postnatal week, 
including EBF3 starting at P440. We next examined P5 GFP/+ control and GFP/∆115 mutant 
retinas for the numbers of GFP, EBF3, and BHLHB5 positive amacrine cells. At P5, nascent IPL 
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lamination was less delineated and thinner in GFP/∆115 retinas (Figs 2.5E-F). Nonetheless, we 
observed only a modest decrease (N=7, t-test, p=0.027) in the number of GFP+ cells in mutant 
retinas compared to heterozygous controls (Figs 2.5E-F, I). EBF3 staining was strongly reduced 
in the INL of GFP/∆115 mice, but was abundant in the GCL of both controls and mutants (Figs 
2.5E-F). Both control and mutant EBF3+ cells in the INL co-expressed GFP, but there were far 
fewer EBF3+ nuclei in GFP/∆115 retinas (Figs 2.5E-I). The near absence of EBF3+ amacrines 
in adult mice is also seen at P5, suggesting that EBF3+ cells are not formed in GFP/∆115 mice. 
While the overall number of BHLHB5+ amacrines did not change significantly, more of these 
cells co-expressed GFP in P5 mutants compared to controls (Figs 2.5E-I). This change suggests 
that some of the PRDM13-GFP+ cells that would have adopted EBF3+ subtype identity failed to 
do so and instead express BHLHB5 and perhaps other subtype markers. This is further supported 
by the modest loss of P5 GFP+ cells compared to adult GFP/∆115 retinas. We reasoned that 
inappropriately specified cells may undergo apoptosis. Staining for activated caspase 3 (AC3) at 
P5 revealed no appreciable overlap with GFP in control mice, but 28.1% of dying AC3+ cells co-
expressed GFP+ in GFP/∆115 mutants (N=4, t-test, p=0.029) (Fig 2.5J and data not shown). 
These data suggest that Prdm13 is required for EBF3+ amacrine subtype formation and survival.  
 
Prdm13 Overexpression is not Sufficient to Drive Ectopic Amacrine Formation 
We observed that Prdm13 is not required for amacrine cell generation as a class. 
Nonetheless, it could play a redundant role in amacrine genesis and an instructive role in subtype 
formation. We hypothesized that ectopic expression of Prdm13 would promote amacrine 
formation, and in particular, subtypes that express EBF3 and/or calretinin. To test this, we 
created plasmid expression vectors to drive Prdm13 (WT), which has been shown to act as a 
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transcriptional repressor217,255. We also created a vector to express a VP16 fusion with Prdm13 
(VP16) to convert it into a transcriptional activator 216. Each of these vectors contains the Ef1α 
enhancer to drive ubiquitous expression and an IRES-Cre cassette for indirect detection. As a 
control, we used an Ef1α driven nuclear cherry plasmid 256. Constructs were electroporated into 
newborn retinas and cultured for 2 or 7 days in vitro (DIV) as intact explants. Electroporation 
preferentially affects retinal progenitor cells, which give rise to photoreceptors and to a lesser 
extent bipolars, glia, and amacrine cells at this stage82,85. Electroporated explants were stained for 
PAX6 and OTX2 (Fig 2.6) as they mark all cell types (OTX2- photoreceptors and bipolars, 
PAX6- horizontals, amacrines, glia, and ganglion cells) in the mature retina. At both 2DIV and 
7DIV, control cherry cells detected with anti-red fluorescent protein (RFP) antibodies were 
overwhelmingly OTX2+ photoreceptors and bipolar cells, consistent with the fate distribution of 
newborn progenitors82 (Figs 2.6A, D). Only about 20% of electroporated control cells made 
PAX6, indicative of an amacrine or glial identity (Figs 2.6A, E). In contrast to cherry controls, 
both PRDM13 WT and VP16 electroporated cells were localized to the nascent INL and were 
much more likely to co-express PAX6 (N = 26, ANOVA, P=0.0003) than OTX2 at 2 DIV (Figs 
2.6A-E). At 2DIV, both WT and VP16 had significantly fewer OTX2+ cells and significantly 
more PAX6+ cells than cherry control. At 7DIV the overall pattern was similar, such that 
PRDM13 WT and VP16 transfected cells co-expressed PAX6 more frequently than cherry 
controls (N=24, ANOVA, 0.0111) (Figs 2.6D-E). However, it was apparent at 7DIV that many 
PRDM13-VP16 transfected cells co-expressed both OTX2 and PAX6 (Figs 2.6C, D-F). The co-
expression of OTX2 and PAX6 was seldom observed in cherry control or PRDM13 WT 
transfections (Fig 2.6F). Some retinal progenitors appear to transiently co-express PAX6 and 
OTX2 raising the possibility that VP16 cells remain as undifferentiated progenitors127,243,. 
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Alternatively, the VP16 fusion may lead to the inappropriate activation of photoreceptor genes, 
like Otx2. PRDM13 WT transfected cells differed from VP16 and control cells in another way. 
Many PRDM13 WT transfected cells failed to express either PAX6 or OTX2 (Fig 2.6B-B’’’, 
inset). These non-PAX6 non-OTX2 cells of unknown identity accounted for nearly 30% of 
PRDM13 WT transfected cells at 7DIV (Figs 2.6B-B’’’, data not show). Non-PAX6, non-OTX2 
electroporated cells were absent from 7DIV Cherry control and PRDM13 VP16 transfections.  
The presence of OTX2+/PAX6+ cells in VP16 electroporations and the non-PAX6 non-
OTX2 cells in PRDM13 WT conditions raised the possibility that these constructs were 
deleterious to cell survival.  Accordingly, both PRDM13 WT and VP16 fusion transfections 
resulted in sparse numbers of Cre+ electroporated cells at both 2DIV and 7DIV compared to 
cherry control transfections (Figs 2.6B-F and data not shown). We observed this reduction at 1, 
3, 4, and 10DIV as well (data not shown). Moreover, our initial electroporation experiments with 
higher concentrations of PRDM13 WT and VP16 plasmids resulted in even fewer Cre+ cells 
after only 1DIV (data not shown). These findings suggested that overexpression of PRDM13 WT 
and VP16 conferred an immediate survival disadvantage to transfected cells. The bias towards 
PAX6 expression and INL localization suggested that both PRDM13 WT and VP16 were 
especially toxic to OTX2+ photoreceptors and bipolar cells. We also searched for upregulation of 
EBF3, calretinin, calbindin, and BHLHB5 at 2, 3, 4, and 7DIV. However, we did not observe 
any ectopic expression of amacrine markers at these time-points (data not shown). Taken 
together, our data suggest that Prdm13 is not sufficient to drive ectopic amacrine cell formation 





 How the developing retina allocates a set number of amacrine cells and diversifies them 
into 30+ subtypes is only partially understood. We investigated the transcription factor Prdm13 
and found that it was expressed broadly in developing amacrine cell precursors and became 
restricted to a heterogeneous subset of amacrines in mature mice. Normal numbers of amacrine 
cells formed in Prdm13 mutant mice, but subtype specification was altered in the early postnatal 
period. EBF3+ amacrine cells were absent and about 25% of amacrine cells were subsequently 
lost to cell death. Our data show that Prdm13 does not control amacrine cell genesis as a class, 
but is instead necessary for subtype fate choice and cell survival. Future work is needed to 
uncover how Prdm13 regulates the formation of EBF3+ amacrines and how individual subtypes 
within this heterogeneous population function in the retina. 
 
Prdm13 is Not Necessary for Amacrine Identity 
 We observed that Ptf1a mutant retinas lack Prdm13 expression216. Therefore, we 
expected PRDM13 to function downstream of PTF1a in the developing retina. Consistent with 
this model, 100% of PRDM13+ cells co-expressed PTF1a at E13.5. In the spinal cord, PTF1a 
drives Prdm13 expression, which then feeds back to inhibit Ptf1a expression217,257. This negative 
feedback loop is also present in the retina since Prdm13 mutant mice had more intensely stained 
PTF1a+ cells. Despite this expression increase, Prdm13 loss did not change the number of 
PTF1a+ cells in the retina or the number of amacrine cells that were initially formed. This 
suggests that feedback is important for controlling Prdm13 levels and in turn, amacrine subtype 
fate choice and survival (see below). Despite PRDM13 being expressed at early stages in 
PTF1a+ cells, it was not required for the formation of amacrine or horizontal cell precursors.    
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Since Prdm13 acts as a repressor, we reasoned that it acts by blocking competing cell 
identities in multipotent precursors216,217. This was reinforced by our observation that some 
PTF1a+ and PRDM13+ cells transiently co-expressed OTX2. This overlap is consistent with 
data suggesting that OTX2+ cells can adopt amacrine and horizontal cell identities167,231,244,245. It 
has been shown that the PTF1a+ lineage contains only horizontal and amacrine cells108. We 
hypothesized that PRDM13 represses Otx2 expression in PTF1a+ cells to restrict fate choice. 
However, we did not observe an increase in OTX2+ cells in Prdm13 mutants or a fate shift to 
photoreceptors or bipolar cells. This shows that Prdm13 is not required to suppress photoreceptor 
identity in PTF1a+ cells. Interestingly, PRDM13-VP16 activator misexpression increased the 
number of PAX6+ cells that co-expressed OTX2. This raises the possibility that PRDM13 
normally inhibits Otx2 expression in the developing retina. For this to be true, other factors must 
compensate for or act redundantly with Prdm13 to suppress Otx2 expression. Since Ptf1a 
misexpression can promote amacrine identity at the expense of photoreceptors and bipolar cells 
fate restriction appears to be downstream of PTF1a. The transcription factors AP2a (Tfap2a) and 
AP2b (Tfap2b) are both decreased in Ptf1a mutants218,258. Gain-of-function analysis showed that 
these factors can promote amacrine formation258. However, deletion of both genes 
simultaneously resulted in only a modest amacrine phenotype and there was no appreciable fate 
shift to OTX2+ photoreceptors or bipolar cells97. It remains unclear how PTF1a+ cells are 
restricted to horizontal and amacrine cell fates and whether Prdm13 plays a redundant role in this 
process.   
 
PRDM13 Marks Multiple Subtypes of Amacrine Cells 
 Amacrine cells are highly diverse, with estimates of 30 or more discrete subtypes in the 
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mouse retina. About one third of amacrine cells were marked by PRDM13 in the adult retina. 
PRDM13 labeled a heterogeneous group of glycinergic and nGnG amacrines, but did not mark 
cholinergic, dopaminergic, or glutamatergic amacrine subtypes. Recent reports have also shown 
that PRDM13 is made by subsets of amacrine cells. In mice and frogs, most PRDM13+ cells are 
glycinergic218,257. The frog retina has more PRDM13+ cells that are GABAergic compared to 
mice218,259. Our characterization of subtype markers is similar to those described previously in 
mice, except that we observed far fewer PRDM13+ cells that co-expressed calbindin or 
GAD65218. The reason for these discrepancies is unclear, but may involve differential 
sensitivities of antibodies used in each study. We examined additional subtype markers, 
including BHLHB5 and EBF3, to further probe the diversity of PRDM13+ amacrine cells. 
Strikingly, we found that EBF3+ cells are the only amacrine population that is entirely PRDM13 
labeled.  
Our experiments revealed that nearly 75% of PRDM13+ amacrine cells co-expressed 
EBF3. The EBF3+ population is itself heterogeneous, representing a 3-to-1 mix of glycinergic 
and Neurod6+ nGnG subtypes40. The glycinergic subpopulation has narrow, multistratified 
dendritic fields that project to sublaminae 1-4 in the IPL40. The nGnG EBF3+ population has 
similar morphology, but projects dendrites to sublaminae 1-340. We observed a small number of 
EBF3+ amacrines that co-expressed BHLHB5, raising the possibility that EBF3+ amacrines can 
be divided into additional subtype groups. This is supported by single cell profiling experiments 
that identified three EBF3+ clusters (one glycinergic and two nGnG) in the retina260. About one 
fourth of the PRDM13+ amacrines did not co-express EBF3. There was no conspicuous marker 
that labeled all of these cells, suggesting they are a heterogeneous population. This likely 
includes the small number of GABAergic amacrines, the bulk of the BHLHB5+ subtypes, and 
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additional glycinergic and nGnG amacrines. Going forward, intersecting PRDM13 with other 
subpopulation markers may uniquely define individual amacrine subtypes and facilitate 
experiments to uncover their physiology. 
 
Prdm13 effects amacrine subtype specification 
Despite expression at early time-points in PTF1a+ cells, Prdm13 mutants had no 
discernable phenotypes embryonically. In fact, there were no conspicuous changes in Prdm13 
loss-of-function mice until P5. This is after the timing of amacrine cell birth, but overlaps with 
subtype maturation and culling of excess generated amacrines40,85,211,212,261–263. At P5, Prdm13-
GFP/∆115 mice showed increased apoptosis and largely lacked EBF3+ amacrines. GFP+ cells in 
these mice were more likely to co-express BHLHB5 than controls, suggesting that subtype 
specification was altered. This supports a model where Prdm13 is required for EBF3+ amacrine 
subtype specification. By the adult stage Prdm13-GFP/∆115 mice have fewer amacrines and 
essentially lack EBF3+ subtypes. This argues that Prdm13 is also required for the survival of 
EBF3+ amacrine cells. It is difficult to determine whether Prdm13 controls amacrine subtype 
specification, survival, or both. One possibility is that EBF3+ amacrines are still specified in 
mutants, but die without Prdm13 due to derepression of genes made by other subtypes. Another 
possibility is that EBF3+ amacrines fail to become specified in mutants. This is consistent with 
our observations of a significant reduction of EBF3 expression that precedes cell death. In the 
absence of subtype specification, cells could die due to a lack of identity or they could adopt a 
different subtype choice. Though calbindin+ amacrines increased subtly in mutants, most 
amacrine types profiled (including BHLHB5+ cells) decreased modestly. This argues against a 
fate shift; however, upwards of 50% of amacrines are normally culled during the early postnatal 
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period261–264. Thus, an excess of improperly specified amacrine subtypes could be masked by 
apoptosis. In the frog, Prdm13 morpholinos reduced glycinergic amacrines without increasing 
GABAergic numbers259. Similarly, Watanabe and colleagues observed a reduction of glycinergic 
amacrines without an increase in other subtypes in Prdm13 mutant mice carrying a distinct allele 
to those used here218. Taken together, these loss-of-function data are consistent with roles for 
Prdm13 in both subtype specification and survival.  
Gain-of-function experiments suggest a more active role for Prdm13 in fate choice. 
Overexpression of Prdm13 in the frog retina biased cells towards glycinergic amacrine fate at the 
expense of bipolar cells and glia259. Watanabe and colleagues overexpressed Prdm13 in newborn 
mice and observed that most transfected cells adopted amacrine fate218. Moreover, Prdm13 
overexpression modestly increased the fraction of transfected cells that expressed calretinin 
and/or calbindin218. These findings argue that Prdm13 is sufficient to specify amacrine type and 
subtype identity. Based on these findings, we expected Prdm13 overexpression to drive ectopic 
EBF3+/calretinin+ amacrine cell formation. Though we observed that Prdm13 overexpressing 
cells were more likely to make PAX6, they did not ectopically express EBF3 or calretinin. Thus, 
Prdm13 is not sufficient to instruct EBF3+ amacrine subtype formation. We also observed a 
strong reduction in the number of Prdm13 transfected cells compared to control. Many 
transfected cells failed to express OTX2 or PAX6, which mark progenitors and specified retinal 
cells. These double negative cells are likely poised for apoptosis. Our data suggest that Prdm13 
overexpression is especially toxic to developing photoreceptors and to a lesser extent, 
progenitors and other cell types. Thus, we may be observing selection instead of fate changes in 
these gain-of-function experiments. Overexpressing PRDM13-VP16 also appeared toxic in the 
retina. This toxicity is likely caused by a different mechanism because PRDM13-VP16 increased 
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the fraction of cells that co-expressed OTX2 and PAX6. This forced activator activity may 
upregulate competing gene regulatory networks and cause apoptosis. Due to the toxicity we 
observed, future experiments where Prdm13 is specifically overexpressed in postmitotic 
amacrine cell precursors will reveal whether it instructs EBF3+ subtype identity.  
North Carolina Macular Dystrophy (OMIM-136550) has been attributed to dominantly 
inherited mutations in PRDM13129. This includes duplication of the coding sequence and non-
coding point mutations flanking PRDM13129,265,266. This disorder is developmental in nature and 
affects the structure of the macula, resulting in a highly variable loss of photoreceptors and 
central vision. It is unlikely that this represents haploinsufficiency, as Prdm13 heterozygous mice 
have no overt deficits in development. Instead, the pathology is consistent with a PRDM13 gain-
of-function. Since PRDM13 is expressed in PTF1a+ committed amacrine and horizontal cell 
precursors, it seems unlikely that increased PRDM13 dosage would negatively affect 
photoreceptor formation. Instead, mutations that drive ectopic PRDM13 expression in 
progenitors or nascent photoreceptors could either bias their fate towards amacrine cell identity 
or cause toxicity. One of these non-coding mutations (V2) creates a potential OTX2 binding site, 
which may create a photoreceptor-specific enhancer for PRDM13129,267. Our initial attempts to 
examine whether the non-coding mutations create novel retinal enhancers in developing mice 
were unsuccessful. Though our experiments suggest that Prdm13 kills nascent photoreceptors, 
other experiments did not note toxicity218,259. Due to the heterogeneity of mutations and the 
disease severity, it seems likely that more than one mechanism underlies the pathophysiology of 




Function of EBF3+ Amacrine Cells in the Retina 
We and others observed a decrease in the number of calretinin+ amacrines in Prdm13 
mutants218. Interestingly, calretinin staining of the IPL was altered such that the prominent 
sublamina 3 band was absent. This suggests that calretinin+ dendrites that project to sublamina 3 
are absent or re-routed. We observed that many EBF3+ amacrine cells co-expressed calretinin 
(~62%). Since EBF3+ cells are essentially absent in Prdm13 mutants, we reasoned that 
EBF3+/calretinin+ cells normally project dendrites to sublamina 3 of the IPL. Kay and 
colleagues showed that EBF3+ glycinergic amacrines (75%) projected to sublaminae 1-4, 
whereas EBF3+ nGnG amacrines (25%) have dendrites in sublaminae 1-340. Overexpression of 
Neurod6 increased the nGnG fraction of amacrines, creating prominent dendritic bands in 
sublaminae 1 and 3 of the IPL40. Thus, the loss of EBF3+ nGnG amacrines in Prdm13 mutants 
may explain the loss of calretinin labeling of sublamina 3. Alternatively, calretinin+ cells that do 
not co-express EBF3 and project to sublamina 3 may be lost or misrouted. Lastly, it is possible 
that loss of EBF3+ and other amacrine subtypes in Prdm13 mutants has a non-autonomous effect 
on the localization of calretinin+ dendrites.  
 The profound loss of EBF3+ amacrines and disruption of the IPL should alter the normal 
physiology of the retina. The complex nature of the cells lost and limited knowledge of amacrine 
physiology make this difficult to study. Watanabe and colleagues showed that scotopic and 
photopic electroretinography was normal in Prdm13 mutants218. They also examined optokinetic 
reflex response behaviors. Interestingly, these behavioral tests showed that Prdm13 mutant mice 
had greater spatial and contrast sensitivity than control mice218. Since EBF3+ amacrines are most 
disrupted in Prdm13 mutants, the loss of these amacrines likely caused the observed sensitivity 
increases, ostensibly at the expense of other visual functions268,269. A more narrow dissection of 
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the amacrines disrupted in Prdm13 mutants is needed to determine how defined amacrine 
subtype(s) contribute to visual behaviors.  
 
Chapter II Figures 
 




(A-A’’’) PRDM13+ cells (green) in E13.5 retinas overlap with PTF1a (red, arrows). 
PTF1a/OTX2 (grey, arrowheads) and PRDM13/PTF1a/OTX2 triple positive cells (stars) are 
always present in low abundance. (B-B’’’) A similar pattern of PTF1a, PRDM13 and OTX2 
expression are seen at E15.5. (C-C’’’) At P0, more PRDM13+ cells are evident and these 
overlap less frequently with PTF1a (arrows). PTF1a/OTX2 (arrowheads) and triple labeled cells 
(stars) are present. (D) Plot of the percentage of PRDM13+ cells that co-express PTF1a over 
time. (E) Plot of the number of PTF1a, PRDM13, and OTX2 labeled cells at each time-point. 
Sample sizes at E13.5 and E15.5 are 4 mice each and 3 mice are quantified at P0. Statistical 
significance determined by unpaired two-sample t-tests: * P < 0.05, ** P < 0.01, *** P < 0.001, 
Error bars represent standard deviation. Scale bar 50μm. Inset scale bar 10μm. GCL, ganglion 









(A-A’) Schematic of wildtype (A) and Prdm13-GFP mice (A’). The first exon of Prdm13 is 
replaced with GFP followed by a stop codon. Note that all homozygous Prdm13-GFP/GFP null 
mice die by birth. (B-B’’’) All PRDM13+ (red) cells co-express GFP (green, arrows) in E17.5 
GFP/+ mice. However, some GFP+ cells do not express PRDM13, likely because of the long 
half-life of GFP. (C-C’’’) Homozygous GFP/GFP mutants have a similar number of GFP+ cells 
compared to heterozygous controls, but lack PRDM13+ cells. A subset of PRDM13-GFP+ cells 
co-express OTX2 (grey, arrowheads). (D-E’’’) Heterozygous control (D) and mutant (E) retinas 
stained for GFP (green), OTX2 (grey), and PTF1a (red). The PTF1a and OTX2 staining patterns 
are equivalent between genotypes. Arrows mark PTF1a+/GFP+ cells, arrowheads mark 
OTX2+/GFP+ cells, and stars mark triple labeled cells. (F-G) Plots showing GFP+ cells in 
heterozygotes (HET) and GFP/GFP knock-outs (KO) (F), and PRDM13+ cells in WT, HET and 
KO animals (G). (H-K) Plots of the number of PTF1a+ cells (H), PTF1a/GFP double labeled 
cells (I), percentage of PTF1a that express GFP (J), and the number of PTF1a+/OTX2+ cells (K). 
Sample sizes are 3-4 mice per condition. Statistical significance determined by unpaired two-
sample t-tests and 1-way ANOVA: * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars represent 






































(A-D’’’) P30 PRDM13-GFP/+ heterozygous animals co-stained with GFP (green) and amacrine 
cell markers (grey/red). (A-A’’’) A small subset of PRDM13-GFP+ amacrine cells co-express 
AP2ɑ ɑ(grey, arrows) and BHLHB5 (red, arrowheads). (B-B’’’) Nearly half of GFP+ cells co-
express calretinin (grey, arrows), while less than 1% of GFP+ cells co-express calbindin (red). 
No intensely calretinin+ horizontal cells co-express GFP. (C-C’’’) A large fraction of GFP+ 
cells co-express the glycinergic amacrine marker GlyT (grey, arrows), but few GFP+ cells co-
express the GABAergic marker GAD65/67 and these were sometimes GlyT+ as well. (D-D’’’) 
The majority of GFP+ cells co-express EBF3 (grey, arrows), but all EBF3+ cells in the INL are 
GFP+. A minority of GFP+ cells co-express BHLHB5 (red, arrowheads) and cells that co-
express BHLHB5, EBF3, and GFP are rarely seen. (E) Plot of the percentage of GFP+ cells that 
co-express a given marker. GFP does not overlap with BRN3, TH, or vGlut3 (not shown). (F) 
Plot showing the percentage of EBF3+ amacrines, PAX6+ INL nuclei, and AP2α+ INL cells that 
co-express PRDM13-GFP. Sample size was 3 mice per condition. Statistical significance 
determined by unpaired two-sample t tests: * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars 





































Figure 2.4 EBF3+ amacrines are lost in adult Prdm13 mutants  
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(A-A’) Schematics of the two transgenic mice, Prdm13-GFP (A) and Prdm13-∆115 (A’). The 
∆115 allele has an 115bp deletion in the first exon of Prdm13. Unlike homozygous Prdm13-GFP 
mice, homozygous ∆115/∆115 mice and compound heterozygous Prdm13-GFP/∆115 are viable. 
(B-B’) Prdm13-GFP/∆115 mice (B’) have far fewer GFP+ cells (arrows) than Prdm13-GFP/+ 
control mice (B). (C) Plot showing the reduction in GFP+ cells between the two genotypes. (D-
K) Prdm13-GFP/+ and Prdm13-GFP/∆115 retinas stained for GFP (green) and various 
amacrine cell markers (red, grey). (D-E’’) The number of GlyT (grey) and GAD+ (red) cells is 
modestly altered in Prdm13-GFP/∆115 mice (E) versus controls (D). The number of 
GlyT+/GFP+ cells (arrows) is reduced in Prdm13-GFP/∆115 mice. (F-G’’) Staining for AP2ɑ 
(grey) and BHLHB5 (red) show a small decrease in both populations in Prdm13-GFP/∆115 mice 
(E) compared to controls (F). Cells expressing GFP, AP2ɑ, and BHLHB5 are marked by stars. 
(H-I’’) Calbindin (red) staining is similar between genotypes and rarely overlaps with GFP, but 
calretinin (grey) stains revealed a disrupted IPL in Prdm13-GFP/∆115 mice. There are fewer 
calretinin+ cells in the INL and far fewer GFP+/calretinin+ cells in Prdm13-GFP/∆115 mice 
compared to Prdm13-GFP controls (arrows). (J-K’’) EBF3+ (grey) amacrine cells are almost 
entirely absent from the INL in Prdm13-GFP/∆115 mice. GFP+/EBF3+ cells (arrows) are rare in 
Prdm13-GFP/∆115 mice (K) compared to control (J). Some BHLHB5+/GFP+ cells are seen in 
both conditions, some of which are EBF3+/BHLHB5+/GFP+ (stars). (L-L’) Close up views of 
calretinin staining in control (L) and Prdm13-GFP/∆115 (L’) retinas. Loss of sublamina 3 and a 
thinning of the IPL are evident. (M) Plot showing the number of marker positive cells in control 
and Prdm13-GFP/∆115 mice. (N) Plot showing the number of marker positive cells that co-
express GFP. Sample sizes are 3 mice per condition for heterozygotes and 6 mice for mutants. 
Statistical significance determined by unpaired two-sample t tests: * P < 0.05, ** P < 0.01, *** P 



























Figure 2.5 Amacrine cells are initially formed, but subsets are lost in the first postnatal 




(A-B) At E17.5, there is no difference in PAX6 (red) numbers between Prdm13-GFP/+ control 
(A) and Prdm13-GFP/GFP null mice (A’). GFP (green) staining is equivalent between these 
genotypes. (C-D) P2 PRDM13-GFP/+ (C) and Prdm13-GFP/∆115 mice (C’) have equivalent 
GFP staining and PAX6 numbers. (E-F’’’) P5 Prdm13-GFP/+ control (E) and Prdm13-
GFP/∆115 (F) retinas stained for GFP (green), BHLHB5 (red) and EBF3 (grey). At this age, 
there are fewer GFP+ cells in Prdm13-GFP/∆115 retinas. Controls have many cells that co-
express GFP and EBF3 (arrows), but EBF3+ cells are nearly absent from the INL of Prdm13-
GFP/∆115 mice. A higher percentage of GFP+ cells co-express BHLHB5 in mutants. (G) Plot 
showing the percentage of marker positive cells that co-express GFP at P5. (H) Plot showing the 
percentage of GFP+ cells that co express EBF3 and BHLHB5. (I) Plot showing the number of 
cells that express GFP, EBF3, and BHLHB5. Sample size for E17.5 is one mouse, 3 mice per 
condition at P2, and 3-4 mice per condition at P5. Statistical significance determined by unpaired 
two-sample t-tests: * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars represent the standard 









































(A-C’’’) Wild-type P0 mouse retinas electroporated (EP’d) with control, wild-type PRDM13, 
and PRDM13-VP16 expression plasmids and cultured for 7 days in vitro (DIV). Electroporated 
cells are detected with antibodies to Cre (PRDM13 and PRDM13-VP16) or to red fluorescent 
protein (RFP, control). Sections are stained for the photoreceptor and bipolar cell marker OTX2 
(grey) and for PAX6 (red), which marks amacrine cells intensely. (A-A’’’) Control Ef1α nuclear 
Cherry transfections have numerous RFP cells (pseudo-colored green), primarily in the 
photoreceptor area after 7DIV. Most of these cells co-express OTX2 (arrows), while a minority 
co-express PAX6 (arrowheads). (B-B’’’) Overexpression of wild-type PRDM13 (PRDM13-WT-
IRES-Cre) yields few Cre+ (green) cells after 7DIV. These cells are localized to the INL and are 
typically PAX6+ (arrowheads). In about 30% of cases, Cre+ cells expressed neither PAX6 nor 
OTX2 (inset). (C-C’’’) Electroporation of a PRDM13-VP16 fusion (PRDM13-VP16-IRES-Cre) 
construct also results in sparse numbers of Cre+ cells. These transfected cells are seen in the INL 
and co-express PAX6 (arrowheads) at high frequency. Many of these cells also co-express OTX2 
(star), which is rarely seen in control or PRDM13 WT transfections. (D-F) Plots showing the 
percentage of electroporated cells at 2DIV and 7DIV that co-express OTX2 (D), PAX6 (E), and 
OTX2/PAX6 (F). (G) Plot showing the number of transfected cells seen after 2DIV or 7DIV. 
Sample sizes for 2DIV are 8-10 retinas per condition and for 7DIV are 7-9 retinas per condition. 
Statistical significance is determined by unpaired two-sample t-tests (D, E, G), and ANOVA (F): 
* P < 0.05, ** P < 0.01, *** P < 0.001. Error bars represent the standard deviation. Scale bar 

































Supplemental Figure 2.1 EBF3 and calretinin co-expression marks a large population of 
amacrines 
(A-A’’) P16 wild-type mouse retinas labeled with antibodies to EBF3 (green) and calretinin 
(red). The majority of both calretinin+ and EBF3+ cells in the INL co-express both markers 
(arrowheads). (B-C) Plots showing the percentage of calretinin+ cells that co-express EBF3 (B) 
and the percentage of EBF3+ cells that co-express calretinin (C) in both the INL and within the 
entire retina. Sample size was 4 retinas. Statistical significance determined by unpaired two-







SIMULTANEOUS DELETION OF PRDM1 AND VSX2 ENHANCERS ALTERS 
RETINAL CELL FATE SPECIFICATION, YET DIFFERS FROM DELTEING BOTH 
GENES6  
 
Chapter III Summary 
The transcription factor Otx2 is required for photoreceptor and bipolar cell formation in 
the retina. It directly activates the transcription factors Prdm1 and Vsx2 through cell type-specific 
enhancers. Prdm1 and Vsx2 work in opposition, such that Prdm1 promotes photoreceptor cell 
fate and Vsx2 bipolar cell fate. To determine how OTX2+ cell fates are regulated, we deleted 
Prdm1 and Vsx2 or their cell type-specific enhancers simultaneously using a CRISPR/Cas9 in 
vivo retina electroporation strategy. Double gene or enhancer targeting effectively removed 
PRDM1 and VSX2 protein expression. However, double enhancer targeting favored bipolar fate 
outcomes whereas double gene targeting favored photoreceptor fates. Both conditions generated 
excess amacrine cells. Combined, these fate changes suggest that photoreceptors are a default 
fate outcome in OTX2+ cells and that VSX2 must be present in a narrow temporal window to 
drive bipolar cell formation. Prdm1 and Vsx2 also appear to redundantly restrict the competence 
of OTX2+ cells, preventing amacrine cell formation. By taking a combinatorial deletion 
approach of both coding sequences and enhancers, our work provides novel insights into the 
complex regulatory mechanisms that control cell fate choice. 
 
 
6The contents of this chapter have been submitted for publication and the work was completed in 





One of the fundamental questions in development is how progenitor cells give rise to the 
incredible variety of cell types found in the central nervous system. The retina is an excellent 
system for studying the mechanisms of fate specification because the major cell types are readily 
discernable. The seven principal cell types are derived from a population of retinal progenitor 
cells in a stereotyped overlapping fashion during embryonic and early postnatal development in 
the mouse81–83,85,219,220. Some cell types, like cone photoreceptors, horizontals, and ganglion 
cells, permanently exit the cell cycle (i.e., they are born) embryonically. Rod photoreceptors, 
bipolar cells, and Müller glia are primarily born in the postnatal period. Amacrine cells are 
mostly formed embryonically, but a small population is born postnatally. It is widely thought that 
retinal progenitors progressively pass through stages where they have the competence (potential) 
to give rise to certain cell types early and others later84,97,100,127,221–224. However, the means by 
which progenitors change their competence and adopt their final cell fates are only partially 
understood.  
The transcription factor Otx2 sits at the top of a regulatory network that controls 
photoreceptor and bipolar cell genesis130. It is expressed by all mature photoreceptors and bipolar 
cells138,227,228. Mice that lack this gene do not generate photoreceptors or bipolar cells, but instead 
produce excess amacrine cells138,139,226. OTX2 is first upregulated in a large fraction of retinal 
progenitors as they permanently exit the cell cycle229. OTX2 directly regulates two additional 
transcription factors, Prdm1 (Blimp1) and Vsx2 (Chx10), through discrete enhancer 
sequences167,234,235. In the absence of Prdm1, OTX2+ cells precociously upregulate Vsx2 and 
form bipolar cells at the expense of photoreceptors127,128,231. Many of these Prdm1 mutant 
OTX2+ cells appear by morphology and immunohistochemistry to start off as photoreceptors 
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and subsequently transition (transdifferentiate) into VSX2+ bipolar cells in the early postnatal 
period231. Conversely, overexpression of PRDM1 suppresses VSX2 and bipolar cell 
formation128,231. These data argue that Prdm1 does not instruct photoreceptor fate, but instead 
suppresses bipolar cell formation. Vsx2 overexpression suppresses photoreceptor genes and Vsx2 
mutant mice fail to generate bipolar cells148–150,232. Taken together, this suggests that OTX2 
establishes competence for photoreceptor and bipolar cell fates while PRDM1 and VSX2 form a 
mutually inhibitory network to influence the fate choice made by these competent OTX2+ cells 
(Fig 3.1A).  
Several non-exclusive mechanisms may explain the role of Prdm1 and Vsx2 in OTX2+ 
cell fate determination (Fig 3.1A). Vsx2 and Prdm1 could fine-tune the numbers of bipolars and 
photoreceptors formed by repressing instructive factors (Fig 3.1A). Another possibility is that 
these transcription factors stabilize specification after a fate choice has occurred. Finally, it is 
possible that either photoreceptor or bipolar cell identity is a default outcome during retinal 
development and that Prdm1 and Vsx2 are used to break away from such a default state to ensure 
both fates are formed. We reasoned that removing the function of Prdm1 and Vsx2 
simultaneously in OTX2+ cells would discriminate between these potential developmental 
mechanisms.   
To simultaneously remove PRDM1 and VSX2, we developed a loss-of-function 
CRISPR/Cas9 targeted gene disruption system that could be delivered in vivo to the developing 
mouse retina. We created two versions of this system. The first targets the coding region of each 
gene to remove its function via deletion in a non-cell type-specific manner from transfected 
retinal cells. The second targets the Prdm1 and Vsx2 enhancers that are directly regulated by 
OTX2. We then delivered these CRISPR/Cas9 plasmids via in vivo electroporation into hundreds 
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of newborn mouse retinas and tracked cell fate under a variety of conditions across multiple time 
points. Similar to prior loss-of-function experiments127,128,148,149, we observed that singly 
targeting Prdm1 and Vsx2, either through their enhancers or coding sequences, affected the 
number of photoreceptors and bipolar cells that were formed. Removing Prdm1 and Vsx2 
simultaneously yielded different fate changes depending on how they were removed. From these 
data we conclude that photoreceptors are a default fate choice during development, but there is a 
critical temporal window when bipolar fate can be driven by VSX2. We found that VSX2 is 
dispensable for bipolar fate maintenance and we also observed that Prdm1 and Vsx2 act 
redundantly in OTX2+ cells to restrict their ability to form amacrine cells. By targeting multiple 
genes and enhancers simultaneously in vivo, we have gained novel insights into the complex 
regulation of cell fate choice within the retina. 
 
Results 
Vsx2 and Prdm1 Enhancers are Necessary for Protein Expression at P2 and P7 
Otx2 is required for the formation of photoreceptors and bipolar cells138,139. The 
transcription factors Prdm1 and Vsx2 are direct targets of OTX2 and appear to have a cross-
repressive relationship (Fig 3.1A)127,128,167,231,234. We reasoned that deleting Prdm1 and Vsx2 
simultaneously would unmask the processes controlling photoreceptor and bipolar fate choices. 
To test this, we developed a CRISPR/Cas9 system to specifically delete these transcription 
factors during the postnatal period, when OTX2+ cells primarily choose between rod 
photoreceptor and bipolar fates81,85,220.  
We first modified existing plasmid constructs (Ran et al., 2013) to so that: (1) S. 
pyogenes Cas9 was driven by a ubiquitous EF1α promotor, and (2) in some cases GFP was 
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replaced with RFP. (Fig 3.1B). Guide RNAs were designed to triply target a key coding exon of 
Prdm1 (PC) and Vsx2 (VC) (Fig 3.1B). By co-electroporating these plasmids into newborn 
retinas, Vsx2 and Prdm1 can be targeted in any transfected cell (Fig 3.1C). 
Prior studies identified OTX2 regulated enhancers for Prdm1 and Vsx2. This included a 
139bp retina-specific enhancer approximately 6kb upstream of Prdm1 and a 164bp bipolar-
specific enhancer about 19kb upstream of Vsx2167,235,270. Because Vsx2 plays a role in promoting 
retinal progenitor proliferation in addition to its role in bipolar cell genesis148,149,271, we generated 
another targeting strategy that would prevent Vsx2 and Prdm1 expression specifically within 
postmitotic OTX2+ cells. To do this we designed a separate trio of guide RNAs to target the 
Prdm1 (PE) and Vsx2 enhancers (VE) (Fig 3.1B). All guides; PC, VC, PE, and VE along with a 
non-targeting control were cloned into plasmids that expressed either RFP or GFP fluorescent 
markers. 
To test whether this CRISPR/Cas9 strategy effectively lowered PRDM1 and VSX2 
protein expression, we electroporated postnatal day 0 (P0) wildtype (WT) CD1 mouse retinas 
with plasmids (PE, PC, VE, VC or non-targeting control) and raised the pups until the desired 
age of tissue collection (Fig 3.1C). PC, PE, and control eyes were collected at P2 when PRDM1 
is quantifiable via immunohistochemistry (Fig 3.1D). Retinas were stained for PRDM1 and the 
fluorescent marker (Fig 3.1D, E). We observed a significant decrease in PRDM1+ cells in PC 
(p<0.001) and PE (p<0.001) compared to control (Fig 3.1F), but no difference between PC and 
PE (p=0.075). This argues that the Prdm1 enhancer is necessary for PRDM1 expression in the 
retina. Next, we conducted electroporations with control, VC, and VE targeting plasmids and 
collected pups at P7, a time when bipolar-specific VSX2 expression is high (Fig 3.1G-H). The 
percentage of electroporated cells that co-expressed VSX2 was significantly lower in VC 
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(p<0.001) and VE (p<0.001) compared to control (Fig 3.1I). There was no difference between 
VC and VE (p=0.39).  
Since VSX2 is made by progenitors, it is possible that both VC and VE affect expression 
in progenitors. To test this, we electroporated embryonic (E) day 13.5 retinal explants with VC, 
VE, or control guides and cultured them for 72 hours (Fig S3.1A). We then quantified the 
percentage of electroporated cells (GFP+) that co-expressed VSX2. At this time-point, VSX2 
only marks progenitors. The VC targeted cells had significantly reduced co-expression 
(p<0.001), whereas the VE cells co-expressed VSX2 at the same frequency as control 
electroporated cells (Fig S3.1 B-C). Thus, the Vsx2 enhancer is only necessary for bipolar-
specific VSX2 expression. Taken together, both coding (PC, VC) and enhancer (PE, VE) 
CRISPR/Cas9 systems were able to equivalently reduce PRDM1 and VSX2 expression.  
 
Vsx2 and Prdm1 Cell Type-Specific Enhancers Control Fate Choice  
If VE and PE are necessary for VSX2 and PRDM1 expression in OTX2+ cells, then 
targeting these enhancers should mimic targeting the coding regions and recapitulate the 
phenotypes reported in Prdm1 and Vsx2 loss-of-function studies127,128,148,149. To test this, we 
raised PC, PE, VC, VE, and control electroporated mice to P28 and quantified the fate of 
electroporated cells (Fig 3.2). 
At P28, PE and PC significantly reduced photoreceptors (p<0.001 both), but increased 
bipolar cells (PE p=0.005, PC p<0.001) (Fig 3.2C,D). There were no changes in the percentage 
of electroporated amacrine interneurons or Müller glia (Fig 3.2E,F). These data mimic Prdm1 
knockout mice and suggest that the Prdm1 enhancer is essential for protein expression. PC 
produced a more robust shift from photoreceptors (p=0.013) to bipolars (p=0.009) than PE (Fig 
95 
 
3.2C,D). We next examined VC and VE targeted mice at P28 (Fig 3.2). Both conditions had a 
significant loss of electroporated bipolar cells (VC p=0.011, VE p=0.008) (Fig 3.2D). There was 
no change in the percentage of electroporated cells that became photoreceptors, amacrines, or 
Müller glia in VE or VC (Fig 3.2C,E,F). There were more photoreceptors in VE and VC 
compared to control, however, our methods did not have the power to detect a significant 
photoreceptor increase (Fig 3.2B-D). Targeting the Vsx2 coding and enhancer regions affected 
cell fate equally (p=0.382). These results are similar to Vsx2 mutants, suggesting that the Vsx2 
enhancer is necessary for bipolar cell genesis148,149. 
 
Simultaneous Deletion of Vsx2 and Prdm1 Enhancers Dysregulates Cell Fate 
  Targeting Prdm1 or Vsx2 was robust, but never reached 100% efficiency in our 
experiments. To ensure that we knocked-out multiple targets consistently, we electroporated 
retinas with PCVC or PEVE, such that PC and PE were labeled with GFP and VC and VE were 
marked by RFP (Fig 3.3). RFP and GFP overlapped 85% of the time regardless of condition (Fig 
3.3B,C). Based on this high degree of overlap, we assume throughout the remainder of this paper 
that a single fluorescent label is sufficient to conclude a cell received multiple constructions.  
To determine whether targeting multiple genes was as effective as just one, we stained 
VC, VE, PCVC, and PEVE for VSX2 expression at P7. We observed an equivalent reduction in 
the percentage of electroporated cells that co-expressed VSX2 in all four conditions (Fig 3.3D). 
This suggested that the effect was not diluted by including guides targeting other genes. Next, we 
asked whether simultaneously targeting Vsx2 and Prdm1 (PEVE, PCVC) diluted its effect (Fig 
3.3E). We quantified the percentage of electroporated cells that expressed VSX2 and PRDM1 at 
P4 and observed a significant reduction of VSX2+ and PRDM1+cells in both conditions (Fig 
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3.3F-H). We concluded that we can simultaneously eliminate PRDM1 and VSX2 using either 
gene or enhancer targeting. Although effective, we chose to utilize a larger number of biological 
replicates throughout our studies to overcome the limitations of incomplete targeting that we 
observed.  
With the ability to target Vsx2 and Prdm1 simultaneously, we next examined the fate of 
doubly targeted cells. To do this, we performed in vivo electroporations at P0 with control, 
PCVC, and PEVE plasmids, raised pups to P28, and quantified the fate of electroporated cells 
based on their morphology and location (Fig 3.4A). Control electroporated cells were mostly 
photoreceptors and bipolars, but a modest number of OTX2-negative amacrines and Müller glia 
were also seen (Fig 3.4). Mice targeted with PEVE had a significantly lower percentage of 
photoreceptors (p=0.014) compared to controls (Fig 3.4B). In contrast, PCVC photoreceptors 
remained indistinguishable from controls (p=0.366) (Fig 3.4B). PCVC had a smaller fraction of 
bipolar cells compared to controls (p=0.002), whereas there was no change in the fraction of 
bipolars in PEVE electroporations (p=0.261) (Fig 3.4B,C). These results were in contrast to 
single VC and VE electroporations that experienced a loss of bipolar cells and single PC and PE 
electroporations that had a loss of photoreceptors (Fig 3.2). Thus, perturbing both genes or 
enhancers simultaneously was not simply the sum of the individual electroporations. 
We expected that targeting Prdm1 and Vsx2 would only alter the fate of OTX2+ cells. 
However, the sum of bipolar and photoreceptor cells was lower than controls in both PEVE and 
PCVC conditions (Fig 3.4B,C). This suggested that there should be changes in the number of 
OTX2-negative Müller glia and amacrine cells. Upon quantification, we saw no changes in the 
number of Müller Glia (not shown). However, we observed a 2-3 fold increase in electroporated 
cells that become amacrine cells in booth PCVC and PEVE conditions compared to control 
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(p<0.001 both) (Fig 3.4D). Both conditions had an equivalent increase in the fraction of 
amacrines observed (p=0.178) (Fig 3.4E). This increase in amacrines accounted for the reduction 
in photoreceptors (PCVC) or bipolar cells (PEVE) (p<0.001 both) (Fig 3.4D,E). 
One explanation for this unexpected result is that some bipolar cells migrate to the wrong 
portion of the inner nuclear layer (INL) and display amacrine-like morphology. To determine 
whether the morphologic characterization was misleading, we examined these mice by 
immunohistochemistry with cell type-specific markers. Both PCVC and PEVE had significantly 
fewer OTX2+ cells compared to controls (p<0.001, p<0.001), matching what we observed 
morphologically (Fig 3.4E-G). Both PCVC and PEVE showed a significant (p<0.001, p<0.001) 
and equal reduction in VSX2 co-staining compared to control, despite the fact that PEVE did not 
lose morphologically identified bipolars (Fig 3.4C,H-I). The few bipolars seen in PCVC 
typically co-expressed VSX2 (rare exception highlighted in center panel, Fig 3.4H). In contrast, 
PEVE had numerous clear VSX2-negative bipolars (Fig 3.4H). These data argue that bipolar 
cells could form or survive without VSX2 or that their morphology remained misleading. To test 
this, we stained with additional bipolar markers (Fig S3.2). We found that co-expression with 
ISLET1/2 (Cone ON and rod bipolars)215,272 matched the morphologically categorized bipolars, 
showing a significant decrease in PCVC (p=0.002) and no change in PEVE compared to controls 
(Fig S3.2B-C). The co-expression with Secretagogin, which marks a subset of ON and OFF cone 
bipolars273, paralleled our observations of VSX2 and showed a significant decrease in PEVE and 
PCVC compared to control (p<0.001, p=0.003) (Fig S3.2D,E). There was no difference between 
the percentage of morphological bipolar cells that lacked both ISLET1/2 and Secretagogin 
between the conditions (Fig S3.2F). Taken together, these data argue that most (perhaps all) 
morphologically identified bipolar cells co-express other bipolar markers even though they lack 
98 
 
VSX2. Thus, our morphological assessment is robust and suggests that bipolars were formed in 
the absence of bipolar-specific VSX2. Nonetheless, loss of VSX2 may alter the subtypes of 
bipolar cells formed.  
To corroborate the change in morphologically identified amacrine cells, we stained for 
the pan-amacrine marker PAX6209. The percentage of electroporated cells that co-expressed 
PAX6 in controls was indistinguishable from the value determined by morphology (Fig 3.4D, J-
K). We observed a significant increase in PAX6+ cells to about 20% in both PCVC (p<0.001) 
and PEVE (p<0.001) (Fig 3.4J,K). This increase was only observed in the PEVE and PCVC 
conditions and was remarkably consistent across litters (Figs S3.4F,S3.5E). We next stained for 
GLYT1 and EBF3, which primarily mark different populations of late-born amacrine 
cells211,212,250,274–276. Like PAX6, the percentage of electroporated cells that co-expressed EBF3 
doubled in both PCVC (p=0.054) and PEVE (p=0.051) compared to controls (Fig S3.3B,C). 
Similarly, the percentage of electroporated cells that co-expressed GLYT1 was strongly 
increased in both PCVC (p<0.001) and PEVE (p<0.001) conditions (Fig S3.3D, E). Thus, 
morphologically identified amacrines express pan-specific and late-born markers. We also 
observed that the number of cells co-expressing EBF3 increased in proportion to the total 
number of amacrines (Fig S3.3F). The extra amacrines in PEVE and PCVC conditions appear to 
proportionally adopt late-born subtype fates, similar to control amacrines formed postnatally.  
 
Fate Changes Do Not Result from Selective Survival 
We reasoned that our Prdm1 and Vsx2 perturbations could alter cell survival, biasing the 
observed fate changes. Because of the temporally precise nature of cell death markers and our 
sparse-label technique, we were not able to directly test differences in cell death. Instead, we 
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took three complementary indirect approaches to show that cell survival was equivalent between 
conditions. First, we quantified the number of cells per image across six litters of control and six 
litters of PEVE (63 total mice and 116 images) and found no differences between conditions (Fig 
3.5A). This suggests that cell survival is comparable at P28 between the two conditions. There 
was one exception where a control litter had significantly more cells per image compared to the 
rest of the controls and PEVE mice (Fig 3.5A, S3.4). However, the variance within a litter was 
equal to or greater than between litters (Fig 3.5B). Second, we asked whether variance in the 
total number of electroporated cells measured in any given litter skews the assessment of cell 
fate. Across six control and six PEVE litters we observed no differences in the percentages 
within a condition and significant differences between conditions in the number of 
photoreceptors and amacrines (Fig S3.4). Indeed, we could compare any control litter to any test 
litter and arrive at the same conclusion. Third, we asked whether there was a progressive loss in 
electroporated cells by quantifying the number of cells per image at intermediate developmental 
time-points. In no condition were there significantly more cells at P7 or P14 compared to P28 
(Fig 3.5C), arguing against a progressive loss of electroporated cells. Taken together, our data 
strongly suggests that cell survival is unaffected by our perturbations and changes are a result of 
shifting cell fates.  
 
Cell Fate Changes Are Seen at Different Times in Development 
Perturbing Prdm1 and Vsx2 could alter cell fate early. Alternatively, doubly targeted cells 
may stall in an intermediate or confused state. To explore this question, we repeated PC, PE, VC, 
VE, PCVC, PEVE, and control electroporations at P0 and collected animals at P7 and P14. 
Electroporated cells were screened by morphology to determine if fate shifts occurred early (by 
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P7) or were delayed, suggesting that fate choice is stalled (Fig 3.5). We considered all radially 
oriented cells that lacked clear neuronal morphology to be progenitors, undifferentiated neurons, 
or Müller glia. For simplicity, we pooled all of these cells in our quantification of electroporated 
retinas (Fig 3.5G). 
Targeting PC and PE revealed an early fate shift, such that there were more bipolars and 
less photoreceptors at all time-points (Fig 3.5D, E). In contrast, perturbing VC and VE only 
showed a loss of bipolars at the P28 time-point (Fig 3.5E). PCVC and PEVE animals showed an 
increase in amacrines at all time points (Fig 3.5F), which was not observed in the single loss-of-
function conditions (Fig 3.5D-G). The number of progenitor-like cells progressively decreased in 
all conditions suggesting that some electroporated cells had not fully differentiated by P7 or P14 
(Fig 3.5G). This likely reflects a delay in these cells adopting clear photoreceptor morphology 
(Fig 3.5D). In particular, the PEVE and PCVC conditions had excess undifferentiated cells at the 
P7 time-point compared to controls and most of the single mutant conditions. This correlates 
with the early deficit and protracted accumulation of photoreceptors in PCVC and PEVE 
conditions. Taken together, our data suggest that cell fate changes seen in Prdm1 mutants occur 
early, Vsx2 mutants were delayed, and double mutants were a mix of both. 
 
Birthdating Shows an Increase in Late-Born Amacrines 
The double mutant conditions may perturb cell-cycle exit timing and thus fate choice. To 
explore this possibility, we conducted an EdU birthdating experiment. Eight litters of P0 pups 
were electroporated with control or PEVE and subsequently received a single EdU pulse at either 
P0, P2, P4, or P6 (Fig 3.6A). All mice were raised to P28 and examined by 
immunohistochemistry to determine the fate of birthdated (EdU+) cells. The total number and 
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percentage of electroporated cells marked by EdU did not vary between control and PEVE 
conditions (Fig 3.6B,C). We concluded there were no major differences in cell cycle exit timing 
between PEVE and control. Nonetheless, there were differences in the fate of cells born at P0, 
P2, and P4 (Fig 3.6, S5). Significantly fewer photoreceptors were born in PEVE compared to 
controls at P0 (p=0.008), P2 (p=0.025), and P4 (p=0.038) (Fig 3.6D). The fraction of birthdated 
photoreceptors was reduced to a similar degree over time, suggesting that the fate shift was 
independent of cell cycle exit timing (Fig 3.6D). In contrast, there was no difference at any time-
point in the number of bipolar cells born (Fig 3.6E). The birthdating pattern of PEVE closely 
matched controls and the unchanged number of morphologically identified bipolars that we 
observed (Fig 3.4,5,6E). However, when we stained for VSX2 we saw a significant decrease in 
birthdated VSX2+ cells in PEVE compared to controls at P0 (p<0.001), P2 (p<0.001), and P4 
(p=0.005) (Fig 3.6G, S5C). This paralleled the decrease in VSX2+ bipolars that we observed in 
PEVE conditions (Fig 3.4H). There were slightly more Müller glia born in the PEVE condition 
at P0 (p=0.035), although this did not result in significantly more total glia and appeared to be 
caused by three outliers (Fig 3.6I, S4G-PEVE litter 1). Taken together, these data indicate that 
cell-cycle exit timing is not contributing to the differences seen in photoreceptor and bipolar cell 
numbers in PEVE. 
Next, we examined amacrine cell birthdates. We observed an increase in birthdated 
amacrines in PEVE compared to controls at P0 (p=0.048), P2 (p=0.004), and P4 (p=0.004) (Fig 
3.6F). This increase matched the loss of photoreceptors at each time-point (Fig 3.6D). Unlike 
photoreceptors (Fig 3.6D), the birthdating profiles of control and PEVE amacrine cells were not 
parallel, with PEVE amacrines extending beyond their normal window. We next asked if the 
percentage of electroporated and birthdated PAX6+ amacrines exceeded the total percentage of 
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all birthdated amacrines in PEVE. Indeed, there were far more electroporated and birthdated 
amacrines (Marker+, PAX6+, EDU+) at P0 (p<0.001, pairwise t-test), P2 (p<0.001), and P4 
(p=0.005) compared to the percentage of all birthdated (EDU+ PAX6+) cells in those same 
images (Fig 3.6H, S5D). Together, these data reveal that many of the increased amacrines in 
PEVE conditions are born later than normal, likely at the direct expense of rods. 
 
Bipolar Fate is Selected Prior to VE Activation and Does Not Require VSX2 for Maintenance 
Previous loss-of-function work148,149 and our own study showed that VSX2 is necessary 
for bipolar formation, leading to the conclusion that bipolar-specific VSX2 is a fate-determining 
regulatory element. Yet, our PEVE data show that in the absence of PRDM1, bipolar-specific 
VSX2 is not necessary to form or maintain bipolar cell identity. We wondered if VE is in fact 
downstream of the bipolar cell fate choice and that this outcome has been obscured by the effects 
of PRDM1.  
To test this, we designed a system to compare the timing of bipolar fate choice with the 
expression of the Vsx2 enhancer. We built a plasmid containing the Vsx2 bipolar-specific 
enhancer driving Cre recombinase (VE-CRE) to fate map newly formed bipolar cells (Fig 3.7A). 
We co-electroporated this construct along with control or VC-Cas9-GFP targeting plasmids into 
newborn ROSA-RFP reporter mice277. In this system, control and VC targeted cells will be 
GFP+, but only cells that activated the Vsx2 enhancer will become permanently RFP+ (Fig 3.7). 
Mice were examined at P7 for RFP, GFP, and VSX2 (Fig 3.7B,I). Since the control and VC 
plasmids are expressed under the ubiquitous EF1α enhancer, there were more GFP+ cells in both 
conditions than RFP+ cells (Fig 3.7B). We saw no differences in the percentage of total GFP+ 
cells that co-expressed RFP+ between control and VC conditions (p=0.169) or in the percentage 
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of RFP+/GFP+ cells in the INL (p=0.199) (Fig 3.7C-D). RFP+ cells in control animals 
overwhelmingly adopted bipolar cell morphology, although about 1 in 7 cells showed rod 
photoreceptor morphology (Fig 3.7B). This is consistent with VE becoming activated in cells 
that are poised between photoreceptor and bipolar fates with most adopting a bipolar fate. We 
then examined the VC condition to determine whether there was a fate change in the VE lineage. 
If VSX2 acts only after the onset of VE activity, we expected to see an increase in the fraction of 
lineage traced cells that become photoreceptors at the expense of bipolars. However, we 
observed the opposite in VC conditions. An even higher fraction of the VC RFP+ cells had 
bipolar morphology (p=0.017) (Fig 3.7E), which came at the direct expense of cells with 
photoreceptor morphology in the outer nuclear layer (ONL) (p=0.017) (Fig 3.7F).  
This result suggested that VSX2 can act before the onset of VE activity. We next 
expanded our analysis by asking if the RFP+ cells within the INL made VSX2. In the control 
condition 98.9% of the RFP+ cells in the INL co-expressed VSX2+, as expected for this bipolar 
cell maker (Fig 3.7G,I). However, only 15.1% of RFP+ cells in the INL co-expressed VSX2+ in 
the VC electroporated retinas (p<0.001) (Fig 3.7G). Thus, RFP+ cells with bipolar morphology 
persisted in the INL of VC electroporations despite the absence of VSX2. This, along with our 
PEVE findings (Fig 3.4), argues that VSX2 is not required for bipolar cell maintenance. We also 
observed that a small percentage of the RFP+ cells were GFP-negative in the VC condition and 
hence untargeted (Fig 3.7D). Not only were there far fewer RFP+ photoreceptors in the ONL of 
the VC condition (Fig 3.7F), of those RFP+ cells, only three across all images co-expressed 
GFP+ (Fig 3.7H, p=0.003). Thus, when VC is targeted, VE gives rise to a purely bipolar cell 
lineage instead of one poised between photoreceptor and bipolar fates. Taken together, these data 
104 
 
argue that targeting VSX2 can alter the fate of OTX2+ cells before the decision to activate VE 
(Fig 3.7J).  
 
Discussion 
OTX2 activates two downstream transcription factors (Prdm1 and Vsx2) to influence 
whether cells adopt bipolar or photoreceptor fates (Fig 3.8A). Lineage tracing experiments of the 
Prdm1 (PE) and Vsx2 bipolar (VE) enhancers show that each can give rise to bipolars and 
photoreceptors167,233,234. This argues that OTX2+ cells are poised between fates and that Prdm1 
and Vsx2 compete to regulate the choice. To investigate how these genes interact, we used a 
CRISPR/Cas9 approach to simultaneously remove Prdm1 and Vsx2 activity from the retina. Our 
results suggest that: (1) the PE and VE elements are necessary in the retina, (2) photoreceptors 
are a default outcome in OTX2+ cells, (3) there is a critical period where VSX2 is needed to 
drive bipolar fate choice, (4) bipolar fate maintenance does not require VSX2, and (5) PRDM1 
and VSX2 act redundantly to suppress amacrine formation. Together, our findings provide a 
framework for how deletion of necessary enhancers and their target genes can cause divergent 
results.  
 
Prdm1 and Vsx2 Enhancers Are Necessary for Gene Expression 
Otx2 regulates both the Prdm1 and Vsx2 enhancers167,231,233,234. Targeting the Prdm1 
enhancer was equally effective at reducing protein expression compared to targeting its coding 
sequence (Fig 3.1). Targeting PE and PC each caused the same type of cell fate changes, arguing 
that the Prdm1 enhancer is necessary for PRDM1 expression (Fig 3.2, 8C-D). Our results 
parallel other work that explored the necessity of the PE sequence indirectly233. Despite effecting 
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protein expression equally during development, targeting PE and PC did not result in the same 
degree of fate changes between photoreceptors and bipolars at P28 (Fig 3.2, 8C-D). It is unclear 
why this was the case. One possibility that accounts for the milder phenotype in the PE condition 
is that targeting PE may result in slightly later timing of PRDM1 loss, allowing more cells to 
develop normally.  
Targeting the VE sequence significantly reduced VSX2 and matched targeting the coding 
region. Correspondingly, there was no difference in the effect on cell fate between VE and VC 
conditions (Figs 3.1-2). In contrast to VC, targeting VE did not affect VSX2 in progenitors (Fig 
S3.1). Taken together, this suggests that the VE region is necessary for VSX2 expression in 
bipolars (Fig 3.8F,G). This is in line with a recent report where a large (~32kb) upstream region 
of Vsx2 (including VE) was deleted, resulting in mice that lacked bipolar cells278. Here we show 
that targeting the 164bp VE enhancer was sufficient to prevent bipolar formation (Fig 3.2D). 
  
Photoreceptors Are the Default Outcome in OTX2+ Cells 
Targeting Prdm1 or Vsx2 resulted in changes in the numbers of photoreceptors and 
bipolar cells (Fig 3.8). Targeting the coding regions of Prdm1 and Vsx2 simultaneously resulted 
in retinas that had reduced numbers of bipolar cells (Fig 3.4,8I). One interpretation is that fate 
choice in double mutant cells is moderately biased against forming bipolar cells. However, the 
percentage of bipolars formed in PCVC electroporations matched the percentage of cells that 
failed to lose VSX2 expression (Fig 3.4C,I). We almost never observed VSX2-negative bipolars 
in PCVC, unlike what we saw in the PEVE condition. This strongly suggests that morphological 
bipolars seen in the PCVC condition were predominantly cells that escaped Vsx2 targeting. This 
indicates that OTX2+ cells that lacked both PRDM1 and VSX2 overwhelmingly adopted 
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photoreceptor fates, leading to the conclusion that photoreceptors are the default outcome of 
postnatal OTX2+ cells (Fig 3.9A). This aligns with our findings and other work showing that 
bipolar cells only form if VSX2 is present148,149,278. Further, our data argue there are additional 
regulatory components that contribute to the specification of OTX2+ cells (Fig 3.1A). The 
identity of these factors and how they work remains to be uncovered.  
   
VSX2 is Not Required for Bipolar Cell Maintenance 
Loss-of-function experiments argue that Vsx2 is necessary to form bipolar cells. 
Throughout our study, the bipolars that formed in PCVC, VC, and VE conditions closely aligned 
with the number of VSX2+ cells. We concluded that the bipolars observed in these conditions 
were a function of the escape rate within our CRISPR/Cas9 technique and not representative of 
what happens in the absence of VSX2. In contrast, many bipolars in the PEVE conditions lacked 
VSX2, yet robustly displayed bipolar morphology (Fig 3.4), bipolar subtype markers (Fig S3.2), 
and were born in a similar pattern (Fig 3.6). These data argue that at some point soon after an 
OTX2+ cell has decided to become a bipolar, it does not need VSX2 to maintain its identity.  
This raises the question; why do adult bipolar cells express VSX2? Under normal 
conditions, mature bipolars express VSX225. When we quantified the subtype fates of the PEVE 
bipolars, we observed that ON type bipolar cell markers were comparable to controls, while 
Secretagogin positive cone bipolars (types 2-6, 8)273 were strongly reduced. This suggests that 
the formation or maintenance of some cone bipolar subtypes requires VE mediated VSX2 
expression. This may be due to complex negative interactions between VSX2 and its paralog 
VSX1, which is needed for the proper formation of cone bipolars279–283. Another possibility is 
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that VSX2 is used to maintain the physiologic functions of mature bipolar cells. Further studies 
are needed to understand the role of VSX2 in mature bipolar cells.  
 
VSX2 Affects Bipolar Fate Choice over a Critical Window of Time 
We were surprised to discover that simultaneously targeting Prdm1 and Vsx2 coding 
regions did not yield the same result as targeting their enhancers. In contrast to PCVC 
electroporations, PEVE cells were more likely to be bipolars and less likely to be rod 
photoreceptors (Fig 3.8J). We reasoned that the most probable explanation for this difference is 
that there was some VSX2 present in the electroporated cells. Since targeting VE has no effect 
on VSX2 made in progenitors (Fig S3.1), it is likely that some VSX2 is carried over as cells 
become postmitotic (Fig 3.8J). This residual VSX2 expression could drive bipolar fate, but only 
in the absence of PRDM1 due to its ability to suppress bipolar formation in OTX2+ cells (Fig 
3.8, 9B). This would not be the case in PCVC conditions, where VSX2 was eliminated in 
progenitors before it has a chance to carry-over into OTX2+ cells and affect fate (Fig 3.8I). The 
decrease in photoreceptors in the PEVE condition is likely explained by the ability of progenitor-
derived VSX2 to promote bipolar fate at the expense of rods. Further support of this carry-over 
model (Fig 3.8, 9B) was found when we traced the Vsx2 enhancer lineage in control and Vsx2 
coding mutant cells. The VE lineage did not gain photoreceptors when VSX2 was targeted, 
suggesting that the choice between photoreceptor and bipolar fates can occur before VE is 
activated (Fig 3.7J). This further suggests that there is a temporal window where VSX2 carry-
over is sufficient to rescue bipolar cell formation, but only in the absence of PRDM1 (Fig 3.8, 
9B). The presence of photoreceptors in the PEVE condition may reflect that only a subset of 
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OTX2+ cells carry-over sufficient VSX2 to rescue bipolar fate. Alternatively, targeting PE may 
not remove PRDM1 quickly or completely enough to prevent photoreceptor formation.  
In the absence of PRDM1, progenitor VSX2 carry-over appears sufficient to rescue 
bipolar cell formation (Fig 3.9). However, VC and VE single targeting equivalently reduced 
bipolar cell formation (Fig 3.2) and mice lacking a 32kb region of DNA upstream of Vsx2 
completely lack bipolars278. This shows that VSX2 expression driven by VE is essential for 
bipolar fate choice when PRDM1 is present. We also observed that bipolar cells as a class do not 
require VSX2 to maintain their fate. Taken together, these data argue that there is a transient 
period where VSX2 is required for bipolar cell formation. This critical period spans a relatively 
narrow window before and after the onset of VE activity. The mechanisms that VSX2 uses 
during this window and its interactions with PRDM1 and other factors remain to be determined.  
 
Prdm1 and Vsx2 Combine to Suppress Amacrine Formation 
Since Prdm1 and Vsx2 are downstream of Otx2, we expected that mutating these genes 
would simply alter the proportion of photoreceptors and bipolar cells that were formed. Indeed, 
mutating Vsx2 or Prdm1 on their own changed the numbers of OTX2+ cell types that formed. 
We were surprised to see a proportional increase in amacrine cells when we perturbed Prdm1 
and Vsx2 (PEVE and PCVC) simultaneously. This mimics what is seen in Otx2 null retinas, 
which form excess amacrine cells at the expense of photoreceptors and bipolar cells138,139. 
OTX2+ cells have the competence to become photoreceptors and bipolar cells, but some 
of these cells likely give rise to OTX2-negative amacrines and horizontals130,167,230,231 (Fig 3.1A). 
We observed that single mutants of Prdm1 or Vsx2 did not alter the number of amacrine cells 
formed. Thus, it seems unlikely that Prdm1 or Vsx2 are necessary for restricting amacrine 
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competence in OTX2+ cells. Since double mutants have excess amacrine cells that are born 
outside of their normal temporal window, it is possible that Prdm1 and Vsx2 act redundantly to 
restrict amacrine competence in OTX2+ cells (Fig 3.8K). It is unclear why only a subset of these 
double mutant cells shifted to amacrines. One possibility is that there are other factors beyond 
Prdm1 and Vsx2 that contribute to inhibiting amacrine formation. Another possibility is that 
signals promoting amacrine identity are limited in the postnatal retinal environment. Future 
experiments with Prdm1 and Vsx2 double enhancer mutant mice will help decipher how 
competence is regulated in the OTX2+ cell population.  
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Chapter III Figures 
 





(A) Schematic for the Otx2 gene regulatory network. (B) CRISPR targeting guide design and 
nomenclature. (C) Schematic of experimental approach. (D) Experiment schematic. (E, H) 
Immunohistochemistry from electroporated cells. (F) Percentage of electroporated cells that also 
express PRDM1. (G) Experiment schematic. (I) Quantification of electroporated cells that also 
express VSX2. Error bars=standard deviation. ns=not significant, ***p<0.001. bars=50µm, inset 






Figure 3.2 Targeting PC, PE, VC, or VE shifts cell fates in mature retinas  
(A) Experimental schematic. (B) Representative immunohistochemistry of electroporated cells 
(grey) for each condition. (C-F) Percentage of electroporated cells that are photoreceptors (C), 














Figure 3.3 Double targeting is as efficient as single at blocking expression  
(A) Experimental schematic. (B) Representative immunohistochemistry of electroporated (RFP 
or GFP) cells co-stained with VSX2. (C) Percentage overlap between GFP and RFP. (D) 
Percentage of electroporated cells (marker+) that co-express VSX2. (E) Experimental schematic. 
(F) Electroporated cells co-stained with VSX2 and PRMD1. (G-H) Percentage of electroporated 
cells that co-express VSX2 (G) or PRDM1 (H). ***p<0.001. Bars=50µm, inset bars=25µm. 




















Figure 3.4 PCVC and PEVE targeting increases amacrines, but have divergent bipolar and 




(A) Experimental schematic. (B-D) Percent of electroporated cells with photoreceptor (B), 
bipolar (C), or amacrine (D) cell morphology. (E) Combined percentage of electroporated cells 
that are photoreceptors, bipolars, and Müller glia. Representative immunohistochemistry of 
electroporated retinas co-stained with OTX2 (F), VSX2 (H), and PAX6 (J). Percentage of 
electroporated cells that are also OTX2+ (G), VSX2+ (I), and PAX6+ (K) **p<0.01, 









(A) Number of electroporated cells per image showing the variability both within and between 
conditions. These are the average cells per image across 12 unique litters electroporated at P0 
and collected at P28 along with the number of mice with quantifiable electroporations. (B) 
Representative immunohistochemistry of two mice from the same litter showing electroporation 
efficiency differences within a condition. (C) Average electroporated cells per image by 
condition over time. (D-G) Percentage of electroporated cells with photoreceptor (D), bipolar 
(E), amacrine (F), or glial/progenitor (G) morphologies by condition over time. *p<0.05, 








(A) Schematic of experimental design. (B-I) Dots represent specific quantified images while the 
top of the shaded area represents the mean. (B-C) The total number (C) and the percentage (D) 
of electroporated cells that are also EdU+ over time. (D-F, I) Percentage of electroporated and 
EdU+ cells with photoreceptor (D), bipolar (E), and amacrine cell (F), or Müller glial (MG) (I) 
morphologies. (G-H) Percentage of electroporated and EdU+ cells that co-express VSX2. (H) 
Percentage of electroporated and EdU+ cells that express PAX6 compared to the percentage of 
all EdU+ cells that expressed PAX6 in the same image. N for EDU0: Cont=6, PEVE=6; for 
EDU2: Cont=7, PEVE=6; for EDU4: Cont=7, PEVE=6; and for EDU6: Cont=5, PEVE=7. 












(A) Schematic of the experimental design. (B) Immunohistochemistry showing RFP+ (lineage 
trace) and GFP+ (control or VC CRISPR/Cas9) electroporated cells at P7. VE-CRE driven RFP 
had a low efficiency that resulted in small numbers of cells and higher than normal standard 
deviations. (C) Percentage of GFP+ cells that are RFP+. (D) RFP+ cells within the INL as a 
percentage of GFP+ cells within the INL. (E-F) Percentage of RFP+ cells in the INL (E) and the 
ONL (F). (G) Percentage of RFP+ cells in the INL that are co-stained for VSX2. (H) Cells 
(photoreceptors) that co-stain for RFP and GFP in the ONL as a percentage of the total RFP+ 
cells located in the ONL. There were only 3 GFP+/RFP+ cells in ONL of the VC VE-CRE 
condition across all images. (I) Immunohistochemistry showing GFP, RFP, and VSX2 overlap at 
P7. (J) Schematic showing that VE enhancer activation can occur after the decision to become a 
bipolar cell. *p<0.05, **p<0.01, ***p<0.001. Bars=50µm, inset bars=25µm. Stars=VSX2+ cells, 











(A) Under control conditions, progenitors express VSX2 and activate OTX2 as they exit the cell 
cycle. These OTX2+ cells generate both photoreceptors and bipolars. The presence of PRDM1 
and bipolar VSX2 control the numbers of each cell that forms. (B) OTX2 drives PRDM1 and 
VSX2 expression, leading to photoreceptor and bipolar fates respectively. (C) PC leads to a 
major loss of photoreceptors and VSX2 is able to drive excess bipolars. (D) PE leads to a more 
modest loss of photoreceptors and increase in bipolars. (E) OTX2+ cells without Prdm1 shift and 
adopt bipolar fates. (F-G) VC and VE cause a loss in bipolars which may become rods. (H) 
OTX2+ cells are unable to adopt bipolar fate and are likely to adopt rod fate instead as Prdm1 is 
intact. (I) PCVC blocks VSX2 and PRDM1 expression. Without VSX2 carry-over from 
progenitors, OTX2+ cells adopt photoreceptor identity. Some cells become amacrines and lose 
OTX2 expression. (J) PEVE targeted cells retain progenitor-derived VSX2, resulting in a 
preference for bipolars in the absence of Prdm1. (K) In the absence of both VSX2 and PRDM1, 
some cells fail to maintain OTX2 expression and become amacrines. Thus, Vsx2 and Prdm1 may 





















Figure 3.9 Summary of changes in OTX2+ cell fates 
(A) Loss of PRDM1 and VSX2 leads to a photoreceptor default state in OTX2+ cells. (B) The 






















Supplemental Figure 3.1 VE does not affect progenitor-derived VSX2 expression 
(A) Schematic of experimental design. (B) Immunohistochemistry of electroporated cells 
(marker) and VSX2 in cultured retinal explants. (C) Percentage of electroporated cells that are 
VSX2+. Error bars=standard deviation. ns=not significant, ***p<0.001. Bars=50µm, inset 











Supplemental Figure 3.2 Bipolar subtype marker expression in doubly targeted retinas  
(A) Schematic of experimental design. (B, D) Immunohistochemistry of electroporated (marker) 
cells co-stained with the pan ON-bipolar marker ISLET1/2 (B) or the cone bipolar marker 
Secretagogin (SCGN) (D). (C, E) Percentage of electroporated cells that are co-labeled with 
ISLET1/2 (C) or SCGN (E). (F) Percentage of electroporated cells that appear to be bipolar cells 
by morphology but lacked ISLET1/2 and Secretagogin co-staining. *p<0.05, **p<0.01, 





Supplemental Figure 3.3 Amacrine subtype marker expression in doubly targeted retinas 
(A) Schematic of experimental design. (B, D) Immunohistochemistry of electroporated (marker) 
cells co-stained with two markers of different late-born amacrine populations. EBF3 (B) 
primarily marks non-glycinergic, non-GABAergic amacrines while GLYT1 (D) marks the 
glycinergic population. (C, E) Percentage of electroporated cells that are co-labeled with EBF3 
(C) or GLYT1 (E). (F) Percentage of electroporated cells that appear amacrine by morphology 
but lacked EBF3 or GLYT1 co-staining. *p<0.05, **p<0.01, ***p<0.001 Bars=50µm, inset 







Supplemental Figure 3.4 Comparison of cell quantification from control and PEVE 
electroporated litter at P28  
(A) Schematic of experimental design. (B) Number of average cells per image across 12 litters of 
mice. (C-D, F-G) Percentage of electroporated cells with photoreceptor (C), bipolar (D), 
amacrine (F), and Müller glial (G) morphologies. (E) Percentage of electroporated cells that co-












(A) Schematic of experimental design. (B-D) Control and PEVE electroporated retinas 
birthdated with EdU at four time-points (P0, P2, P4, and P6). (B) P28 retinas showing 
electroporated (marker) cells in green and EdU+ cells in purple. (C-D) Control and PEVE 
electroporated retinas at P28 additionally stained with VSX2 (C) and PAX6 (D) to mark bipolars 
and amacrine cells, respectively. (E) Percentage of electroporated PEVE cells that co-express 
PAX6 across three litters. Bars=50µm, inset bars=25µm. Stars=cells with all markers, 
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Supplemental Table 3.1 List of guide primers utilized in CRISPR/Cas9 experiments  






PRDM1 OVEREXPRESSION CAUSES A PHOTORECEPTOR FATE-SHIFT IN 
NASCENT, BUT NOT MATURE BIPOLAR CELLS7 
Chapter IV Summary 
The transcription factors Prdm1 (Blimp1) and Vsx2 (Chx10) work downstream of Otx2 to 
regulate photoreceptor and bipolar cell fates in the developing retina. Mice that lack Vsx2 fail to 
form bipolar cells while Prdm1 mutants form excess bipolars at the direct expense of 
photoreceptors. Excess bipolars in Prdm1 mutants appear to derive from rods, suggesting that 
photoreceptor fate remains mutable for some time after cells become specified. Here we tested 
whether bipolar cell fate is also plastic during development. To do this, we created a system to 
conditionally misexpress Prdm1 at different times during bipolar cell development. We found 
that Prdm1 blocks bipolar cell formation if expressed before the fate choice decision occurred. 
When we misexpressed Prdm1 just after the decision to become a bipolar cell was made, some 
cells were reprogrammed into photoreceptors. In contrast, Prdm1 misexpression in mature 
bipolar cells did not affect cell fate. Surprisingly, we also found that sustained misexpression of 
Prdm1 was selectively toxic to photoreceptors. Our data show that bipolar fate is malleable, but 
only for a short temporal window following fate specification. Prdm1 and Vsx2 act by stabilizing 
photoreceptor and bipolar fates in developing OTX2+ cells of the retina. 
 
 
7The contents of this chapter have been submitted for publication and the work was completed in 
collaboration with co-authors including Ko U. Park, Jason S. Silver, Vince A. Chiodo, William 




During development, a population of retinal progenitor cells gives rise to all six major 
classes of neurons within the eye: rod and cone photoreceptors, ganglion, amacrine, bipolar, and 
horizontal cells, as well as Müller glia82,83. Retinal progenitors permanently exit the cell cycle 
(their birthdate) and generate these cell fates in a stereotyped overlapping fashion from 
approximately embryonic (E) day 11.5 to postnatal (P) day 7 in mice85,219,220,284. These 
progenitors have more than one fate option they can select from at nearly any given time in 
retinal development. Nonetheless, it is unclear how these cells choose their fate and subsequently 
make that decision permanent. 
Mouse retinal progenitors in the postnatal period choose between four fates: amacrine 
cells, Müller glia, bipolar cells, and rod photoreceptors82,85. Of these, rods and bipolars are the 
most abundant and both types express the key transcription factor Otx225,138,227,228. Otx2 is 
required for the formation of photoreceptors and bipolar cells138,139. Its expression is activated in 
the final cell cycle and precedes the decision to adopt photoreceptor versus bipolar cell fates243. 
Otx2 directly regulates two downstream transcription factors, Vsx2 (Chx10) and Prdm1 
(Blimp1), through defined enhancer sequences167,231,233,234. When Prdm1 is knocked out in the 
developing retina, there is a severe reduction in the number of photoreceptors that form127,128,231. 
In these mutants, there is a 1:1 fate shift within OTX2+ cells such that bipolars are increased at 
the expense of photoreceptors. Overexpression of Prdm1 in early development suppresses 
bipolar cell formation127,128. No bipolar cells are formed when Vsx2 is mutated148,149,285. In 
contrast, when Vsx2 is overexpressed it inhibits photoreceptor gene expression and increases 
bipolar cell formation at the expense of rods150,232. These data suggest that there is a mutually 
inhibitory gene regulatory network within OTX2+ cells where Prdm1 represses bipolar fate and 
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Vsx2 blocks photoreceptor formation. Correspondingly, loss of Prdm1 results in precocious and 
excess expression of Vsx2 in the retina127,128,231. We observed that bipolar cells in Prdm1 mutants 
could be derived from cells that make rod-specific markers231. This suggests that photoreceptor 
fate is transiently plastic after it has been selected and is subsequently stabilized as a rod or 
superseded by the bipolar cell program. In Vsx2 mutant retinas, non-functional Vsx2 mRNA 
remains and was found in developing photoreceptors150. This raises the possibility that OTX2+ 
cells destined for bipolar fate can have their identity superseded by the photoreceptor program. 
Here, we asked whether and when bipolar fate can be superseded in developing OTX2+ cells.  
 Since Prdm1 can block bipolar cell formation, we misexpressed PRDM1 at different 
stages of retinal development to determine whether bipolar fate is plastic. To do this, we first 
created a mouse line that allowed us to conditionally drive Prdm1 expression via CRE-mediated 
recombination. We then drove constitutive PRDM1 expression using three distinct sources of 
CRE during unique timeframes in development: (1) Before bipolar fate choice is made, (2) just 
after bipolar fate selection, and (3) in mature bipolar cells. Prdm1 had different effects at each of 
these developmental stages. It blocked bipolar formation if present before the choice, partially 
converted bipolars into photoreceptors just after bipolar specification, and had no effect on the 
fate of mature bipolar cells. Surprisingly, we also observed that long-term misexpression of 
Prdm1 was toxic, but only to photoreceptors. Taken together, our data show that bipolar cells are 
transiently plastic after their fate is selected. Nonetheless, shortly after fate selection bipolar cells 
become stabilized and refractory to the effects of PRDM1. One role of the interplay between 





 Photoreceptor and bipolar cell formation requires the transcription factor Otx2138,139. 
OTX2 directly activates two downstream transcription factors, Prdm1 and Vsx2, which have 
been hypothesized to play a cross-repressive role to set the balance of photoreceptors and bipolar 
cells formed127,128,130,167,231,233,270. If so, constitutive expression of PRDM1 in OTX2+ cells 
should block bipolar genesis and force these cells to adopt photoreceptor fate. Since Prdm1 is not 
permanently expressed in photoreceptors, there may only be a transient period when Prdm1 can 
affect fate choice. To test how Prdm1 affects cell fate, we built systems to misexpress Prdm1 in 
a spatially and temporally controlled fashion. To drive Prdm1 expression, we first constructed a 
CRE-inducible Prdm1 mouse line. We replaced the red fluorescent protein sequence (tdTomato) 
in the Ai9 targeting vector with the cDNA for mouse Prdm1277. This targeting vector was used to 
make knock-in mice, resulting in the insertion of a Lox-stop-Lox Prdm1 allele into the ROSA26 
locus (Fig 4.1A). Throughout, we refer to these ROSA-Prdm1 knock-in animals as PRDM1 mice. 
As detailed below, we permanently misexpressed Prdm1 in different spatial and temporal 
patterns by combining these PRDM1 mice with multiple CRE expression systems.  
 
Constitutive Prdm1 expression alters cell fates within the retina 
 To test that our misexpression system worked and that Prdm1 can induce cell fate 
changes, we crossed PRDM1 mice with αPAX6-Cre-IRES-GFP mice (PAX6-CRE) (Fig 4.1A)141. 
The PAX6-CRE line drives CRE and GFP expression in nearly all retinal progenitors of the 
peripheral retina starting before the onset of neurogenesis and persisting in a subset of amacrine 
cells across the whole mature retina141,286. This transgene also drives expression in the 
developing ciliary structure of the eye that is immediately adjacent to the retina and within a 
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small number of peripheral retinal pigmented epithelial (RPE) cells. We collected PAX6-
CRE/PRDM1 experimental and PRDM1/+ control mice at P0. Immunostaining for PRDM1 
showed a dramatic increase in the number and distribution of labeled cells in the peripheral 
retinas of PAX6-CRE/PRDM1 eyes compared to controls (Fig 4.1B). This included PRDM1+ 
cells in the RPE and ciliary body, which were never observed in controls (Fig 4.1B). Thus, the 
PRDM1 mice operate as expected, leading to robust PRDM1 misexpression following CRE-
mediated recombination in the eye.  
Misexpressing PRDM1 throughout the periphery at P0 had no observable effect on retinal 
architecture (Fig 4.1B-D). Despite the increase in PRDM1 expression in experimental mice, 
immunostaining retinal progenitors in the P0 peripheral retina with VSX2 showed no changes in 
gross morphological pattern or overlap with PRDM1+ cells compared to control (Fig 4.1C-D)148–
150,287. This is consistent with a role for PRDM1 in controlling cell fate choice in OTX2+ cells, 
rather than proliferative progenitors.  
To examine cell fate choice, we next collected mice at P7, when bipolar cells are readily 
detectable in the retina (Fig 4.2A). PAX6-CRE/PRDM1 mice had morphologically similar 
peripheral retinas compared to CRE-negative controls (Fig 4.2B-C). We stained P7 sections with 
multiple markers for bipolar cells. These include: (1) OTX2, which marks newly postmitotic 
rods and bipolars at higher intensity than mature photoreceptors, (2) VSX2, which marks 
bipolars intensely and progenitors weakly, (3) ISLET1/2, which marks cone ON and rod bipolar 
cells, and (4) Secretagogin (SCGN), which marks a subset of ON and OFF cone 
bipolars25,138,149,215,227,272,273. PAX6-CRE/PRDM1 mice had fewer intensely labeled VSX2+ and 
OTX2+ cells (Fig 4.2B-E). The overall number of OTX2+ cells was slightly, but not 
significantly, reduced (Fig 4,2F). We observed mosaic patterns of VSX2+ bipolar cell reduction 
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(Fig 4.2D) and continuous stretches of near complete bipolar cell loss (Fig 4.2E). When we 
quantified bright VSX2 cells, which generally represent bipolar-specific expression, we observed 
a significant decrease in our test condition compared to control (Fig 4.2D-E, G, p<0.001). This 
was consistent with a reduction in bipolar cells. We found that SCGN+ cone bipolar cells were 
reduced in experimental retinas compared to control (Fig 4.2D-E, H, p<0.001). All areas that 
lacked intense OTX2 or VSX2 staining also lacked SCGN or ISLET1/2 staining (Fig 2B-E, H-I). 
ISLET1/2+ bipolar cells showed a severe loss of labeling in PAX6-CRE/PRDM1 retinas 
compared to control (Fig 4.2B-C, I, p<0.001). In contrast, we saw no differences in the number 
of amacrine and ganglion cells that were also labeled by ISLET1/2 between conditions (Fig 
4.2B-C, J, p=0.355)215,272. Our results show that misexpressing Prdm1 before the onset of bipolar 
cell formation can prevent their genesis. This aligns with previous findings where overexpression 
of Prdm1 in postnatal retinal progenitors suppressed bipolar cell formation127,128. Moreover, our 
results show that Prdm1 misexpression does not significantly interfere with other cell fate 
choices that occur in retinal development. 
 We next tested whether Prdm1 could affect fate choice in OTX2+ cells that have already 
decided to become bipolar cells. To do this, we first obtained VSX2-CRE mice from Jackson 
Labs288. This line uses sequences upstream of Vsx2 to drive CRE in a bipolar cell-specific 
fashion starting shortly after they become specified in the early postnatal period288. We then 
crossed the VSX2-CRE mice with our PRDM1 animals to test whether Prdm1 misexpression at 
the onset of bipolar fate specification could alter fate choice (Fig S4.1A). However, we 
consistently had trouble breeding these mice. When litters were obtained, they were small (3-5 
pups) and no VSX2-CRE/PRDM1 double-transgenic mice were seen across dozens of crosses. 
Since Prdm1 promotes the germ cell lineage at the expense of somatic development289–291, we 
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suspected that CRE expression might be occurring early in development and preventing 
embryogenesis. To test this, we crossed the VSX2-CRE mice with ROSA-RFP (RFP) reporter 
mice (Fig S4.1)277. When mature VSX2-CRE/RFP retinas were stained for CRE, the pattern of 
expression was limited to bipolar cells as expected (Fig S4.1D). However, these mice had visibly 
red skin and their entire eye was RFP+, including the lens and surrounding ocular tissues (Fig 
S4.1D). When the VSX2-CRE was maternally derived, all pups (even those that were VSX2-CRE-
negative) ubiquitously expressed RFP (Fig S4.1E). When VSX2-CRE was paternally inherited, 
VSX2-Cre/RFP pups had mosaic, yet global, RFP expression (Fig S4.1F). We concluded that 
VSX2-CRE mice have CRE activity in retinal bipolar cells, but also at very early stages of 
development. When crossed with PRDM1 mice, the VSX2-CRE allele will drive widespread 
PRDM1 expression. Based on Prdm1’s early role in development, this is incompatible with 
embryogenesis. Early PRDM1 misexpression explains why we never recovered any VSX2-
CRE/PRDM1 mice, which necessitated a different approach to misexpress Prdm1 in bipolar 
cells. To do this, we designed viral and plasmid-electroporation strategies to deliver CRE 
recombinase to mature and developing bipolar cells, respectively. 
  
AAV driven PRDM1 does not alter bipolar fate choice and is toxic to mature photoreceptors  
To ascertain if PRDM1 expression in mature bipolar cells is sufficient to cause a fate 
shift to photoreceptors we created adeno-associated viruses (AAV) that drive CRE-recombinase 
under the control of an ON bipolar cell-specific PCP2 enhancer (Bipolar-CRE-AAV)292,293. 
PRDM1 mice were crossed with RFP mice to generate trans-heterozygous experimental 
(RFP/PRDM1) and control (RFP/+) mice. Bipolar-CRE-AAV was injected into the vitreous of 
P28 eyes and the mice were raised till P60 (Fig 4.3A). This allowed us to track cells that 
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expressed the bipolar-specific CRE because they will permanently express RFP. We then 
compared RFP/+ controls to RFP/PRDM1 mice by immunostaining for RFP. Cell fates were 
assessed by morphology and location within the retina. In addition to RFP+ bipolar cells, we also 
observed RFP+ ganglion cells, amacrines, Müller glia, and photoreceptors (Fig 4.3B). We 
quantified cells and found that both control mice and their RFP/PRDM1 littermates had an equal 
number of amacrines and ganglion cells, which were proximal to the site of the intravitreal 
injections (Fig 4.3D). This suggested that amacrine and ganglion cell labeling was the result of 
transient off-target CRE expression, as previously noted with similar viruses293. Thus, we 
excluded amacrine and ganglion cells from further calculations. While off-target expression 
accounts for RFP labeling of photoreceptors and Müller glia in controls, we quantified them to 
determine whether any cell fate changes occurred upon PRDM1 misexpression. When summed, 
the number of RFP+ bipolars and photoreceptors were similar between conditions (Fig 4.3C). If 
PRDM1 reprogrammed bipolar cell fate, we expected to see an increase in RFP+ photoreceptors 
at the expense of bipolars. However, when we specifically examined each cell fate, we observed 
fewer photoreceptors and more bipolar cells in our Prdm1 misexpression condition compared to 
our controls, exactly the opposite of our hypothesis (Fig 4.3E-G). Indeed, there were almost no 
RFP+ photoreceptors found in the RFP/PRDM1 condition (Fig 4.3E).  
 We next tested whether PRDM1 misexpression repressed VSX2 expression in RFP+ 
bipolar cells. VSX2 stains revealed that significantly more cells in RFP/PRDM1 mice were 
VSX2+ compared to controls (Fig 4.3H-I). However, we did not observe diminished VSX2 
staining intensity compared to neurons in the control condition or in RFP-negative bipolar cells 
within the same image. We concluded that constitutive PRDM1 expression cannot alter the fate 
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of mature bipolar cells, does not affect VSX2 expression, and is toxic only to mature 
photoreceptors.  
  
Overexpression of PRDM1 in nascent bipolar cells causes a fate shift to rods 
 In the absence of Prdm1, VSX2 is precociously upregulated in the retina127,128,231. Early 
overexpression of Prdm1 reduces VSX2 and bipolar cell formation (Fig 4.2)127,128. Nonetheless, 
long-term misexpression of Prdm1 in adult bipolar cells does not repress VSX2 expression or 
change cell fate (Fig 4.3). We hypothesized that there is a critical period in OTX2+ cells where 
PRDM1 can suppress VSX2 and promote photoreceptor fate at the expense of bipolar cell 
development.  
To test this, we designed a plasmid containing a 164bp bipolar-specific Vsx2 enhancer 
driving CRE-recombinase expression that we called VE-CRE (Fig 4.4A)270. Previous work 
showed that this enhancer is sufficient to drive bipolar-specific expression and our recent 
findings (See Chapter III) suggest it is necessary for VSX2 expression and bipolar cell 
formation270. We electroporated VE-CRE into the retina of P0 RFP/+ controls and RFP/PRDM1 
littermates and raised the pups to P7 (Fig 4.4A). RFP+ cells were quantified based on 
morphology and location within the retina. As expected, the majority of RFP+ cells were 
bipolars (Fig 4.4B, D). However, about 12% of RFP+ cells were photoreceptors, arguing that 
some VE-expressing cells are poised between bipolar and photoreceptor fates (Fig 4C). We also 
observed a small number of amacrines and Müller glia in control electroporations, which likely 
reflects off-target CRE activity (Fig 4.4B, E, H). VE-CRE electroporations in RFP/PRDM1 mice 
had three times more RFP+ photoreceptors compared to control, which came at the direct 
expense of RFP+ bipolar cells (Fig 4.4B-D). We stained for VSX2 and found that the loss of 
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RFP+ bipolar cells perfectly matched the loss of RFP+/VSX2+ cells (Fig 4.4E-F). The presence 
of VSX2 in morphologically identified bipolar cells suggested that they were accurately 
quantified and had repressed photoreceptor fate despite the misexpression of PRDM1. 
Photoreceptors did not co-express VSX2 in either condition. Thus, overexpression of PRDM1 in 
VSX2+ nascent bipolars was sufficient to force a fate change in some (~25%), but not all of the 
cells. Upon quantification, we observed no differences in the number of amacrines or Müller glia 
between conditions (Fig 4.4G, data not shown). We also stained for OTX2 and the pan-amacrine 
marker PAX6 and found no differences in either between conditions (Fig 4.4H-J)209. This 
suggests that Prdm1 misexpression only alters fate choice within OTX2+ cells.  
 
Constitutive PRDM1 expression is toxic to mature photoreceptors 
 PRDM1 is expressed by OTX2+ cells throughout retinal development but is 
downregulated in the early postnatal period and becomes undetectable by immunohistochemistry 
between P6 to P10127. Although PRDM1 is important for photoreceptor formation, it is not 
appreciably expressed by mature rods or cones.  When Prdm1 is turned on earlier in developing 
bipolars, it can cause a fate shift to photoreceptor identity (Fig 4.4). However, our Bipolar-CRE-
AAV experiment suggests that expressing Prdm1 in mature photoreceptors is toxic (Fig 4.3). 
This suggested that constitutive PRDM1 expression would eventually kill photoreceptors that 
were formed from nascent bipolar cells.  
 To test this, we electroporated P0 RFP/+ control pups and RFP/PRDM1 littermates with 
the VE-CRE plasmid and raised them to P28 when the retina is mature. We assessed the fate of 
RFP+ cells by morphology and immunohistochemistry (Fig 4.5A). Unlike at P7, we did not 
observe differences in the number of RFP+ photoreceptors and bipolar cells between control and 
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RFP/PRDM1 conditions (Fig 4.5B-D). The percentage of electroporated cells that were 
photoreceptors at P28 in the RFP/PRDM1 condition matched controls at both P7 and P28 
(~10%). This argues that the increase in photoreceptors caused by Prdm1 misexpression was lost 
by P28. While it is likely that photoreceptor cell death is the cause, the sparse label nature of our 
approach and the narrow time frame of cell death markers prevented us from directly measuring 
cell death. Additionally, there was large variation in the total number of electroporated cells per 
eye that prevented us from determining if there were significantly fewer cells in the 
RFP/PRDM1 condition at P7 and P28. We saw no differences in the number of RFP+ amacrines 
or Müller glia at P28 (Fig 4.5G, data not shown). There were also no differences in the number 
of RFP+ cells that co-expressed VSX2+, OTX2+, or PAX6+ between conditions (Fig 4.5E-J). 
Taken together with the Bipolar-CRE-AAV findings, we conclude that sustained Prdm1 
expression in photoreceptors is toxic. Nonetheless, it appears that Prdm1 misexpression in other 
cell types does not affect their survival.  
   
Discussion 
 During late retinogenesis, OTX2+ cells decide between rod photoreceptor and bipolar 
fates. This is driven in part by the actions of OTX2’s downstream targets, Vsx2 and Prdm1 (Fig 
4.6D). The loss of Prdm1 from the retina results in a fate shift to VSX2+ bipolar cells, even after 
cells have started to show photoreceptor-like morphology and markers (Brzezinski et al., 2013). 
This suggests that there is some window wherein developing OTX2+ cells have selected a 
specific fate but remain susceptible to signals driving an alternative identity. Here, we tested 
whether OTX2+ cells can change their identity at different stages of maturity (Fig 4.6A-C). Our 
findings show that some specified bipolar interneurons can be shifted to photoreceptor fates by 
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PRDM1 (Figs 4.4, 4.6B). However, there is a narrow temporal limit to this fate conversion, and 
mature bipolars do not change their fate in response to PRDM1 (Fig 4.3, 4.6C). While Prdm1 is 
critical for photoreceptor development, we found that if PRDM1 is constitutively expressed in 
mature photoreceptors it will cause their death (Figs 4.3, 4.5, 4.6C). 
 
Bipolar cell fate choice is plastic over a narrow window of development 
 We used Prdm1 misexpression to ask whether bipolar cell fate can be superseded at three 
different stages of retinal development. Using PAX6-CRE mice, we were able to drive Prdm1 
misexpression before the decision to become a bipolar cell is normally made. As predicted from 
prior work, this early Prdm1 misexpression was highly effective at preventing bipolar cell 
formation (Figs 4.1-4.2, 4.6A)127,128. Next, we used an electroporation approach to permanently 
activate Prdm1 in newly specified bipolar cells. Misexpression at this stage blocked a portion of 
bipolar cell formation while increasing the number of photoreceptors (Fig 4.4). Thus, bipolar fate 
can be superseded by Prdm1 around the time of specification, although at a modest efficacy 
compared to early misexpression (Fig 4.6A-B). This fate plasticity is similar to what is seen in 
Prdm1 conditional knock-out retinas, where a substantial number of rod photoreceptors appear to 
directly transition into bipolar cells in the early postnatal period231. Lastly, we activated Prdm1 
expression in mature bipolar cells using an AAV strategy. This had no discernable effect on 
bipolar cell fate stability (Figs 4.3, 4.6C). Taken together, our results suggest that bipolar cell 
fate is malleable. Nonetheless, plasticity is limited to a narrow time period around the bipolar 
fate specification event (Fig 4.6).  
Bipolar cell plasticity is similar to what has been observed in rods. Knocking out the rod-
instructive factor Nrl prevents rod formation and massively increases cone genesis if done early 
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in development294,295. Removing Nrl shortly after birth incompletely converts rods into cones, 
while targeting Nrl in the adult retina has a more modest effect that is limited to changes in rod- 
and cone-specific gene expression295–297. These data argue that OTX2+ neurons are transiently 
plastic and progressively alter their epigenetic states to “lock-in” their identities (Fig 4.6E)295. 
The ability to reprogram bipolar cell identity around the time of fate specification appears more 
modest than what occurs to photoreceptors in Nrl or Prdm1 knockouts. This raises the possibility 
that some cell types, such as photoreceptors, take longer to “lock-in” their identities. This may 
correlate with the highly specialized chromatin architecture that slowly forms in rods over 
several weeks in postnatal mice298. In this model, Prdm1 may inhibit bipolar fate while rods 
develop their “locked-in” stabilized state. This could explain why PRDM1 is only active for a 
relatively short period during photoreceptor development.  
Our previous loss-of-function data and current PRDM1 gain-of-function experiments 
show that cell fate choice is plastic in developing OTX2+ cells (Fig 4.6E)231. While this 
plasticity appears to be short-lived in newly specified bipolar cells, it is unclear how long 
photoreceptors remain plastic. As PRDM1 expression is low in photoreceptors by P7, it is 
unlikely that plasticity extends beyond the first postnatal week (Fig 4.6E). Since fate plasticity is 
only widespread in genetically perturbed conditions, it is likely that PRDM1 and VSX2 robustly 
stabilize fate choices in OTX2+ cells. How PRDM1 and VSX2 interact with OTX2 and other 
factors to select and maintain cell fate decisions remains to be determined. 
 
PRDM1 acts in a context-specific fashion in OTX2+ cells 
OTX2 directly activates the expression of Prdm1 and Vsx2 through essential retina-
specific enhancer elements (see Chapter III)167,231,233,270. Gain- and loss-of-function experiments 
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argue that the balance of photoreceptors and bipolar cells is controlled by direct cross-repression 
between Prdm1 and Vsx2127,128,150,231. Overexpression of Prdm1 early in development blocked 
the intense VSX2 labeling that is characteristic of bipolar cells (Fig 4.2). However, permanently 
misexpressing Prdm1 at later times did not block VSX2 expression in morphologically identified 
bipolar cells (Figs 4.3-4.5). There are several possible explanations for this observation. As 
mentioned above, one possibility is that mature bipolar cells become “locked-in” and can no 
longer respond to PRDM1. This could be through changes in the epigenetic state that prevents 
PRDM1 from silencing Vsx2 in mature bipolar cells. This could also occur if there are unique 
enhancers that maintain VSX2 expression in mature bipolar cells that are not regulated by 
PRDM1. We observed that misexpression of Prdm1 in early development did not block VSX2 
expression in progenitor cells (Fig 4.1C-D), which would be expected to severely limit retinal 
progenitor proliferation148–150,287. This argues that PRDM1 regulates Vsx2 expression in a 
context-specific fashion. This could occur if PRDM1 has no regulatory effect on Vsx2 enhancers 
that control progenitor-specific expression, while binding the bipolar-specific enhancer and 
suppressing its activity. However, the 164bp bipolar-specific Vsx2 enhancer sequence lacks a 
high-confidence PRDM1 binding site, raising the possibility that PRDM1 silences Vsx2 by 
binding at a different site or by acting indirectly on Vsx2 expression128,270. We observed that most 
retinal cell types were unaffected by Prdm1 misexpression during development or in adults (Figs 
4.1-4.5). This further argues that Prdm1 acts in a context-specific fashion, only affecting fate in 
cells that are competent to become bipolar cells. Other cells are either unaffected by PRDM1 
activity or “locked-in” and refractory to its influence. Additional studies examining PRDM1 and 
VSX2 binding sites in the developing retina are needed to understand the mechanisms these two 




PRDM1 is toxic to mature photoreceptors  
 In the retina, Prdm1 is transiently expressed in OTX2+ cells. Expression does not persist 
into mature photoreceptors127. There are several other systems where transient PRDM1 
expression affects fate determination, such as primordial germ cell genesis in mice as well as 
slow twitch muscle and neural crest development in zebrafish289,290,299–302. We presumed that 
Prdm1 expression was transient because it was no longer needed in mature photoreceptors. 
However, we were surprised to see that sustained Prdm1 expression was toxic to photoreceptors. 
This was in contrast to other retinal cell types, including mature bipolar cells, which appeared 
unaffected by Prdm1 misexpression. Thus, the apparent toxicity of PRDM1 was not simply due 
to its overexpression, but rather because of a specific effect on photoreceptors (Fig 4.6C). We did 
not observe acute toxicity with Prdm1 overexpression at P0 or P7. This suggests that toxicity 
occurs relatively late, during or after the process of maturation. It is unclear why sustained 
PRDM1 expression is toxic only in photoreceptors. One possibility is that by blocking bipolar 
formation, PRDM1 also inhibits photoreceptor maturation. The inability to mature may then 
cause photoreceptor cell death. Another possibility is that PRDM1 expression is incompatible 
with the formation or maintenance of the specialized rod nuclear architecture that forms in the 
postnatal period298. Due to chromatin accessibility differences between photoreceptors versus 
other retinal cell types, PRDM1 may have the ability to regulate deleterious gene expression 
networks only in photoreceptors. Lastly, alterations in the dosage of key transcription factors 
may destabilize gene regulatory networks required for photoreceptor function and survival. In 
support of this possibility, a recent report showed that overexpressing OTX2 in photoreceptors 
caused mild toxicity within rods226. Taken together, these data suggest that careful control of 
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transcription factor expression timing and levels are essential for rod survival. The mechanisms 
that underlie PRDM1-induced photoreceptor toxicity remain to be uncovered.  
 













Figure 4.1. Constitutive PRDM1 expression driven by PAX6-CRE does not prevent 
progenitor VSX2 expression 
A) Schematic of transgenic mice utilized. To make the PRDM1 strain, the ROSA26 locus on 
chromosome 6 was targeted to insert the Prdm1 cDNA downstream of a CAG enhancer and a 
LoxP-stop-LoxP sequence. Further downstream is a woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) and a bovine growth hormone polyadenylation 
(bGH pA) site. Introduction of CRE removes the stop sequence and allows for permanent 
PRDM1 expression. B) Representative immunohistochemistry of PRDM1/+ control compared to 
PAX6-CRE/PRDM1 retinas stained for PRDM1 (purple) and GFP (green) and imaged at the 
same exposure level. Note the ectopic expression of PRDM1 in the RPE and ciliary body of 
PAX6-CRE/PRDM1 eyes (arrowheads). C-D) P0 PRDM1/+ control compared to PAX6-
CRE/PRDM1 retinas stained for VSX2 (white), GFP (green), and PRDM1 (purple, inset-only). 
Arrowheads mark PRDM1+/VSX2+ cells. There is VSX2 background staining in the ganglion 






Figure 4.2. Constitutive PRDM1 expression driven by PAX6-CRE prevents bipolar cell 
formation at P7 
A) Schematic of transgenic mice utilized. B-C) P7 PRDM1/+ control compared to PAX6-
CRE/PRDM1 retinas stained for ISLET1/2+ (purple), OTX2 (white), and GFP (green). Stain of 
VSX2 (purple) and SCGN (green) with D) mosaic loss and E) complete loss of bipolars in the 
peripheral retina. Note that SCGN marks some photoreceptors at this stage. F) The total number 
of OTX2+ cells (bright and faint) is not significantly decreased. G-I) Quantification of bipolar 
cell markers. There are fewer G) bright VSX2+ cells, H) SCGN+ bipolars, and I) ISLET1/2+ 
bipolars in in PAX6-CRE/PRDM1 retinas compared to controls. J) There is no difference in the 
number of ISLET1/2+ amacrines or ganglion cells between conditions. Statistics calculated 
based on number of mice (N), Cont N=4, PAX6-CRE/PRDM1 N=5. Error bars=standard 
deviation. ns=not significant, ***p<0.001. bars=50µm, inset bars=25µm, INL=Inner Nuclear 
















A) Schematic of experimental design. ROSA-RFP and PRDM1 mice are as described in figure 1. 
B) Representative immunohistochemistry of RFP/+ controls compared to RFP/PRDM1 
littermates. Arrowheads mark bipolar cells and asterisks mark photoreceptors. C-D) There is no 
difference in the total number of RFP+ bipolars and photoreceptors when summed, or in the total 
number of amacrines and ganglion cells. Amacrines and ganglion cells were excluded from the 
rest of the calculations. RFP/PRDM1 mice have E) significantly fewer RFP+ photoreceptors, F) 
increased bipolar cells, G) and no change in Müller glia compared to controls. H) There is no 
observable difference in VSX2 levels (red) in RFP+ bipolars and I) there are significantly more 
VSX2+ bipolars in RFP/PRDM1 mice. Statistics calculated based on number of eyes (N), Cont 
(RFP/+) N=6, RFP/PRDM1 N=11. Error bars=standard deviation. ns=not significant, *p<0.05, 

















A) Schematic of experimental design. Mice are as described in figure 1. B) Representative 
immunohistochemistry of RFP/+ controls compared to RFP/PRDM1 littermates. Arrowheads 
mark bipolar cells and asterisks mark photoreceptors. RFP/PRDM1 pups have C) significantly 
more RFP+ photoreceptors, D) significantly fewer bipolar cells, and G) no change in amacrines 
compared to controls. E) Stains of electroporated cells (red) and VSX2 (purple). F) 
Quantification showing a significant loss of VSX2+ bipolar cells, but no change in the levels of 
VSX2 in remaining bipolars of the RFP/PRDM1 mice. H) Stains for electroporated cells (red) 
that express PAX6 (green) or OTX2 (purple). I-J) There is no difference in the expression 
patterns of PAX6 and OTX2. Statistics calculated based on number of mice (N), RFP/+ N=6, 
RFP/PRDM1 N=3. Error bars=standard deviation. ns=not significant, ***p<0.001. bars=50µm, 




































A) Schematic of experimental design. Mice are as described in figure 1. B) Representative 
immunohistochemistry of RFP/+ controls compared to RFP/PRDM1 littermates. Arrowheads 
mark bipolar cells and asterisks mark photoreceptors. RFP/PRDM1 pups have no differences in 
C) RFP+ photoreceptors, D) bipolar cells, or G) amacrines compared to controls. E) Stains of 
electroporated cells (red) and VSX2 (purple). F) Quantification showing no change in the 
number of VSX2+ cells. H) Stains for electroporated cells (red) that express PAX6 (green) or 
OTX2 (purple). I-J) there is no difference in the expression patterns of PAX6 and OTX2. 
Statistics calculated based on number of mice (N), RFP/+ N=6, RFP/PRDM1 N=4. Error 
bars=standard deviation. ns=not significant, bars=50µm, inset bars=25µm, INL=Inner Nuclear 

































Figure 4.6. Summary of chapter IV findings 
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A) Turning on PRDM1 in prenatal retinas prevents bipolar cell formation, increasing rods. B) 
Misexpressing PRDM1 in nascent bipolar cells causes some to convert into rods by P7. C) 
Activating PRDM1 in a mature retina has no apparent effect on bipolar cell fate but is toxic to 
rods. These PRDM1-expressing bipolar cells still make VSX2, however, it is possible these 
bipolar cells have abnormal gene expression patterns despite their normal morphology. D) 
During normal development, OTX2+ cells express PRDM1 and VSX2. These transcription 
factors interact to control the decision between rod photoreceptor and bipolar cell interneuron 
fates. This is done, in part, by stabilizing fate decisions. E) OTX2+ cells are initially competent 
to form rods and bipolars. Rod and bipolar fates are plastic even after fate is specified, but this 
plasticity is rapidly lost as the cells mature.  
 





Supplemental Figure 4.1. Early CRE expression in VSX2-CRE mice leads to a broad 




A) Schematic of experimental design. The VSX2-CRE mice are designed to drive bipolar-specific 
CRE expression. ROSA-RFP and PRDM1 mice are as described in figure 1. B-F) Adult mice 
stained for CRE (green), RFP (red) and OTX2 (purple). B). No CRE or RFP staining is present 
in wildtype mice. C) VSX2-CRE retinas have CRE expression in OTX2+ bipolar cells but lack 
RFP staining. The green vascular staining is non-specific background. D) The VSX2-CRE/RFP 
mice have bipolar CRE expression, but pan-retinal RFP expression. E) An RFP/+ mouse, 
without VSX2-CRE or CRE staining, has global RFP expression when the mother carried a 
VSX2-CRE allele. F) Paternally inherited VSX2-CRE mice also show global, yet mosaic RFP 



































CCTSI TL1 CLINICAL EXPERIENCE IN OPHTHALMOLGY 
Throughout my doctoral work, I maintained an interest in clinical applications of basic 
research and the translation of our fundamental understanding into the practice of medicine. 
During my second full year in the Brzezinski lab, I was afforded the opportunity to shadow 
several clinicians in the Sue Anschutz-Rodgers Eye Center. My work started with Dr. Scott 
Oliver, and I saw a range of patients from pediatric through geriatric with a variety of ocular 
cancers, including melanomas and retinoblastoma. I next spent time with Dr. Naresh Mandava, 
exploring clinical approaches to age related macular degeneration. I then worked with Dr. Alan 
Palestine in a clinic focusing on immune-mediated disease of the retina.  
 This diverse clinical experience led to my application to the Colorado Clinical and 
Translational Sciences Institute (CCTSI) TL1 training program. I recognized a gap in our 
understanding of the fundamental mechanisms of uveitis, an autoimmune mediate inflammation 
of the eye and was awarded a grant to study “Cell type specific degeneration in retinal 
inflammatory disease.” The objective of the TL1 training program is to provide pre-doctoral 
trainees the opportunity to develop and refine their understanding of clinical and translational 
efforts in team science by exposing them to a broad curriculum of research across the health 
spectrum. Thus, my work incorporated two parts, first I conducted a series of experiments in lab 
on the effects of repetitive uveitis inflammatory events on the mouse retina. Second, I spent more 
than 100 hours in clinic with Dr. Alan Palestine, observing the clinical treatment of uveitis and 
other inflammatory diseases of the eye.  
 To satisfy the course requirements for the TL1 certification in clinical and translational 
research, I completed the following courses: BIOS 6606 Statistics for the Basic Sciences, CLSC 
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6260 Conducting Clinical Trials for Investigators, IDPT 8890 Clinical Experience for CTSI PhD 
Students, NRSC 7661 Grant Proposal Writing, NRSC 7610 Fundamentals of Neurobiology, 
NRSC 7600 Cell/Molecular Neurobiology, PHCL 7605 Ethics in Research. In addition to this 
training, I participated in the Responsible Conduct of Research and HIPAA training through the 
CCTSI and department of Ophthalmology. I presented work funded through the TL1 training 
program at international conference for the Association for Research in Vision and 
Ophthalmology (ARVO), held in May 2019, in Vancouver, Canada, where I presented a poster 
entitled “Utilizing CRISPR to perturb photoreceptor/bipolar cell fate decisions in the mouse 
retina.” This work, along with the significant training in team science and exposure to diverse 
fields of research significantly enriched my graduate training experience and prepared me for a 
career in clinical and translational research.  
 
CCTSI Clinical Experience 
 The work with Dr. Alan Palestine in the ophthalmology clinic exposed me to over 100 
patients aged 7-89, male and female, with a variety of symptoms and diseases. Here we list a few 
of the patients and their disease symptoms and treatment paradigms. 
78 y/o, African American, female. This patient had post-operative uveitis. This occurs in 
some surgeries where the body responds with an autoimmune mediated inflammation of the 
anterior or posterior chamber. The patient was given the corticosteroid Kenalog as a sub-Tenon’s 
injection.  
 12 y/o, white, male. The patient was diagnosed previously with Pars Planitis. This 
disease is characterized by inflammation of the pars plana, which is the narrow field between the 
iris and choroid303. The patient was on 0.6mL of Methotrexate once a week. He had received 
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injections for approximately 6 months and the inflammation was beginning to decrease. There 
was decreased center and peripheral leakage and patient reported decreased vitreous floaters.  
86 y/o, white, female. Patient had intraocular pressure (IOP) of 38, questionable 
glaucoma, and severe anterior uveitis. It was unclear if high IOP was related to uveitis, 
glaucoma, or both. Suggested diagnosis was Uveitis-Glaucoma-Hyphema Syndrome. The 
syndrome is a complication of intraocular chafing from an implanted intraocular lens304. The 
proposed treatment was a combination of topical corticosteroids and IOP lowering systemic 
medication.  
30 y/o, white, male. Patient experience an Acute Retinal Necrosis event ~10 weeks prior. 
These events are broadly thought to be caused by Zoster Simplex Virus infecting the retina and 
causing direct neuronal death as well as secondary death from frequent retinal detachment305. No 
cutaneous zoster simplex was detected. Patient was on 30mg of prednisone. No further retinal 
detachments or holes were detected during visit. Vision had stabilized with some blind spots.  
 
CCTSI Translational Research 
Uveitis, a condition marked by inflammation of the eye, is responsible for up to 10% of 
visual impairments globally, with 35% of those afflicted experiencing significant visual loss or 
blindness306. A variety of etiologies result in uveitis, but a common mechanism is inflammation 
and organ-specific immune responses that cause permanent vision loss due to retinal cell 
death306,307. Experimental animal work has addressed the immune pathways involved in various 
forms of uveitis, but little work has been done to understand how these conditions affect the 
retinal tissue itself308–312. We set out to investigate the effects of intraocular inflammation on the 
retina, probing the histological and physiological changes in parallel.  
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Uveitis involves inflammation of the eye’s most vascular layer, the uvea. It can affect 
both the anterior and posterior segments of the eye, but all inflammations have the potential to 
affect the entire organ306,307,313,314. For individuals with uveitis, it is critical to provide retinal 
neural protection to prevent permanent visual loss. Clinically, many patients with uveitis 
experience bouts of acute inflammation with major intrusions of immune cells into the eye with 
longer intervals of chronic low to moderate inflammation313. Clinical evidence suggests that 
repetitive acute events are more likely to lead to permanent deficits, but little laboratory work has 
been done to validate or explain the cell type specificity of this retinal degeneration307,313,315. 
Loss of retinal tissue is the cause of permanent visual deficits in uveitis, but which cell types of 
the retina are most effected by inflammation remains unknown. Understanding, in detail, the 
effects acute ocular inflammation on specific cell types within the retina is a key step in fighting 
uveitis.   
To test how uveitis affects unique populations of retinal neurons, we employed endotoxin 
induced uveitis (EIU), a common reproducible rodent model where intraocular injection of 
bacterial lipopolysaccharide endotoxins results in uveitis314. After injection, acute uveitis peaks 
at 18 hours, but chronic inflammation will persist for up to a week afterward314 (Fig 4.1A). We 
induced EIU in adult mice and took their retinal tissue at acute (18 hour, Fig 5.1B-i), chronic (1 
week, Fig 5.1B-ii), or resolved (1 month, Fig 5.1B-iii) time points and utilized 
immunohistochemistry for various cell type-specific markers to assess the effects of EIU (Fig 
4.1G)230. We observed obvious inflammation of the retina and accumulation of inflammatory 
immune cells in the vitreous of EIU mice at 18 hours and 7 days post EIU event (Fig 5.2C-B). 
Our analysis for this work is ongoing.  
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Our goal was to directly connect the work in mice to clinical applications. In order to do 
this, we utilized three techniques available in the clinic and the laboratory on all mice weekly 
during the experiments. 1) The scalar visual assessment (SVA) of inflammation, which involves 
examining the anterior chamber based on specific visual criteria, provides a gross assessment of 
uveitis severity on a scale of zero to five316 (Fig 5.1D). 2) Electroretinography (ERG) was used 
to test the electrical function of retinal neurons in vivo and will show how functional the retina 
remains after EIU (Fig 5.1E). 3) Optical coherence tomography (OCT) utilizes light to non-
invasively image the cross-sectional structure of the retina in vivo and was used to reveal any 
major structural disruptions without sacrificing the animal (Fig 4.1F)317. We established all of 
these techniques in lab and employed them in our EIU mouse model.  
Our next goal was to quantify the differential loss of retinal cells in individual versus 
repetitive uveitis events. In general, multiple acute uveitis events lead to greater retinal 
degradation in humans306,307. It is possible that increased degradation progresses through the 
same cellular mechanisms, compounded by frequency. Alternatively, repetitive events may cause 
certain cell types (e.g. rod photoreceptors) to die more readily than other types, indicating unique 
sensitivity of some neuronal subtypes to inflammation. To how repetitive acute uveitis events 
differentially affect cell types within the retina we directly compared the effects of single verses 
multiple uveitis events. We created three cohorts of mice: 1) A single EIU group (Fig 5.1C-i), 2) 
a group with two EIU events two weeks apart (Fig 5.1C-ii), and 3) a group with EIU events 
weekly for four weeks (Fig 5.1C-iii). All groups were tested pre-EIU and then weekly for scalar 
visual assessment, OCT, and ERG (Fig 5.1C-F). Five weeks after initial injection, tissue was 
collected, and the retinas assessed utilizing IHC for cell type-specific changes compared to each 
other as well as sham injected littermates (Fig 5.1C, G). While these experiments were 
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performed and showed robust deficits via ERG, OCT, and IHC we have made no conclusions 
that this time (Fig 5.2). Our analysis for this work is ongoing. 
 
Broad Translational Applications of Work 
 Outside of this direct translational work, our other work on the fundamental mechanisms 
of retinal development and fate-stability may have critical applications for approaches to curing 



















Chapter V Figures 
 
Figure 5.1 Endotoxin induced uveitis (EIU) approach and assessments in mouse model.  
A) The EIU model involves intraocular injection of endotoxin producing retinal inflammation. 
B) Aim 1 includes examining retinal tissues at acute (B-i), chronic (B-ii) and resolved (B-iii) 
times. C) Aim 2 compares single (C-i), double (C-ii), or four EIU events (C-iii). D) example of 
scalar visual assessment (SVA) under different levels of inflammation. E) Electroretinogram 
(ERG) tests neuronal functionality within the retina and allows separation of cell type-specific 
responses. F) Optical Coherence Tomography visualizes the retinal structure in vivo and can be 
quantified by layer thickness as well as degree of inflammation over time. G) 
Immunohistochemistry allows us to selectively label and count specific cell types within the 





Figure 5.2 Endotoxin induced uveitis (EIU) causes inflammation in mice 
A) EIU eyes show distinct inflammation 18 hours post injection compared to contralateral 
control. Early intrusion of cells into the vitreous and a distinct inflammation of the retina were 
observed. B) EIU eye has major intrusion of inflammatory immune cells into the vitreous after 7 
days compared to contra-lateral control. C) OCT of EIU and control eye after 7 days showing 
major inflammation of the vitreous and enlarged or inflamed retina cross section. D) ERG 
showing distinct loss of function in EIU vs control eye. There is obvious loss of visual function 












MATERIALS AND METHODS 
Mice 
Mice were used in accordance with procedures approved by the local IACUCs at the 
University of Colorado Denver and the University of Texas Southwestern Medical Center 
(UTSW). Wild-type mice, C57BL/6J, were obtained from The Jackson Labs (Bar Harbor, ME). 
ROSA-RFP mice (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J) (Strain #007914)277 and 
VSX2-CRE mice (129S1.Cg-Tg(Vsx2-cre)2690Chow/J) (strain #026200)288 were obtained from 
Jackson Labs (#026200) (Bar Harbor, ME, USA). The αPax6-Cre-IRES-GFP mice were a gift 
from Dr. Ruth Ashery-Padan (Tel Aviv University, Israel)141. All pups were housed with their 
parent and sibling following electroporation until collected. Animals older than P28 were 
separated by sex and housed in groups of 3-5 mice until tissue was collected 
 
Prdm13-GFP and Prdm13-∆115 Mouse Construction 
Prdm13 gene targeted mouse lines used in chapter II were created at UTSW217. Briefly, 
Prdm13-GFP (GFP/GFP) mice were developed using zinc-finger nuclease targeting technology 
such that a GFP cassette followed by a stop codon was inserted into the first exon of Prdm13 
(Fig. 2.2A). Homozygous mutant mice died at or before birth. Mice were genotyped by PCR at 
60°C annealing with three primers: 5’-GCTGCTCCTGGTTCTGTCA-3’, 5’-
CCTTTTCTCTGCTGCTCGTC-3’ and 5’-GCTGGAGTACAACTACAACAGCCA-3’ to 
generate 313bp wild-type and 549bp mutant bands (Mona et al., 2017). A presumed 
hypomorphic allele of Prdm13 (∆115) was the result of creating a 115bp deletion within the first 
exon of Prdm13 (Fig. 2.4A’). While this deletion was predicted to create a null allele, 
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homozygous ∆115 /∆115 mice live to adulthood and express PRDM13 protein in the developing 
neural tube217. The features of the two Prdm13 alleles used here and those of two additional 
mutant lines are described in detail by Mona and colleagues217. PCR genotyping was done at 
60°C annealing with two primers: 5’-GCTGCTCCTGGTTCTGTCA-3’ and 5’- 
CCTTTTCTCTGCTGCTCGTC-3’ to yield 313bp wild-type and 198bp mutant bands. 
 
ROSA-PRDM1 Mouse Construction 
To build the ROSA-PRDM1 (PRDM1) mouse line in chapter IV, we first obtained the Ai9 
targeting vector from Dr. Hongkui Zeng (Allen Institute, Seattle, WA, USA)277. This construct is 
designed to insert a CAG enhancer/promoter, LoxP-stop-LoxP sequence, and a tdTomato 
cassette into the ROSA26 locus (Madisen et al., 2010). We cut the Ai9 vector with FseI to 
remove the tdTomato sequence and re-ligated the plasmid. We PCR-amplified the mouse Prdm1 
cDNA sequence and used IN FUSION cloning (Takara Bio, Mountain View, CA, USA) to insert 
it into the remaining FseI site in the modified Ai9 vector. This drives the expression of an 823 
amino acid PRDM1 protein (NCBI: NP_031574.2). The targeting vector was validated by 
Sanger sequencing and used to target C57BL/6 embryonic stem cells with the assistance of the 
University of Colorado Bioengineering Core facility. After selection for neomycin resistance, 
several properly targeted clones were obtained and two were karyotyped. One normal 
karyotyped embryonic stem cell line was then used to generate chimeras. From this, one chimera 
was used to establish the ROSA-PRDM1 line. RFP and PRDM1 mice were genotyping using 
primers for both wildtype and mutant genes, including the forward primer 5’-
CTCTGCTGCCTCCTGGCTTCT and the reverse primer 5’-
CGAGGCGGATCACAAGCAATA for wildtype or 5’-TCAATGGGCGGGGGTCGTT for 
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mutants. PCR was performed using 35 cycles of 94°C for 25”, 61°C for 30”, and 72°C for 30”. 
Cre PCR genotyping was performed at 59°C annealing as previously described127. 
 
Prdm13 Plasmid Creation 
A Prdm13 expression plasmid for work in chapter II was made by inserting the wild type 
mouse Prdm13 cDNA sequence under the control of a ubiquitous human Ef1α enhancer, 
followed by IRES2 sequence and cDNA for Cre recombinase and a β-globin polyadenylation 
sequence. The Prdm13-VP16 construct was cloned similarly, but used a previously constructed 
C-terminal VP16 fusion protein sequence216. Both constructs were validated by Sanger 
sequencing and Cre immunostaining of transfected explants (data not shown). We used a plasmid 
containing an Ef1α enhancer driving nuclear localized cherry fluorescent protein as an 
electroporation control256. 
 
CRISPR Guide Design and Production 
CRISPR constructs utilized in chapter III were designed based on a plasmid from Dr. 
Feng Zhang’s Lab; pSpCas9(BB)-2A-GFP (PX458) (Addgene plasmid # 48138)318. The original 
PX458 plasmid was modified by exchanging the CMV promoter for an Ef1α promoter driving 
Cas9. In some conditions, the eGFP was replaced with Cherry. Guide RNAs were designed 
using the CRISPR Guide tool in Benchling (Benchling.com). Potential guides were sorted for 
their on-target and off-target scores319,320. Three non-overlapping guides with the highest 
aggregate score were selected per condition (Supplemental Table 3.1). Guides were inserted into 





Adeno-Associated Virus (AAV) vector preparations for work in chapter IV were 
produced by the 2-plasmid, co-transfection method321,322. Briefly, one Cell Stack (Corning Inc., 
Corning, NY, USA) with approximately 1 X 109 HEK 293 cells was cultured in Dulbecco’s 
Modified Eagle’s Medium (Hyclone Laboratories, Logan UT, USA), supplemented with 5% 
fetal bovine serum and antibiotics. A CaPO4 transfection precipitation was done by mixing a 1:1 
molar ratio of recombinant (r) AAV vector plasmid DNA and serotype-specific rep–cap helper 
plasmid DNA. For the virus payload, we used a 1.65kb DNA sequence upstream of the human 
PCP2 gene (also known as Ple155) to drive bipolar cell-specific expression of Cre 
recombinase292,293. The capsid was engineered to generate AAV2 vectors with the following 
substitutions: Y272F, Y444F, Y500F, Y730F, and T491V (AAV2, quad Y-F + T471V)323. After 
transfection, the cells grew at 37°C, 7% CO2, for 60 hours and were then harvested and lysed by 
three freeze/thaw cycles. The crude lysate was clarified by centrifugation and the resulting 
vector-containing supernatant was divided among four discontinuous iodixanol step gradients. 
The gradients were centrifuged at 350,000g for 1 hour, and 5 mL of the 60–40% step interface 
was removed from each gradient and combined. This iodixanol fraction is further purified and 
concentrated by column chromatography on a 5-mL HiTrap Q Sepharose (anion exchange) 
column using a Pharmacia AKTA FPLC system (GE Healthcare Life Sciences, Pittsburgh, PA, 
USA). The vector was eluted from the column using 215 mM NaCl, pH 8.0, and the rAAV peak 
collected. The vector-containing fraction was then concentrated and buffer exchanged in Alcon 
BSS with 0.014% Tween 20, using a Biomax 100K concentrator (Millipore, Billerica, MA, 
USA). The vector was then titered for DNase-resistant vector genomes by Real-Time PCR 
relative to a standard. The purity of the vector was validated using three standard assays. First by 
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silver-stained SDS– PAGE (the three AAV capsid proteins are the only visible protein bands in 
an acceptable prep). The second assay screens for bioburden by adding 10 µL of the final 
product to 15 mL of non-selective LB and monitored for 5 days. Lastly, the sample was assayed 
for Endotoxin using an Endosafe-PTS test system (Charles River, Durham, NC, USA). Passing 
criteria was ≤ 5 EU/mL.  
 
AAV Injections 
 In Vivo CRE-AAV injections in chapter IV were performed on P28 mice utilizing 
common intraocular injection methods. In short, the concentrated CRE-AAV stock (7.28 X 1013 
vector genomes per mL) was diluted 1:10 in sterile nuclease-free water. Mice were anesthetized 
utilizing 2% isoflurane mixed with oxygen and were kept under utilizing a nose cone giving a 
continuous 2% isoflurane and oxygen mixture (NDC 66794001725). Under a dissecting 
microscope and light the mice were held steady and a 31G needle was used to create a 
perforation of the sclera nasally near the junction with the cornea. A Hamilton syringe (Hamilton 
Company, Reno, NV) was inserted into the vitreous and 0.5µL of diluted AAV solution was 
injected. The mouse was allowed to recover on a heat block before being returned to housing.  
 
In Vivo Electroporation  
In Vivo electroporation’s in chapters III and IV were performed on P0 pups following 
previously described methods324. All electroporated DNA was delivered at a concentration of 
2µg/µL. Mice were cryoanesthesized for approximately five minutes until all response to 
external stimulation ceased. Under a dissecting microscope and light, the mice were placed on a 
frozen block and held steady while a 31G needle was used to create an opening along the eye-
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crease. The lid was then opened and a second 31G needle was utilized to create a perforation of 
the sclera nasally near the junction with the cornea. A Hamilton syringe (7653-01, Hamilton 
Company, Reno, NV) was inserted into the opening and pressed medially back against the 
central anterior portion of the retina. 0.5µL of 2µg/µL DNA in sterile H2O was then injected 
between the retina and underlying membrane. The syringe was removed. The mouse’s head was 
placed between a tweezertrode electrode (BTX, Holliston, MA) and electroporated with 5 80V 
square wave pulses for 50ms with a 950ms delay between each pulse using a Bio-Rad Gene 
Pulser Xcell (BioRad, California, USA). Neosporin was placed on the surface of the eyelid to 
prevent infection. The mouse was brought back up to normal body temperature on a heat pad and 
returned to the mother.  
 
In Vitro Electroporation and Culturing 
For work in chapters II, III, and IV, Newborn eyes were collected immediately after 
animals were sacrificed. The eyes were extracted with forceps, dissected in cold HBSS+ (HBSS, 
Ca2+, Mg2+, 6 mg/mL glucose, and 0.05M HEPES), and transferred to calcium and magnesium 
free phosphate buffer solution (PBS) for electroporation167,230. Retinas were oriented with the 
photoreceptor side up and 1µL of 2µg/µL DNA in 30% glycerol with methyl green was pipetted 
onto their surface. They were then electroporated with five 50ms square-wave pulses of 50mV at 
125ms intervals from a BioRad Gene Pulser Xcell (BioRad, Hercules, CA, USA). Retinas were 
cultured in Neurobasal media, with 1X N2 supplement, 1X L-glutamine, 1X 
penicillin/streptomycin, and 1% FBS (Gibco/ThermoFisher Scientific, Waltham, MA, 
USA)167,230. For 1 DIV cultures, retinas were placed in 12 well plates floating in 1mL of media. 
For all other cultures, retinas were flat mounted with their photoreceptor surface facing up on 
174 
 
0.4μm Milicell CM cell culture inserts (Milipore, Billerica, MA, USA) in 6 well plates with 1mL 
of media in the well, such that retinas were maintained at the air-media interface. Half the media 
was changed every other day. All cultures were kept at 37°C and 5% CO2.  
 
PRDM13 Antibody Creation 
 Three different rabbit antibodies used in chapter II against PRDM13 were generated in 
the Johnson lab at UTSW: PRDM13-Ab1 (ZF) PA6658, PRDM13-Ab1 (ZF) PA6659, and 
PRDM13-Ab2 (FL) TX970217. The antigens were bacterially expressed C-terminal domain of 
PRDM13 including amino acids 622 to 755 (ZF) or full length protein (FL), respectively. 
PA6658, PA6659, and TX970 were validated by western blot and tested on embryonic retinas. 
All three antibodies showed an equivalent expression pattern, but preparation PA6658 was the 
most robust reagent. To validate the specificity of the antibody, we immunostained (see below) 
E17.5 Prdm13-GFP/GFP null animals with the PA6658 antiserum and observed a total loss of 
signal compared to equivalently stained heterozygous E17.5 retinas (Fig 2.2).   
 
Retina collection and Immunohistochemistry 
For work throughout, under a dissecting scope, a 31G needle was used to create 3-4 
perforations in the sclera near the junction of the cornea ensuring fluid access to the vitreous, the 
eyes were then placed in 2% paraformaldehyde for 2-4 hours, followed by cryoprotection at 4°C 
with an increasing concentration series (10-30%) of sucrose solutions in PBS230. Eyes were 
stored in 30% sucrose overnight and flash frozen in OCT (Sakura Finetech, Torrance, CA, USA). 
Eyes were cryosectioned at 12µm and transferred to Shandon Colorfrost Plus microscope slides 
(ThermoFisher Scientific, Waltham, MA, USA). Slides were stored in a -20°C freezer until 
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immunohistochemistry was performed.  
Immunohistochemistry procedures were conducted as previously103,127,167,230. Slides were 
washed in PBS, blocked for two hours in 5% milk block (the supernatant of a solution of 5% 
powdered milk, 0.5% TX100, 0.2% NaN3, in PBS), and placed in primary antibody in 5% milk 
block overnight at room temperature. The next day slides were washed with PBS then 5% milk 
block along with secondary antibodies was applied and slides left two hours in the dark. Slides 
were washed in PBS and covered with Flouromount-G (eBioscience, San Diego, CA, USA) and 
a glass coverslip.  
The following primary antibodies: AP2α (1:400; 5E4-c, DSHB Iowa City, Iowa USA); 
goat anti-BHLHB5 (1:500; sc-6045, Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA); 
mouse anti-BRN3a (1:500; sc-6026, Santa Cruz Biotechnology, Inc); rabbit anti-Calbindin 
(1:400; AB1778, Millipore, Temecula, CA, USA); mouse anti-Calretinin (1:500; MAB1568. 
Millipore); rabbit anti-ChAT (1:400; AB143, Millipore); mouse anti-CRE (1:250; MAB3120, 
Millipore); mouse anti-EBF3 (1:400; H00253738-M05, Abnova, Taipei, Taiwan); rabbit anti-
GAD65/67 (1:400; AB1511, Millipore, Burlington, MA, USA); rabbit anti-GAD65/67 (1:400; 
AB1511, Millipore); mouse anti-GFP (1:1000; ab13970, Abcam, Cambridge, MA, USA); goat 
anti-GLYT1 (1:500; AB1770, Millipore); mouse anti-ISLET1/2 (1:200, 39.4D5, Developmental 
Studies Hybridoma Bank, Iowa City, IA USA); goat anti-OTX2 (1:250; AF1979, Bio-Techne 
Corporation, Minneapolis, MN, USA); mouse anti-LHX1 (1:400; 4F2-c, DSHB); rabbit anti-
PAX6 (1:500; PRB-278P, Covance, Princeton, NJ, USA); guinea pig anti-PTFA1a (Hori et al., 
2008); rabbit anti-PRDM13 (see above) (1:250); rabbit anti-recoverin (1:500; AB5585, Abcam 
Inc); chicken anti-RFP (1:100; 600-901-379, Rockland, Gilbertsville, PA, USA); chicken anti-
RFP (1:100; 600-901-379, Rockland Antibodies & Assays); mouse anti-RFP (1:1000; ab65856, 
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Abcam); Rabbit anti-Secretagogin (1:2500, RD181120100; Biovendor LLC, Ashville, NC, 
USA); and goat anti-SOX2 (1:500; sc-17320, Santa Cruz Biotechnology, Dallas, TX, USA); 
rabbit anti-tyrosine hydroxylase (TH) (1:100, ab152, Milipore); rabbit anti-vGlut3 (1:100; Cat# 
135 203, Synaptic Systems, Göttingen, Germany); sheep anti-VSX2 (1:400; X1179P, Exalpha 
Biologicals, Shirley, MA, USA). EdU staining was done according the manufacturer’s 
instructions (ThermoFisher, Waltham, MA, USA) after immunostaining. 
 
Imaging, Cell Counts, and Statistics 
Across all chapters, slides were imaged following immunohistochemical staining with a 
20x objective on a Nikon C2 laser scanning confocal scope (Melville, NY, USA). Retinas were 
imaged at multiple layers 1.5 µM thick and 4-6 images were collected per a section as a Z-stack 
and then compressed to a single layer utilizing a maximum intensity stack compression in 
ImageJ325. All images were minimally processed in Adobe Photoshop (San Diego, CA, USA), 
and cell counts were conducting utilizing manual counting.  
Images were taken from the eyes of both male and female mice. Bipolar-CRE-AAV 
images were taken in both central and peripheral retina but no differences were observed 
between these regions. Images from PAX6-CRE mice were taken in the peripheral retina. Due to 
the nature of in vivo retina electroporations, most sections covered central or mid-peripheral 
retina, however, some mice had electroporated cells that extended to the periphery. In the case of 
electroporations, which require a subretinal injection, counts were only conducted on sections of 
relatively intact retina, and disrupted sections were excluded from quantification. We also 
excluded images with less than 10 cells. Retinas were imaged in 2-6 locations and the counts 
pooled to calculate the mean and standard deviation.  
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For plots throughout this work, error bars represent standard deviation. Generally, one-
tailed unpaired t-test with the assumption of heteroscedasticity were used for statistics. The 
degrees of freedom were based on the number (N) of eyes in AAV experiments and the number 
of animals examined when electroporations or transgenic mice were involved. In Chapter II, 
two-tailed unpaired t-tests with the assumption of heteroscedasticity were utilized for statistical 
comparisons, and the degrees of freedom are based on the number (N) of mice examined or the 
number (N) of retinas electroporated. Additionally, in Chapter II for multiple comparisons, one-
way ANOVA was used. In chapters III and IV, one-tailed unpaired t-test with the assumption of 
heteroscedasticity were used for statistics except for a specifically noted paired t-test. 
Throughout, p<0.05 was considered significant, and was calculated utilizing GraphPad Prism 8 







 The development of retinal neural tissue is a complex and multifaceted processes. Here I 
have explored mechanisms that impact cell fate choice, competence of progenitor cells, stability 
of mature neurons, and the functions of a gene regulatory network. I will now look at how our 
findings impact developmental biology as well as the implications for therapeutic treatment of 
human diseases of the eye. 
 
The Roles of PRDM13 in Developing and Maturing Amacrine Cells 
The developing retina is able to specify 30+ morphological subtypes of amacrine 
interneurons which in turn may represent dozens to hundreds of specific roles in the neural 
circuits of the retina. I found that the zinc-finger transcription factor Prdm13 turns on in a subset 
of developing interneurons of the mouse retina (Fig 2.1-2.2). It then remains on in some cells, 
which go on to become a heterogenous group of amacrine interneurons (Fig 2.3). The largest 
group are co-labeled with the transcription factor EBF3 and the calcium binding protein 
calretinin. When PRDM13 is reduced using hypomorphic mice, there are no obvious immediate 
developmental effects embryonically (Fig 2.5). However, when amacrines would normally turn 
on EBF3 and mature in early postnatal mouse eyes, approximately 25% of the cells go through 
apoptosis, resulting in a deficit in amacrine interneurons and the failure to form the third lamina 
of the IPL (Fig 2.4-2.5).  
 
Prdm13 in Early Amacrine Development 
 When PRDM13 was knocked down with hypomorphs, there were no immediate effects 
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on cell fate. Despite the fact that it comes on as early as E13.5, no phenotypes were observed till 
P5 (Figs 2.1, 2.5). Our study was not able to identify the purpose of PRDM13 embryonically in 
developing amacrine cells. While it is clear that PRDM13 is necessary to for a subpopulation of 
amacrines to mature and correctly laminate the IPL, it was not obvious why it was on for more 
than a week and a half within the retina before any observable phenotype manifested.  
 It was previously observed that Prdm13 is directly downstream of Ptf1a in the spinal 
cord216. As early as E13.5 I observed robust PRDM13 expression in a subset of PTF1a cells, and 
all PRDM13+ cells descended from this lineage. PTF1a expression decreased over time and was 
likely negatively regulated by Prdm13, as it is in the spinal cord217,257. However, when Prdm13 
was absent, there were no observable changes in the numbers or fate of PTF1a+ cells during 
embryonic development.  
In opposition to this lack of change in Prdm13 loss-of-function experiments, gain-of-
function experiments showed increased PAX6+/OTX2+ cells, suggesting a potential role of 
Prdm13 in suppressing Otx2 fates. I hypothesized that perhaps there are redundant mechanisms 
for restricting amacrine/horizontal cell fates within the PTF1a+ lineage. Our double knockout 
experiments with PRDM1 and VSX2 led credence to this possibility. While the specific timing 
and gene regulatory networks are not the same, the fact that double loss-of-function experiments 
late caused an increase in amacrine fates, suggests that a similar mechanism could be in place in 
early retina development to restrict Ptf1a fates. 
 Many of these experiments were performed before the prevalence of single-cell RNAseq 
technology. An obvious experiment is to utilize our GFP+ labeled Prdm13 mice as well as the 
hypomorph knock downs in a scRNAseq experiment. This could be performed by taking the 
retinas at various developmental time-points and flow-sorting the cells to only analyze GFP+ 
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cells, then comparing the transcriptional profile of hypomorphs to their control littermates. This 
could elucidate more about the role of PRDM13 in nascent amacrine cells as well as highlight 
transcriptional regulators that may be able to account for relatively normal early amacrine 
development in Prdm13 mutants. 
 Throughout development, transcription factors are used repetitively in different contexts 
to perform unique, and sometimes contradictory operations in developing cells. I suspect this 
may be the case with Prdm13. Early, it may play a role in restricting amacrine fates by 
repressing OTX2 expression. In the postnatal development it may be required in a subset of 
amacrine cells to activate the EBF3 subtype machinery. An alternative explanation is that 
developing neurons pass through stages of progressive activation of transcription factors that 
lead to subtype fates. The deficits in PRDM13 embryonically in our hypomorph mice could have 
led to a failure to engage a set of transcriptional machinery that only had consequences when the 
cells differentiated into mature neurons. Our experiments were not able to discriminate between 
these mechanisms.  
 
The Future of Retinal Amacrine Subtype Research  
 Our experiments showed that PRDM13 was present in about 30% of the amacrines and 
clearly marked multiple subtypes. While only the EBF3+ population died in the Prdm13 
hypomorph, it is likely that PRDM13 is playing other roles in the cells that survived. All the 
PRDM13+ cells in the adult retina were from late born amacrine fates, including glycinergic and 
nGnG amacrines. It is possible that PRDM13 is restricting amacrine subtype fates. Conditional 
knock out mice need to be created to test if there are distinct early and late roles for Prdm13. 
However, if the characteristics of other transcription factors are indicators of general themes in 
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retinal development, I suspect that Prdm13 will be shown to possess a variety of roles across 
developmental time frames.  
Three out of four mature PRDM13+ amacrines co-expressed EBF3. While EBF3+ 
amacrines represent at least two and possibly three unique subtypes, this limited population 
remains an excellent target for future studies40. A group of EBF3+ amacrines are glycinergic and 
project dendrites to both ON and OFF lamina 1-4 of the IPL, while the nGnG population only 
projects to the OFF lamina 1-2 and partially to the mixed lamina 3, which contains both ON and 
OFF projections40. These subtypes of PRDM13+/EBF3+ amacrines may play a distinct role in 
retinal circuits. A fluorescently labeled Ebf3 mouse line could be an excellent system for 
attempting to understand an additional amacrine circuit as it could empower studying the 
physiological function of these cells.  
There are a variety of reasons to study EBF3+ amacrines. First, in their absence, the IPL 
fails to laminate properly. I was not able to discern if this was because the cells died, the axons 
were rerouted, or their entire lamina failed to properly pattern. By studying the role of these 
EBF3+ amacrines in IPL patterning, a deeper understanding of cell-cell signaling as well as 
lamination of the retina could be uncovered. Second, EBF3+ amacrines are multistratified with 
narrow dendritic fields40. This suggests that they may be playing a role in more localized circuits 
compared to the far-field SACs. I am curious why the glycinergic population project arbors to 
both ON and OFF lamina. Are they mitigating signals to control specific retinal output? What 
ganglion cell population do these amacrines interact with during signal processing? Finally, are 
all dendritic laminations of a given EBF3+ cell expressed uniformly, or do they vary depending 
on if they project to an ON or OFF layer of the INL? Unpacking these differences and 
understanding the role of EBF3+ amacrine cells could help further elucidate the diverse circuit 
182 
 
machinery at work within the retina.  
 Retinal ganglion cells have been implicated in 49 unique signaling patterns55. This 
suggests a huge range of retinal circuits remain unstudied. These circuits may provide insights 
into the fundamental mechanisms of sensory signal processing. When Prdm13 mutants were 
examined by another group, they showed that scotopic and photopic electroretinography was 
normal in Prdm13 mutants218. They also examined optokinetic reflex response behaviors. For 
some unexplained reason, Prdm13 mutant mice had greater spatial and contrast sensitivity than 
control mice218. Since EBF3+ amacrines are most disrupted in Prdm13 mutants, the loss of these 
amacrines likely caused the observed sensitivity increases, ostensibly at the expense of other 
visual functions268,269. This suggests that EBF3+ amacrines may be playing a role in setting the 
sensitivity of contrast discrimination. If true, it could explain why EBF3+ amacrines project to 
both ON and OFF lamina of the IPL. One possibility is that they perform an inhibitory role in 
identifying edges or calculating the severity of contrast. SACs shunt signals across lateral space 
to precisely discriminate motion in a directionally selective way. EBF3+ amacrines may be 
performing similarly complex calculations over a narrow, or even columnar space. 
Distinguishing EBF3+ amacrine populations and studying their physiological role in retinal 
circuits may provide novel insights into the processing of visual information by the mammalian 
central nervous system.  
 
Gene Regulatory Networks in the Developing Retina  
In early eye formation, OTX2 plays a role in patterning of the eye cup, and distinguishing 
RPE from the neural retina. Later it comes on in progenitors around the time they exit the cell 
cycle. If OTX2 remains on in late born progenitors, they will be competent to form bipolar cells 
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or rods. Previous work shows that this fate decision is influenced by a gene regulatory network 
which includes the zinc-finger transcription factor Prdm1 and the homeodomain transcription 
factor Vsx2. In general, cells that turn on Vsx2 become bipolars, and cells that turn on Prdm1 
become rods, however lineage tracing shows that under normal developmental circumstances, 
some cells will turn on one, but then deactivate it and become the alternative fate167,233,234. This 
suggests that there is some form of competition within the cells to determine the specific fate. In 
this section I will explore the implications of several of our findings. Specifically, I look at the 
role of cell type-specific enhancers in development, how redundant mechanisms may impact cell 
fate and competence, the critical role of timing in developmental patterns, and finally the 
inhibitory and instruction roles of transcription factors in gene regulatory networks.  
 
Necessary Cell Type-Specific Enhancers Govern Cell Fate  
Evidence accumulated from various systems over years of research has shown that long 
distance enhancers play a critical role in gene expression153–155. This regulation may be 
particularly important when it comes to transcription factors. I have highlighted how 
transcription factors may be turned on early with one effect, later with a second role, and even a 
third or fourth time. Each activation causes that transcriptional regulator to play a unique role as 
the chromatin ultrastructure as well as associated transcriptional regulators may be different. As 
the epigenetic state of a cell shifts, the role of a specific transcription factor may also change.  
This is certainly the case with Prdm13, which plays an inhibitory role via the recruitment of 




I show that two cell type-specific enhancers are in fact necessary for the expression of 
VSX2 and PRDM1 downstream of OTX2 in late retinal development. When a short long-
distance necessary enhancer regions were removed from the genome of developing neurons, the 
effect in protein loss was equal to that of removing the genes themselves (Fig 3.1). Without these 
enhancers, the gene regulatory network breaks down and cells have dysregulated fate-choice. To 
our knowledge, this is the first work to precisely target multiple cell type-specific enhancers 
within a developing system. It is possible that this type of temporally precise, systemically 
limited, cell type-specific enhancer is unique to the developing retina, but evidence from other 
systems suggests this is not the case153,327. This may highlight a general mechanism of cellular 
diversity and specification. It is possible that nearly every transcription factor in every system 
has multiple long-distance regulatory elements or it could be that fewer regulatory elements are 
precisely layered with a suite of transcriptional regulators at specific times in development. If 
most transcription factors are regulated by multiple cell type-specific enhancers it could explain, 
to some extent, their diverse and precise activation and repression across diverse developmental 
contexts. 
Our work highlights a critical technical advancement in our ability to target systems in a 
developmentally precise way. For example, transgenic mice that lack Prdm1 are embryonically 
lethal, as previously discussed (Chapter IV). But, by targeting cell type-specific enhancers that 
only affect later development an elegant means of testing the effect of one or more enhancers on 
a specific system becomes available for future studies. Our work here provides a general 
strategic approach; by deleting putative enhancers and their genes in vivo or in vitro with 
CRISPR/Cas9 and comparing protein expression, others may be able to identify additional 




Prdm1 and Vsx2 Redundantly Maintain Restricted Cell Competence  
There were two findings in our work that surprised us so much that I went back and 
recounted our images twice, assuming I had made an error. 1) Targeting Prdm1 and Vsx2 at the 
same time resulted in a doubling of amacrine cells at the expense of OTX2+ cells. 2) Even more 
surprising was the finding that deletion of Prdm1 and Vsx2 genes simultaneously differed from 
deleting their necessary cell type-specific enhancers.  
I did not expect double deletion to increase the number of amacrine cells (Fig 3.4). 
Indeed, no previous evidence suggested there would be any outcome other than excess bipolars, 
excess photoreceptors, or cells that were “confused” between these states. Previous work, 
including that in Chapter II, has shown that progenitors can express OTX2, then lose expression 
and go on to become amacrines and horizontals130,167,230,231. Additionally, mice with inactivated 
Otx2 have no bipolar cells or rods and supernumerary amacrines138,139. Taken together, this 
suggests that OTX2 restricts cell fates to rods and bipolars, but loss of OTX2 may de-restrict 
fate.  
 There are several possible mechanistic explanations for this finding. First, VSX2 and 
PRDM1 may act directly on OTX2 to maintain its expression. In this case, if at least one of the 
two were present, Otx2 would continue to be transcribed and restrict the competence window. 
Alternatively, they may be acting through a similar mechanism, but upstream of OTX2 and not 
on the gene directly. In this scenario, VSX2 and PRDM1 indirectly maintain OTX2 expression 
by somehow preserving cell competence, which includes Otx2 expression. Both mechanisms 
would have an identical outcome and allow amacrine cells to form when VSX2 and PRDM1 
were simultaneously absent. Studies examining the binding of VSX2 and PRDM1 to OTX2 
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enhancers could show if the first explanation were possible. A third possibility is that they work 
through directly restricting amacrine fates. PRDM1 and VSX2 may be acting on some amacrine 
activators by restricting their ability to upregulate pro-amacrine transcriptional regulators. 
Alternatively, it may be that OTX2+ cells which fail to activate Prdm1 or Vsx2 turn on amacrine 
machinery, which subsequently downregulates Otx2. Finally, there may be a mixed effect 
between several of these mechanisms, and while VSX2 and PRDM1 both restrict cells to rod and 
bipolar fates, they do it through unique mechanisms. While functionally similar in outcome, each 
of these possibilities present a unique mechanistic explanation for the role of PRDM1 and VSX2 
in redundantly maintaining OTX2+ cell identity. In my opinion, the most probable explanation is 
that the two genes indirectly maintain OTX2 identity, which in turn represses amacrine identity.  
 How and why PRDM1 and VSX2 work redundantly to restrict OTX2+ cell identity 
presents a curious conundrum, highlighting the fact that most transcription factors play more 
than one role at a given time. Since only a portion of the population go on to become amacrines, 
perhaps only a subset of OTX2+ cells are susceptible to adopting amacrine fates, though the 
mechanisms whereby this occurs are unclear. An obvious experiment to test all of these 
hypotheses is to perform serial scRNAseq analysis on developing tissue and compare 
Prdm1/Vsx2 loss-of-function cells to their normal counterparts. What transcription regulators 
change? What is the difference between the cells that become amacrines and those that adopt 
OTX2+ fates? What other transcriptional regulators are playing a role upstream of Vsx2 and 
Prdm1 as well as downstream to direct cell fates? The fact that loss of two genes within a gene 
regulatory network causes a shift in competence restriction suggests there may be critical 





Development Occurs within Critical Temporal Windows 
 Overexpressing PRDM1 in nascent VSX2+ bipolar cells results in a cell fate-shift early, 
but not late (Chapter IV). If VSX2 is lost early, bipolar cells will not form, but if VSX2 and 
PRDM1 are lost via enhancer targeting, transient progenitor-derived VSX2 is sufficient to drive 
bipolar fates (Figs 3.4, 3.8). Additionally, some bipolar cells form normally without VSX2 once 
they have made it through a critical developmental window (Chapter III). The same PRDM1 that 
causes bipolar cells to fate shift early will have no observable effect on mature bipolar cells. Yet 
the PRDM1 that drives rod fates early is toxic to them if it remains on or is constitutively 
activated in mature rods.  
 These findings are in contrast to those of Prdm13, which is normally activated as early as 
E13.5 and comes on in a large population of PTF1a+ nascent interneurons. Yet, loss of PRDM13 
did not appear to have any effect on these cells in terms of number, patterning, or markers, until 
the cells began to mature. As discussed above, PRDM13 may be playing distinct roles 
embryonically and in mature amacrines.  
 Thus, in some circumstances, a transcriptional regulator can be lost with no observable 
impact on the developing tissue. At other times, loss or overexpression may result in an 
immediate and dramatic change. Our results confirm broad findings across neural systems that 
regulation of development is often tied to specific temporal windows328,329. Once neurons of the 
retina are mature, they do not readily shift fates. A transcription factor like PRDM1 is critical to 
generating the correct number of rods in the retina yet must be downregulated before the cells 
mature (Figs 4.2-4.4). Conversely, the very cells it inhibits, bipolar cells, appear to be unaffected 
by its presence late after they have matured (Fig 4.2).  
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 Here I have shown that VSX2+ nascent bipolar cells have a specific temporal window in 
which the loss of VSX2 or the presence of PRDM1 are both sufficient to cause a fate shift. 
However, once that window is closed, the environment of the cell is changed in such a way that 
PRDM1 is no longer able to inhibit the bipolar machinery and loss of VSX2 does not stop the 
cells from maturing into bipolars. It is possible that there is some inhibition of correct circuit 
functions in these cells that I was not able to observe, but the general fate as assessed via 
immunohistochemistry remained stable. 
 Future studies employing advanced computational methods may be required to better 
understand what constitutes a competence or fate restriction window and how these can be 
manipulated. The systems examined here could provide an excellent starting place for studies 
attempting to understanding the timing and complex regulation of competence restriction and 
permanent fate choice within the retina.  
 
Inhibitory and Instructive Transcription Factors in Retinal Fates  
 Targeting the coding regions for Prdm1 and Vsx2 resulted in the dominance of rod 
photoreceptor fates. It was only when the enhancers were targeted and there was transient VSX2 
from progenitors that bipolar fates were formed. Indeed, this finding agrees with all previous 
work suggesting that VSX2 must be present for bipolar cells to form148,149,278. It is not clear if 
VSX2 has a primarily inhibitory, fate-driving, or mixed role in bipolar fates. However, it does 
appear to have a functionally unique role from Prdm1 within this gene regulatory network.  
PRDM1 is expressed over a short temporal window and may play a predominately 
inhibitory role. Indeed, leaving Prdm1 active is toxic to photoreceptors. PRDM1 appears to work 
in this short temporal window to inhibit bipolar fates, not necessarily instruct photoreceptor 
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fates. The absence of PRDM1 seemed to have no effect on rod formation, unless there is VSX2 
present. This is in contrast to VSX2 which is required for bipolar cells to form. Bipolar cells did 
form without bipolar-specific VSX2, but there was still VSX2 within the system and they only 
did this in the absence of PRDM1.  
In addition, it is possible there is cross repressive activity. Previous studies showed that 
conditional loss of PRDM1 in nascent rods was sufficient to turn off rod machinery and cause a 
fate shift to bipolar cells. Indeed, lineage tracing of PRDM1+ cells shows that in some cases, 
PRDM1 is deactivated and VSX2 machinery takes over. The same is true in VSX2+ cells. We 
specifically demonstrated that when constitutive PRDM1 is driven by the bipolar-specific VSX2 
enhancer, cells will fate shift to rods. This suggests that PRDM1 is able to inhibit, directly or 
indirectly, VSX2 expression, and VSX2 is certainly able to downregulate photoreceptor 
machinery, though it is not clear if it does this by acting on PRDM1 directly. 
Rods developed later in evolution than cones and bipolar cells17,84,150. One can imagine a 
situation in which VSX2 was on in progenitors and later drove the expression of bipolar cells. 
With the advent of rods, a means of inhibiting this VSX2 from progenitors so that more rods 
could form could become necessary. Transient PRDM1 expression could then act as an 
inhibitory transcriptional regulator to block the formation of excess bipolar cells. This retina 
would now have too many rods. In this scenario, the retina would need a novel solution for 
maintaining the correct number of bipolar cells, while not stopping the formation of rods. We 
mentioned previously that cis-regulatory enhancers are thought to be a major means of driving 
evolution155. A “simple” mechanistic solution to balancing rod and bipolar fate numbers would 
be to create a bipolar-specific VSX2 enhancer. Whether this hypothetical order of events 
matches evolution is beyond the scope of this thesis. However, it is clear that these two 
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transcription factors are critical to setting the correct numbers of rods and bipolar cells in OTX2+ 
cells of the mouse retina.  
Taken together, we suspect that PRDM1 and VSX2 are acting through unique 
mechanisms to set the correct balance of rods and bipolar cells within this circuit. PRDM1 
appears to be primarily inhibitory, blocking the bipolar-specific machinery and allowing rods to 
develop, then turning off as the cell matures. VSX2 is necessary for bipolar cell formation and in 
its absence bipolars will not form. However, once bipolars pass through a specific temporal 
window, VSX2 can be deactivated, however certain subtypes may not develop as a result. Rods 
will form in the absence of PRDM1 and we broadly classify this as an inhibitory transcription 
factor that blocks specific fate outcomes. VSX2 is an instructive transcription factor that actively 
drives bipolar fates, though it may mechanistically work through transcriptional inhibition. 
Future studies may reveal if PRDM1 and VSX2 interact directly or are working through other, as 
yet unknown mechanisms, to regulate the fate of cells in the retina.  
 
Types, Subtypes, and Transcriptional Regulation of Fate 
 We previously noted that transcription factors may often play unique roles at different 
times in a developing tissue. I was not able to define the role of PRDM13 in embryonic retinas, 
but we know that in its absence, 25% of amacrines die when they should normally mature (Figs 
2.5). One mechanistic explanation for this is that PRDM13 is necessary to correctly drive 
amacrine subtype formation and in the absence of this, they do not integrate correctly into retinal 
circuits and are culled.  
 VSX2 normally remains on in nearly all bipolar interneurons. We also know that it is 
necessary to form bipolar cells130,148–150,232. However, once bipolar cells passed through a 
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temporal window, they were able to robustly express a suite of bipolar-specific markers and 
maintain apparently normal morphology (Fig 3.4). However, one noticeable change was that 
there was a shift in the subtypes of bipolar cells and a loss of Secretagogin+ cone bipolars (Fig 
S3.2D-E). This suggests that VSX2 may remain on for a reason, and that some bipolar diversity 
is lost when VSX2 is absent. Unlike in our PRDM13 model, these cells were not lost. It was not 
clear if this difference is because the bipolar cells still form a meaningful cell type and 
incorporate into a circuit or if using a CRISPR/Cas9 sparse label approach generated different 
outcomes from transgenic mice. It could simply be that PRDM13 and VSX2 have vastly 
different roles. Finally, we were not able to test if cells that shifted fates were fully functional 
mature neurons, or just retained correct morphology and cellular markers. Future studies will be 
needed to better understand how fate-shifted neurons integrate into retinal tissue.  
   
Retinal Development and Neural Regenerative Therapies  
 On December 17th, 2017 the FDA approved Luxterna. This was the first in vivo gene 
therapy approved to treat a genetic heritable disease in humans. The treatment utilizes a viral 
system to deliver human RPE65 cDNA to the RPE supporting tissue of the retina. This therapy 
not only stops a disease state, it results in restoration of visual function and elimination of night-
blindness in patients with RPE65 Leber’s congenital amaurosis.  
 This remarkable treatment was the result of years of research into the fundamental 
mechanisms of retinal degenerative diseases330–334. It was also a hallmark advancement in our 
ability to deliver genetic material to mature cells within human tissue. Despite expenditures in 
the billions relatively few new gene therapies have subsequently been developed and delivered. 
However, significant ongoing efforts are currently in place attempting to devise approaches to 
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treating neural degradation in the retina, autosomal dominant diseases, and development of 
neural protective strategies. In this section we explore the therapeutic applications currently in 
development around the globe to cure retinal disease and restore vision and highlight the 
implications of our findings for these fields of inquiry. While not all of our work has direct 
applications in moving clinical and translational research forward, many of our findings have 
implications that we highlight throughout this section.  
 
Challenges in Neural Regeneration 
 A central challenge in all neural protective treatments, gene therapy, and regenerative 
medicine, is that mature neurons in the mammalian central nervous system are resistant to 
change. Not only do neurons in mammalian retinas fail to reproduce in response to injury they 
often fail to regrow their axons whether in the spinal cord or retina335,336. Significant work has 
been done exploring the role of the extracellular matrix in both driving and inhibiting axonal 
regrowth after injury, however no solutions have been generated to date336,337.  
 The challenges of neural regeneration do not exist in all systems. Neurons of the 
olfactory system regenerate throughout the lifetime of most mammals, including humans. Toxic 
application of zinc sulfate to the olfactory epithelium causes cell death338–341. Yet, these neurons 
readily divide, generate new cells, and project their axons to the correct glomeruli resulting in a 
cohesive sense of smell, despite loss of all original sensory neurons342,343. Years of work into the 
regenerative capacity of these neurons has highlighted the fact that mature neurons of the central 
nervous system can regenerated at least in certain specific tissue contexts344.  
This regenerative capacity is not limited to the surface facing olfactory sensory neurons. 
Extensive studies have explored the effects of transection of the olfactory nerve. When cut, the 
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projection neurons from the olfactory bulb crossing the cribriform plate experience retrograde 
degeneration and apoptosis345,346. Despite the enormous loss of cells resulting from nerve bundle 
severing, the cells can be regenerated and re-project their axons, resulting in a nearly complete 
recovery of functional olfactory sensory tissue347,348. However, it is important to note that both of 
these sensory neuron and projection neuron regenerative processes involve a variety of extrinsic 
cell signaling molecules, including various Bone Morphogenetic Proteins (BMPs), Transforming 
Growth Factors (TGFs), and Insulin-like Growth Factors (IGFs)344.  
If new neurons in the central nervous system can be born, migrate to the correct tissue, 
specify into a subtype of sensory neuron, and project axons to the correct target in the olfactory 
system, why do they fail to perform similar functions in other CNS tissues like the retina? A 
simple argument is that the retina cannot function properly when the neurons are regenerating. 
This could be the case if, for example, mapping of ganglion cells axonal projections into the 
lateral geniculate nucleus of the thalamus failed to function properly in a regenerative context. 
Olfactory sensory neurons target specific glomeruli based on the olfactory signals to which they 
respond296. This is not the case with visual processes which encode a wide array of visual 
information before ganglion cells project through to the thalamus and send signals on to the 
visual cortex or other neural targets349. Making computational sense of visual signals requires 
precise spatio-temporal mapping of the signals and that suggests re-wiring could be more 
complex in the retina than the olfactory bulb. However, non-mammalian retinas continue to grow 
throughout the lifetime of the animal and can be regenerated in response to injury. Thus, there is 
not a clear explanation for why neural regeneration varies by tissue within mammals. However, 
there are a number of approaches currently being pursued to surmount these difficulties, 
including inducing retinal regeneration, causing stable neurons to fate change, implanting neural 
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tissue into a degenerating retina, and growing entirely new eyes through the use of retinal 
organoids.  
  
Neural Regeneration in the Retina 
Most neural degenerative diseases of the retina will only cause a dysfunction in one cell 
type, for example rods, or a portion of the phototransduction cascade, as is the case in RPE65 
Leber’s congenital amaurosis. However, this single degrading event can lead to a cascade of cell 
death that ultimately effects the entire tissue334,350,351. Permanent loss of visual function due to 
cell death occurs in all cases of physical ablation of the retina in mammals. But this is not the 
case non-mammalian vertebrate, despite the fact that most vertebrate retinas have roughly similar 
lamination and all share the common major cell types352. 
In urodeles (salamanders), the entire retina can be physically removed or chemically 
ablated and it will regrow. In these circumstances, the RPE will re-enter the miotic cycle and 
transition from epithelial tissue into laminated neural tissue353–356. Fish grow throughout their 
lifetime and their eyes grow along with the rest of their body. This leads to a steady formation of 
new cells at the periphery of their retina357. This process is separate and distinct from the injury 
response in fish retinas. When damage occurs in a fish retina, the Müller glia will undergo what 
is referred to as a gliosis response and give rise to a variety of neurons, including rods, as well as 
amacrine, bipolar, and ganglion cells352. The new neurons are able to migrate properly, network 
with existing retinal tissue, and form fully functional circuits357,358.  
In contrast to studies within olfactory regeneration, which have largely looked at the 
impact of extrinsic signals driving cells through a series of steps to transform them into sensory 
or project neurons, studies within the retina have largely focused on the roles of intrinsic 
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signaling in driving the transformation of Müller glia into progenitors. It is known that retinal 
progenitors respond to some extrinsic signals like EGFs, FGFs, and SHH359. But most work has 
focused in on the transcription factors ASCL1 and PAX6, which have been shown to be critical 
to these processes, though the full mechanism is not yet fully understood109,173,359,360. However, 
additional factors have been shown to be upregulated in transdifferentiated Müller glia including 
Notch, HES5, SOX2, FOXN4, and PEA3173. It is not clear why non-mammalian vertebrates are 
so much more capable of regeneration.  
Müller glia of higher vertebrates may have lost their regenerative capacity. But the key 
genes upregulated in fish, salamanders, and avians are also critical to mammalian progenitors, 
especially Notch1, Pax6, and Ascl1352. This has led to the belief by some, that given the right 
cocktail, mammalian Müller glia could be stimulated to regenerative potential. However, there 
are currently no efficient strategies for causing regeneration within mammalian systems. 
One explanation for the regenerative resistant in mammalian Müller glia could be 
redundancy. We showed that loss of PRDM1 or VSX2 alone was not sufficient to dysregulate 
the function of OTX2+ cells. While they did fate shift, they remained within a specific 
competence window, choosing between rods and bipolar cells. Only when both VSX2 and 
PRDM1 were simultaneously absent did OTX2+ cells shift their competence, lose OTX2, and 
adopt amacrine fates. It is possible that the regenerative capacity of Müller glia is restricted in a 
similar redundant fashion. If this were the case, then studies attempting to downregulate or 
upregulate a single transcriptional regulator may fail to generate results. Under this paradigm 
only when two or more critical factors were shifted simultaneously would Müller glia 
transdifferentiate through gliosis into regenerative progenitors.  
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Identifying such a mechanism through trial and error would be a monumental endeavor. 
However, one approach could be to explore cross-species single-cell RNAseq profiles between 
zebrafish and mice, specifically asking how zebrafish Müller glia differ from those in mice and 
by targeting the transcriptional changes that occur in response to a gliosis transdifferentiation 
initiating event. Since there are many conserved developmental paradigms across mammals there 
may be meaningful insight provided by this computational line of inquiry. Indeed, initial studies 
in this field have already been published on BioRxiv and suggest a possible role for NFI family 
transcription factors in zebrafish proliferative capabilities361. Ultimately, this could provide a 
means of identifying specific regulatory changes that have resulted in the loss of regenerative 
capacity in mammalian retinal neural tissue.   
 
Neurons of the Retina Are Resistant to Fate Change 
 In the absence of regenerative therapies, one potential line of inquiry is causing cells to 
fate convert. This is particularly relevant to certain degenerative diseases like retinitis 
pigmentosa. In this disease state, loss of rods leads to cone death. Loss of cones is particularly 
challenging to humans because we use high acuity cone vision for most of our behavioral 
functions362. One hypothesis is that if you cause rods in retinitis pigmentosa patients to covert to 
cones, then you could prevent the catastrophic breakdown of the outer nuclear layer that 
ultimately leads to blindness in these patients295. The cost of this would be immediate night-
blindness or at least a significant loss of low light visual function but this eventually occurs in 
these patients regardless. This is a tradeoff most patients would be willing to take as it could 
theoretically preserve some day-light vision long term, rather than suffering complete blindness. 
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 The transcription factor Nrl is required for the formation of rods but not cones. One group 
took advantage of this and created a conditional Nrl knockout mouse and crossed it with a known 
retinitis pigmentosa mouse model. They then knocked out Nrl in mature retinas295. Surprisingly, 
the cells converted from rods into cone-like photoreceptors. The mice had a significant reduction 
in night-vision but were able to maintain robust daytime visual function as assessed by 
electroretinogram (ERG). The new cells were not fully cones and maintained some of their rod 
like functions, however they did not die off as they normally would in this disease state 
suggesting there was a neural protective effect295.  
 This study indicates the significant therapeutic potential of converting one cell type into 
another in order to prevent degeneration in a disease state. However, it also highlights a key 
challenge in fate-conversation studies: Mature neurons are resistant to change. This is likely 
because mature neurons, unlike developing ones, have a strongly established chromatin 
ultrastructure and conversion to an alternative fate will likely require more than a single change. 
Indeed, the simplest protocols for generating induced pluripotent stems cells (iPSCs), involves at 
least four Yamanaka factors363. That does not include any of the steps needed to re-differentiate 
cells into alternative fates.  
 Our work builds on these findings in a novel system. We showed that driving PRDM1 
expression during retinal development can shift bipolar cells to rod fates, even after they make 
their initial fate choice (Fig 4.3). However, we also saw that mature bipolar cells do not respond 
in any observable way to the presence of PRDM1 suggesting that their fate was stabilized and 
resistant to change (Figs 4.2, 4.4). We also showed that cells lacking VSX2 and PRDM1 can 
mature into bipolar cells once their fate is set or mature into photoreceptors when neither is 
present (Chapter III). Within this complex network it is clear that once retinal cells pass through 
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a specific transient fate choice window they will no longer readily shift their identity. Taken 
together, it is likely that significant more work into the fundamental mechanisms of cell fate and 
maturation will be required before any functional therapies are realized.  
  
Transplantation of Neural Tissue into a Mature Retina 
 The prospect of successful and complete cell fate conversion within the retina remains 
somewhat elusive, particularly in a therapeutic context. While it is possible that one day we will 
develop the capability to genetically manipulate Müller glia to regrow a retina or fully fate shift 
mature rods to cones, substantial barriers still exist. This has led to significant work into 
transplantation strategies. The prevailing thought is that most retinal degenerative diseases have 
already caused some permanent loss of function before the disease is detected or treated. A wide 
range of diseases could be theoretically treated by the implantation of novel neural tissue into the 
retina provided it appropriately differentiated and integrated into the existing circuits. There are 
number of strategies for transplantation that include 1) transplantation of stem cells from 
embryonic, adult, or induced sources, 2) transplantation of mature cells and 3) transplantation of 
whole tissue. 
 Initial transplant studies were done using entire pieces of mouse tissue and grafting them 
into an extant retina. These had limited success in generating functional neural tissue, but there 
was some formation of outer-segment like structures that were promising364–367. This was 
followed by work attempting to place photoreceptors alone into a healthy or degraded retina. 
While these approaches generally had tissue survival, there was little restored visual function368–
371. These studies were followed by work transplanting retinal progenitor cells369. Unfortunately, 
there is little evidence that transplanted retinal progenitor cells into a mature retina causes any 
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meaningful recovery of vision or indeed the generation of novel healthy retinal neurons372–375. 
Despite this evidence, clinical trials are in place inserting retinal progenitor cells into human 
retinas (jCYTE; www.clinicaltrials.gov; ID: NCT02320812)376. Others have grafted whole 
sections of human fetal retina into retinitis pigmentosa patients. While the tissue survived and 
there were no autoimmune effects, there was no change in visual function377. 
 The transplantation of retinal progenitor cells or other stem cell derivatives had little to 
no functional integration into healthy or degraded retinas across numerous studies364. However, 
early post-mitotic nascent photoreceptors seem to have far more success in surviving when 
transplanted than mature photoreceptors or progenitors378. Little functional change has been 
shown in healthy retinas in response to transplantation. However, a few studies have shown that 
rod transplantation into a night-blind mouse model resulted in both restoration of 
electroretinograms (ERGs) and ability to perform low-light visual tasks379,380. Follow up studies 
using female/male transplants revealed that the transplanted cells were not in fact integrating, but 
their genetic or protein material was taken up into existing photoreceptors, leading to false 
conclusions based on fluorescent labels381–383. Taken together this suggests that restoration of 
vision in transplantation mouse models may be a result of material transfer from functional cells 
to host mutant cells rather than integration of transplanted cells. On the surface, this presents a 
major challenge to transplantation studies. However, if true, this could lead to a potential 
mechanism for delivering novel genetic material to rods, beyond those currently employed in 
gene therapy. It is possible that studies focused on transplantation will ultimately lead to the 
discovery of a mechanistic tool for gene therapy or cell trans-differentiation. However, to date, 
there are no studies showing conclusive evidence for the successful restoration of vision in a 
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disease model via the integration of transplanted tissue, whether it be whole tissue sections, 
progenitors, stem cells, immature postmitotic cells, or mature photoreceptors.  
I suspect that further advancements in this field necessitate a better understanding of how 
neural circuits are created within the retina. I identified the fact that EBF3+ amacrines are 
necessary for properly laminated the IPL of the retina. There are no known mechanistic reasons 
for this. Future studies that attempt to define the neural circuits that EBF3+ amacrines form as 
well as their cell-cell communications and how that might impact IPL patterns are excellent lines 
of inquiry. Insights into the underlying biological drivers of retinal patterning and circuit 
formation  could provide understanding into the means by which new neurons from implanted 
tissue might be integrated into an existing retina.  
 
Retinal Organoids and Regenerative Therapy 
 There are variety of excellent vertebrate models for studying retinal development. 
However, many of them differ significantly from humans. Zebrafish have regenerative 
capabilities and their retinas grow throughout their lifetime. Mice and rats are primarily 
nocturnal and do not have a fovea or macula, the central part of the retina critical to human high 
acuity vision. This has led to the search for an alternative means of studying human retinal 
development. Human eyes develop significantly slower than mice or rats and studies on human 
fetal tissue are problematic for a variety of reasons. Human embryonic stem cells (ESCs) and 
iPSC have provided some insights into retinal development, but their uses are limited as neurons 
in a dish often vary significantly from those integrated into a laminated tissue384,385. Years of 
work lead to the ability to develop human iPSC derived organoids in culture386,387. Given the 
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right series of treatments and growth factors, small organized tissue sections can be grown that 
replicate aspects a developing organ388.  
 There are a variety of critical developmental insights that organoids empower and a host 
of human-specific genetic modification approaches that are now available for testing but much of 
this work is still under development. Obstructions include the challenges spoken of previously 
regarding limitations in transplantation technology. Additionally, while organoids can mimic the 
development of human tissue, the process is not yet fully refined and critical differences have 
been shown by lamination, cell types, cell markers, and single-cell RNA sequencing compared to 
a normal developing tissue388–390.  
 Fundamental to all the regenerative therapies and associated technologies discussed here 
is the need for increased understanding of intrinsic and extrinsic regulation of retinal 
development. How do cells choose a cell fate and how are those fates maintained? Under what 
circumstances is a cells fate maintained or lost? How is the retina patterned and how are 
plexiform layers formed? The work elucidated within this document sheds light on all of these 
questions and provides insights into the mechanisms of retinal cell fate regulation in developing 
and mature neurons, maintenance of cell identity, transcriptional regulation, and laminar 
patterning of tissue. 
 In mice, Prdm13 derived EBF3+ amacrine cells are necessary to correctly laminate the 
IPL. Current organoid technologies have focused on driving the production of photoreceptors yet 
they frequently suffer from issues in the correct cell types and proper lamination 388. It is possible 
that by changing the media, growth context, or birthdate order of progenitors the proper neuronal 
subtypes could form, resulting in a more robust and complete neural tissue. Conversely, if a 
group wanted to grow a rod-rich organoid tissue, our findings in chapter III may provide a 
202 
 
mechanism. I showed evidence that OTX2+ cells default to photoreceptors in the absence of 
VSX2 and show that deletion of a 164bp enhancer element is sufficient to stop bipolar formation. 
If a similar enhancer were identified in humans, a cell line could be created without the 
necessary bipolar-specific enhancer and could result in tissue that defaulted to rod-fates.  
 
Closing Remarks 
 I have explored the developmental roles of a number of key transcriptional regulators that 
contribute to human disease including Prdm13, Vsx2, and Otx2. I have also unpacked more of 
the fate stabilizing functions played by Prdm1, a gene implicated in numerous developmental 
diseases and cancers. This work highlights the enormous challenges associated with causing a 
fate change within neurons of a mature retina and the temporally precise regulation of cell fate 
when the tissue is developing. The finding that simultaneous loss of PRDM1 and VSX2 
produces amacrine cells and has alternative outcomes based on the way the gene is deleted 
provides insight into potential unforeseen complexities gene therapeutic approaches may face in 
the future. The fact that Prdm13 mutants share common fate outcomes with humans afflicted by 
Prdm13 North Carolina Macular Dystrophy suggests a future potential solution, provided an in-
utero gene therapy were available. Cures such as this were once thought impossible. Actualizing 
them will be challenging. However, I can envision a future, built on the foundations of 
fundamental mechanisms of retinal development, in which no person suffers from permanent 
blindness.  
 I see this work as a modest contribution to the lifechanging global effort to let blind eyes 
see. The findings here represent an incremental advance in our understanding of retinal neural 
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development. Yet, I hope it will empower the work of dedicated scientists around the world who 
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